US20040048844A1

US20040048844A1 - Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents

Info

Publication number: US20040048844A1
Application number: US10/427,540
Authority: US
Inventors: David Nugiel; David Carini; Susan DiMeo; Anup Vidwans; Eddy Yue
Original assignee: Bristol Myers Squibb Pharma Co
Current assignee: Bristol Myers Squibb Pharma Co
Priority date: 1999-10-20
Filing date: 2003-05-01
Publication date: 2004-03-11
Also published as: US7250435B2; US20050261353A1

Abstract

The present invention relates to the synthesis of a new class of indeno[1,2-c]pyrazol-4-ones of formula (I):

that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-7 and their regulatory subunits know as cyclins A-G.

This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt form thereof. Alternatively, one can treat cancer or other proliferative diseases by administering a therapeutically effective combination of one of the compounds of the present invention and one or more other known anti-cancer or anti-proliferative agents.

Description

FIELD OF THE INVENTION

This invention relates generally to novel 5-substituted-indeno[1,2-c]pyrazol-4-ones which are useful as cyclin dependent kinase (cdk) inhibitors, pharmaceutical compositions comprising the same, methods for using the same for treating proliferative diseases, and intermediates and processes for making the same.

BACKGROUND OF THE INVENTION

One of the most important and fundamental processes in biology is the division of cells mediated by the cell cycle. This process ensures the controlled production of subsequent generations of cells with defined biological function. It is a highly regulated phenomenon and responds to a diverse set of cellular signals both within the cell and from external sources. A complex network of tumor promoting and suppressing gene products are key components of this cellular signaling process. Over expression of the tumor promoting components or the subsequent loss of the tumor suppressing products will lead to unregulated cellular proliferation and the generation of tumors (Pardee, Science 246:603-608, 1989).

Cyclin dependent kinases (cdks) play a key role in regulating the cell cycle machinery. These complexes consist of two components: a catalytic subunit (the kinase) and a regulatory subunit (the cyclin). To date, six kinase subunits (cdk 1-7) have been identified along with several regulatory subunits (cyclins A-H). Each kinase associates with a specific regulatory partner and together make up the active catalytic moiety. Each transition of the cell cycle is regulated by a particular cdk complex: G1/S by cdk2/cyclin E, cdk4/cyclin D1 and cdk6/cyclinD2; S/G2 by cdk2/cyclin A and cdk1/cyclin A; G2/M by cdk1/B. The coordinated activity of these kinases guides the individual cells through the replication process and ensures the vitality of each subsequent generation (Sherr, Cell 73:1059-1065, 1993; Draetta, Trends Biochem. Sci. 15:378-382, 1990)

An increasing body of evidence has shown a link between tumor development and cdk related malfunctions. Over expression of the cyclin regulatory proteins and subsequent kinase hyperactivity have been linked to several types of cancers (Jiang, Proc. Natl. Acad. Sci. USA 90:9026-9030, 1993; Wang, Nature 343:555-557, 1990). More recently, endogenous, highly specific protein inhibitors of cdks were found to have a major affect on cellular proliferation (Kamb et al, Science 264:436-440, 1994; Beach, Nature 336:701-704, 1993). These inhibitors include p16^INK4(an inhibitor of cdk4/D1), p21^CIP1(a general cdk inhibitor), and p27^KIP1(a specific cdk2/E inhibitor). A recent crystal structure of p27 bound to cdk2/A revealed how these proteins effectively inhibit the kinase activity through multiple interactions with the cdk complex (Pavletich, Nature 382:325-331, 1996). These proteins help to regulate the cell cycle through specific interactions with their corresponding cdk complexes. Cells deficient in these inhibitors are prone to unregulated growth and tumor formation.

This body of evidence has led to an intense search for small molecule inhibitors of the cdk family as an approach to cancer chemotherapy. There are no known examples of molecules related to the current invention which describe 5-substituted-indeno[1,2-c]pyrazoles as cdk inhibitors. There is one case describing indeno[1,2-c]pyrazoles having anticancer activity. There are two other examples which describe indeno[1,2-c]pyrazoles having unrelated utilities and structures.

A series of indeno[1,2-c]pyrazoles having anticancer activity are described in JP 60130521 and JP 62099361 with the following generic structure:

No substitution is claimed on the indenophenyl portion of the molecule and the molecules are not indicated to be cdk inhibitors. In addition, we discovered that substitution at the 5-position was critical for cdk inhibitory activity.

A series of indeno[1,2-c]pyrazoles having herbicidal activity are described in GB 2223946 with the following generic structure:

The above compounds differ from the presently claimed invention in X _nis defined as halo, alkyl, haloalkyl, and haloalkoxy; n=0-2. In addition, R₁is defined as acyl and R₂is defined as alkyl or cycloalkyl.

A series of 1-(6′-substituted-4′-methylquinol-2′-yl)-3-methylindeno[1,2-c]pyrazoles having CNS activity are described by Quraishi, Farmaco 44:753-8, 1989 with the following generic structure:

Compounds of this series are not considered to be part of the presently claimed invention.

SUMMARY OF THE INVENTION

The present invention describes a novel class of indeno[1,2-c]pyrazol-4-ones or pharmaceutically acceptable salt forms thereof that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk 1-7 and their regulatory subunits know as cyclins A-H.

It is another object of this invention to provide a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt form thereof.

It is another object of this invention to provide a novel method of treating cancer or other proliferative diseases, which comprises administering a therapeutically effective combination of one of the compounds of the present invention and one or more other known anti-cancer or anti-proliferative agents.

These and other objectives have been achieved by the inventors' discovery that compounds of formula (I):

wherein R ₁, R₂and X are defined below or pharmaceutically acceptable salts thereof are cyclin dependent kinase inhibitors.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. The inhibitors of this invention are indeno[1,2-c]pyrazol-4-one analogs. Certain analogs were selective for their activity against cdks and their cyclin bound complexes and were less active against other known serine/threonine kinases such as Protein Kinase A (PKA) and Protein Kinase C (PKC). In addition, these inhibitors were less active against tyrosine kinases such as c-Abl.

As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently would be useful in modulating cell-cycle progression, which would ultimately control cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation, such as the treatment of cancer, psoriasis, immunological disorders involving unwanted leukocyte proliferation, in the treatment of restinosis and other smooth muscle cell disorders, and the like.

The present invention, in a first embodiment, describes a novel compound of formula (I):

or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein:

X is selected from the group: O, S, and NR;

R is selected from the group: H, C _1-4alkyl, and NR⁵R^5a;

R ¹is selected from the group: H, C_1-10alkyl substituted with 0-3 R^c, C_2-10alkenyl substituted with 0-3 R^c, C_2-10alkynyl substituted with 0-3 R^c, —NHR⁴, C_3-10carbocycle substituted with 0-5 R^a, and 3-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 R^b;

R ²is selected from the group: H, C_1-10alkyl substituted with 0-3 R^c, C_2-10alkenyl substituted with 0-3 R^c, C_2-10alkynyl substituted with 0-3 R^c, —(CF₂)_mCF₃, C_3-10carbocycle substituted with 0-5 R^a, and 3-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 R^b;

R is selected from the group: H, halo, —CN, NO ₂, C_1-4haloalkyl, NR⁵R^5a, NR⁵NR⁵R^5a, NR⁵C(O)OR⁵NR⁵C(O)R⁵═O, OR⁵, COR⁵, CO₂R⁵, CONR⁵R^5a, NHC(O)NR⁵R^5a, NHC(S)NR⁵R^5a, SO₂NR⁵R^5a, SO₂R^5b, C_1-4alkyl, phenyl, benzyl, C_1-4alkyl substituted with 1-3 R^c, C_5-10alkyl substituted with C_2-10alkenyl optionally substituted with 0-3 R⁶, C_2-10alkynyl substituted with 0-3 R⁶, —(CF₂)_mCF₃, C_3-10carbocycle substituted with 0-5 R⁶, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R⁶; and

provided that if R ³is phenyl, it is substituted with 1-5 R^a;

R ⁴is independently at each occurrence selected from the group: H, —CN, C_1-4alkyl, C_1-4haloalkyl, NR³R^3aNR³C(O)OR³, NR³C(O)R³, OR³, COR³, CO₂R³, CONR³R^3a, NHC(O)NR³R^3a, NHC(S)NR³R^3a, SO₂NR³R^3a, SO₂R^3b, C_3-10carbocycle substituted with 0-5 R^a, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R³;

provided that at least one R ³is present and that this R³is selected from the group: C_1-4alkyl substituted with 1-3 R⁶, C_5-10alkyl substituted with C_2-10alkenyl optionally substituted with 0-3 R⁶, C_2-10alkynyl substituted with 0-3 R⁶, —(CF₂)_mCF₃, C_3-10carbocycle substituted with 0-5 R⁶, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R⁶;

R ^ais independently at each occurrence selected from the group: halo, —CN, N₃, NO₂, C_1-4alkyl, C_1-4haloalkyl, NR³, R^3a, ═O, OR³, COR³, CO₂R³, CONR³R^3a, NHC(O)NR³R^3a, NHC(S)NR³R^3a, NR³C(O)OR³, NR³C(O)R³, SO₂NR³R^3a, SO₂R^3b, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

alternatively, when two R ^a's are present on adjacent carbon atoms they combine to form —OCH₂O— or —OCH₂CH₂O—;

R ^bis independently at each occurrence selected from the group: halo, —CN, NO₂, C_1-4alkyl, C_1-4haloalkyl, NR³R^3a, NR³C, NR³C(O)R³, OR³, COR³, CO₂R³, CONR³R^3a, NHC(O)NR³R^3a, NHC(S)NR³R^3a, SO₂NR³R^3a, and SO₂R^3b;

R ^cis independently at each occurrence selected from the group: halo, —CN, NO₂, C_1-4alkyl, C_1-4haloalkyl, NR³R NR⁵NR⁵R^5a, NR³C(O)OR³, NR³C(O)R³, ═O, OR³, COR³, CO₂R³, CONR³R^3a, NHC(O)NR³R^3a, NHC(S)NR³R^3a, SO₂NR³R^3a, SO₂R^3b, C_3-10carbocycle substituted with 0-5 R^a, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R³;

R ^3ais selected from the group: H, C_1-4alkyl, phenyl, and benzyl;

alternatively, R ³and R^3a, together with the nitrogen atom to which they are attached, form a heterocycle having 4-8 atoms in the ring containing an additional 0-1 N, S, or O atom and substituted with 0-3 R^3c;

R ^3bis selected from the group: H, C_1-4alkyl, phenyl, and benzyl;

R ^3cis independently at each occurrence selected from the group: halo, —CN, N₃, NO₂, C_1-4alkyl, C₁-4 haloalkyl, NR³R^3b, ═O, OR³, COR³, CO₂R³, CONR³R^3b, NHC(O)NR³R^3b, NHC(S)NR³R^3b, NR³C(O)OR³, NR³C(O)R³, SO₂NR³R^3b, SO₂R^3b, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

R ⁵is independently selected from the group: H, C_1-4alkyl, phenyl and benzyl;

R ^5ais independently selected from the group: H, C_1-4alkyl, phenyl and benzyl;

R ^5bis independently selected from the group: H, C_1-4alkyl, phenyl and benzyl;

R ⁶is independently at each occurrence selected from the group: halo, —CN, NO₂, C_1-4alkyl, C_1-4haloalkyl, NR⁵R⁵, NR⁵NR⁵R^5a, NR⁵C(O)OR⁵, NR⁵C(O)R⁵, ═O, OR⁵, COR⁵, CO₂R⁵, CONR⁵R^5a, NHC(O)NR⁵R^5a, NHC(S)NR⁵R^5a, SO₂NR⁵R^5a, SO₂R^5b, C_3-10carbocycle substituted with 0-5 R⁵, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R⁵; and

m is selected from 0, 1, 2, and 3.

In a preferred embodiment, the present invention provides a novel compound of formula (I), wherein:

X is selected from the group: O, S, and NR;

R is selected from the group: H, C _1-4alkyl, and NR⁵R^5a;

R ¹is selected from the group: H, C_1-5alkyl substituted with 0-3 R^c, C_2-5alkenyl substituted with 0-3 R^c, C_2-5alkynyl substituted with 0-3 R^c, —NHR⁴, C_3-6carbocycle substituted with 0-5 R^a, and 3-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 R^b;

R ²is selected from the group: H, C_1-5alkyl substituted with 0-3 R^c, C_2-5alkenyl substituted with 0-3 R³, C_2-5alkynyl substituted with 0-3 R^c, —(CF₂)_mCF₃, C₃-6 carbocycle substituted with 0-5 R^a, and 3-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 R^b;

R ³is selected from the group: H, halo, —CN, NO₂, C_1-4haloalkyl, NR⁵R^5a, NR⁵NR⁵R^5a, NR⁵C(O)OR⁵, NR⁵C(O)R⁵, ═O, OR⁵, COR⁵, CO₂R⁵, CONR⁵R^5a, NHC(O)NR⁵R^5a, NHC(S)NR⁵R^5a, SO₂NR⁵R^5a, SO₂R^5b, C_1-4alkyl, phenyl, benzyl, C_1-4alkyl substituted with 1-3 R^c, C_5-10alkyl substituted with C_2-10alkenyl optionally substituted with 0-3 R₆, C_2-10alkynyl substituted with 0-3 R⁶, —(CF₂)_mCF₃, C_3-10carbocycle substituted with 0-5 R⁶, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R⁶; and

provided that if R ³is phenyl, it is substituted with 1-5 R^a;

R ⁴is independently at each occurrence selected from the group: H, —CN, C_1-4alkyl, C_1-4haloalkyl, NR³R^3a, NR³C(O)OR³, NR³C(O)R³, OR³, COR³, CO₂R³, CONR³R^3a, NHC(O)NR³R^3a, NHC(S)NR³R^3a, SO₂NR³R^3a, SO₂R^3b, C_3-10carbocycle substituted with 0-5 R^a, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R³;

R ^ais independently at each occurrence selected from the group: halo, —CN, N₃, NO₂, C_1-4alkyl, C_1-4haloalkyl, NR³R^3a, NR³C(O)OR³, NR³C(O)R³, ═O, OR³, COR³, CO₂R³, CONR³R^3a, NHC(O)NR³R^3a, NHC(S)NR³R^3a, SO₂NR³R^3a, SO₂R^3b, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

R ^bis independently at each occurrence selected from the group: halo, —CN, NO₂, C_1-4alkyl, C_1-4haloalkyl, NR³R^3a, NR³C(O)OR³, NR³C(O)R³, OR³, COR³, CO₂R³, CONR³R^3a, NHC(O)NR³R^3a, NHC(S)NR³R^3a, SO₂NR³R^3a, and SO₂R^3b;

R ^cis independently at each occurrence selected from the group: halo, —CN, NO₂, C_1-4alkyl, C_1-4haloalkyl, NR³R^3a, NR³C(O)OR³, NR³C(O)R³, NR⁵NR⁵R^5a, ═O, OR³, COR³, CO₂R³, CONR³R^3a, NHC(O)NR³R^3a, NHC(S)NR³R^3a, SO₂NR³R^3a, SO₂R^3b, C_3-10carbocycle substituted with 0-5 R^a, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R³;

R ^3ais selected from the group: H, C_1-4alkyl, phenyl, and benzyl;

R ^3bis selected from the group: H, C_1-4alkyl, phenyl, and benzyl;

R ^3cis independently at each occurrence selected from the group: halo, —CN, N₃, NO₂, C_1-4alkyl, C_1-4haloalkyl, NR³R^3b, ═O, OR³, COR³, CO₂R³, CONR³R^3b, NHC(O)NR³R^3b, NHC(S)NR³R^3b, NR³C(O)OR³, NR³C(O)R³, SO₂NR³R³, SO₂R^3b, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

R ⁵is independently selected from the group: H, C_1-4alkyl, phenyl, and benzyl;

R ^5bis independently selected from the group: H, C_1-4alkyl, phenyl, and benzyl;

m is selected from 0, 1, 2, and 3.

In a more preferred embodiment, the present invention provides a novel compound of formula (I), wherein:

X is selected from the group: O and S;

R ¹is selected from the group: H, C_1-5alkyl substituted with 0-3 R^c, C_2-5alkenyl substituted with 0-3 R^c, —NHR⁴, C_3-6carbocycle substituted with 0-5 R^a, and 3-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 R^b;

R ²is selected from the group: H, C_1-5alkyl substituted with 0-3 R^c, C₂-s alkenyl substituted with 0-3 R^c, —(CF₂)_mCF₃, C_3-6carbocycle substituted with 0-5 R^a, and 3-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 R^b;

provided that if R ³is phenyl, it is substituted with 1-5 R^a;

provided that at least one R ³is present and that this R³is selected from the group: C_1-4alkyl substituted with 1-3 R⁶, C_5-10alkyl substituted with C_2-10alkenyl optionally substituted with 0-3 R⁶, C_2-10alkynyl substituted with 0-3 R⁶, (CF₂)_mCF₃, C_3-10carbocycle substituted with 0-5 R⁶, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R⁶;

R ^ais independently at each occurrence selected from the group: halo, —CN, N₃, C_1-4alkyl, C_1-4haloalkyl, NR³R^3a, NR³C(O)R³C(O)R³, OR³, COR³, CO₂R³, CONR³R^3a, NHC(O)NR³R^3a, SO₂NR³R^3a, SO₂R^3b, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

R ^bis independently at each occurrence selected from the group: halo, —CN, C_1-4alkyl, C_1-4haloalkyl, NR³R^3a, NR³C(O)OR³, NR³C(O)R³, OR³, COR³, CO₂R³, CONR³R^3a, NHC(O)NR³R^3a, SO₂NR³R^3a, and SO₂R^3b;

R ^cis independently at each occurrence selected from the group: halo, —CN, C_1-4alkyl, C_1-4haloalkyl, NR³R^3a, NR⁵NR⁵R^5a, NR³C(O)OR³, NR³C(O)R³, ═O, OR³, COR³, CO₂R³, CONR³R^3a, NHC(O)NR³R^3a, SO₂NR³R^3a, SO₂R^3b, C_3-10carbocycle substituted with 0-5 R^a, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R³;

R ^3ais selected from the group: H, C_1-4alkyl, phenyl, and benzyl;

alternatively, R ³and R^3a, together with the nitrogen atom to which they are attached, form a heterocycle having 5-6 atoms in the ring containing an additional 0-1 N, S, or O atom and substituted with 0-3 R^3c;

R ^3bis selected from the group: H, C_1-4alkyl, phenyl, and benzyl;

R ^3cis independently at each occurrence selected from the group: halo, —CN, N₃, NO₂, C_1-4alkyl, C_1-4haloalkyl, NR³R^3b, ═O, OR³, COR³, CO₂R³, CONR³R^3b, NHC(O)NR³R^3b, NHC(S)NR³R^3b, NR³C(O)OR³, NR³C(O)R³, SO₂NR³R^3b, SO₂R^3b, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

m is selected from 0, 1, 2, and 3.

In a even more preferred embodiment, the present invention provides a novel compound of formula (I), wherein:

X is selected from the group: O and S;

R ¹is selected from the group: H, C_1-5alkyl substituted with 0-2 R^c, —NHR⁴, C_3-6carbocycle substituted with 0-5 R^a, and 5-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 R^b;

R ²is selected from the group: H, C_1-5alkyl substituted with 0-3 R^c, —(CF₂)_mCF₃, C_3-6carbocycle substituted with 0-5 R^a, and 5-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-3 R^b;

R ³is selected from the group: H, halo, —CN, NO₂, C_1-4haloalkyl, NR⁵R^5a, NR⁵NR⁵R^5a, NR⁵C(O)OR⁵, NR⁵C(O)R⁵, ═O, OR⁵, COR⁵, CO₂R⁵, CONR⁵R^5a, NHC(O)NR⁵R^5a, NHC(S)NR⁵R^5a, SO₂NR⁵R^5a, SO₂R^5b, C_1-4alkyl, phenyl, benzyl, C_1-4alkyl substituted with 1-3 R^c, C_5-10alkyl substituted with C_2-10alkenyl optionally substituted with 0-3 R⁶, C_2-10alkynyl substituted with 0-3 R⁶, —(CF₂)_mCF₃, C_3-10carbocycle substituted with 0-5 R⁶, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R⁶; and

provided that if R ³is phenyl, it is substituted with 1-5 R^a;

R ^ais independently at each occurrence selected from the group: halo, —CN, N₃, C_1-4alkyl, C_1-4haloalkyl, NR³R^3a, NR³C(O)OR³, NR³C(O)R³, OR³, COR³, CO₂R³, CONR³R^3a, NHC(O)NR³R^3a, SO₂NR³R^3a, SO₂R^3b, and 5-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

R ^bis independently at each occurrence selected from the group: halo, C_1-4alkyl, C_1-4haloalkyl, NR³R^3a, NR³C(O)OR³, NR³C(O)R³, OR³, COR³, CO₂R³, CONR³R^3a, NHC(O)NR³R^3a, SO₂NR³R^3a, and SO₂R^3b;

R ^cis independently at each occurrence selected from the group: halo, C_1-4alkyl, C_1-4haloalkyl, NR³R^3a, NR⁵NR⁵R^5a, NR³C(O)OR³, NR³C(O)R³, OR³, COR³, CO₂R³, CONR³R^3a, NHC(O)NR³R^3a, SO₂NR³R^3a, SO₂R^3b, C_3-10carbocycle substituted with 0-5 R^a, and 5-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R³;

R ^3ais selected from the group: H, C_1-4alkyl, phenyl, and benzyl;

R ^3bis selected from the group: H, C_1-4alkyl, phenyl, and benzyl;

R ⁵is independently selected from the group: H and C_1-4alkyl;

R ^5bis independently selected from the group: H and C_1-4alkyl;

m is selected from 0, 1, 2, and 3.

In a most preferred embodiment, the compounds of formula (I) are selected from:

3-(4-methoxyphenyl)-5-(2-benzoylhydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

3-(4-methoxyphenyl)-5-(2-isonicotinoylhydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

3-(4-methoxyphenyl)-5-(2-nictinoylhydrazinecarbox amido)indeno[1,2-c]pyrazol-4-one;

3-(4-methoxyphenyl)-5-(2-(3,4-dihydroxybenzoyl)hydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

3-(4-methoxyphenyl)-5-(2-(4-hydroxybenzoyl)hydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

3-(4-methoxyphenyl)-5-(2-(3-aminobenzoyl)hydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

3-(4-methoxyphenyl)-5-(2-(4-aminobenzoyl)hydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

3-(4-methoxyphenyl)-5-(2-(2-aminobenzoyl)hydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

3-(4-methoxyphenyl)-5-(2-(4-N,N-dimethylaminobenzoyl) hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

3-(4-methoxyphenyl)-5-(2-phenethylacetylhydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

3-(4-methoxyphenyl)-5-(2-(2-hydroxybenzoyl)hydrazine carboxamido)indeno[1,2-c]pyrazol-4-one; and

3-(4-methoxyphenyl)-5-(2-methoxycarbonyl hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

or pharmaceutically acceptable salt form thereof.

Another embodiment of the present invention is a pharmaceutical composition comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula (I).

Another embodiment of the present invention is a method of treating cancer and proliferative diseases comprising: administering to a host in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically effective salt form thereof.

DEFINITIONS

As used herein, the following terms and expressions have the indicated meanings. The compounds of the present invention may contain an asymmetrically substituted carbon atom, and may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomer form is specifically indicated.

The term “alkyl” is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, and s-pentyl. In addition, the term is intended to include both unsubstituted and substituted alkyl groups, the latter referring to alkyl moieties having one or more hydrogen substituents replaced by, but not limited to halogen, hydroxyl, carbonyl, alkoxy, ester, ether, cyano, phosphoryl, amino, imino, amido, sulfhydryl, alkythio, thioester, sulfonyl, nitro, heterocyclo, aryl or heteroaryl. It will also be understood by those skilled in the art that the substituted moieties themselves can be substituted as well when appropriate.

The terms “halo” or “halogen” as used herein refer to fluoro, chloro, bromo and iodo. The term “aryl” is intended to mean an aromatic moiety containing the specified number of carbon atoms, such as, but not limited to phenyl, indanyl or naphthyl. The terms “cycloalkyl” and “bicycloalkyl” are intended to mean any stable ring system, which may be saturated or partially unsaturated. Examples of such include, but are not limited to, cyclopropyl, cyclopentyl, cyclohexyl, norbornyl, bicyclo[2.2.2]nonane, adamantly, or tetrahydronaphthyl (tetralin).

As used herein, “carbocycle” or “carbocyclic residue” is intended to mean any stable 3- to 7-membered monocyclic or bicyclic or 7- to 13-membered bicyclic or tricyclic, any of which may be saturated, partially unsaturated, or aromatic. Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl; [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, or tetrahydronaphthyl (tetralin).

As used herein, the term “heterocycle” or “heterocyclic system” is intended to mean a stable 5- to 7-membered monocyclic or bicyclic or 7- to 10-membered bicyclic heterocyclic ring which is saturated partially unsaturated or unsaturated (aromatic), and which consists of carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, O and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. If specifically noted, a nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1. As used herein, the term “aromatic heterocyclic system” is intended to mean a stable 5- to 7-membered monocyclic or bicyclic or 7- to 10-membered bicyclic heterocyclic aromatic ring which consists of carbon atoms and from 1 to 4 heterotams independently selected from the group consisting of N, O and S. It is preferred that the total number of S and O atoms in the aromatic heterocycle is not more than 1.

Examples of heterocycles include, but are not limited to, 1H-indazole, 2-pyrrolidonyl, 2H,6H-1,5,2-dithiazinyl, 2H-pyrrolyl, 3H-indolyl, 4-piperidonyl, 4aH-carbazole, 4H-quinolizinyl, 6H-1,2,5-thiadiazinyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, carbazolyl, 4aH-carbazolyl, b-carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinylperimidinyl, phenanthridinyl, phenanthrolinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, piperidonyl, 4-piperidonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, carbolinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, xanthenyl. Preferred heterocycles include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, indolyl, benzimidazolyl, 1H-indazolyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, or isatinoyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.

As used herein, “pharmaceutically acceptable salts” refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.

The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Company, Easton, Pa., 1990, p. 1445, the disclosure of which is hereby incorporated by reference.

The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit/risk ratio.

“Prodrugs”, as the term is used herein, are intended to include any covalently bonded carriers which release an active parent drug of the present invention in vivo when such prodrug is administered to a mammalian subject. Since prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (i.e., solubility, bioavailability, manufacturing, etc.) the compounds of the present invention may be delivered in prodrug form. Thus, the present invention is intended to cover prodrugs of the presently claimed compounds, methods of delivering the same, and compositions containing the same. Prodrugs of the present invention are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound. Prodrugs include compounds of the present invention wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when the prodrug of the present invention is administered to a mammalian subject, it cleaves to form a free hydroxyl, free amino, or free sulfydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate, and benzoate derivatives of alcohol and amine functional groups in the compounds of the present invention.

“Substituted” is intended to indicate that one or more hydrogens on the atom indicated in the expression using “substituted” is replaced with a selection from the indicated group(s), provided that the indicated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substituent is keto (i.e., ═O) group, then 2 hydrogens on the atom are replaced.

As used herein, the term “anti cancer” or “anti-proliferative” agent includes, but is not limited to, altretamine, busulfan, chlorambucil, cyclophosphamide, ifosfamide, mechlorethamine, melphalan, thiotepa, cladribine, fluorouracil, floxuridine, gemcitabine, thioguanine, pentostatin, methotrexate, 6-mercaptopurine, cytarabine, carmustine, lomustine, streptozotocin, carboplatin, cisplatin, oxaliplatin, iproplatin, tetraplatin, lobaplatin, JM216, JM335, fludarabine, aminoglutethimide, flutamide, goserelin, leuprolide, megestrol acetate, cyproterone acetate, tamoxifen, anastrozole, bicalutamide, dexamethasone, diethylstilbestrol, prednisone, bleomycin, dactinomycin, daunorubicin, doxirubicin, idarubicin, mitoxantrone, losoxantrone, mitomycin-c, plicamycin, paclitaxel, docetaxel, topotecan, irinotecan, 9-amino camptothecan, 9-nitro camptothecan, GS-211, etoposide, teniposide, vinblastine, vincristine, vinorelbine, procarbazine, asparaginase, pegaspargase, octreotide, estramustine, hydroxyurea.

SYNTHESIS

The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those methods described below. Each of the references cited below are hereby incorporated herein by reference.

An approach to preparing indeno[1,2-c]pyrazol-4-ones is presented in Scheme 1 and can be used to prepare compounds of the present invention. The nitro group of dimethyl 3-nitrophthalate was reduced to the amine using catalytic hydrogenation. The aniline was acylated using acetic anhydride and pyridine as a base. A mixture of the resulting acetamide 2 and an acetophenone were treated with a strong base in an appropriate solvent at elevated temperature to give the desired triketone 3. Additional means of preparing triketones are known to one skilled in the art as described in Kilgore et al, Industrial and Engineering Chemistry 34:494-497, 1946, the contents of which are hereby incorporated herein by reference. The triketone was treated with hydrazine at elevated temperature in an appropriate solvent to give the indeno[1,2-c]pyrazol-4-one ring system. Additional means of preparing indeno[1,2-c]pyrazol-4-ones are known to one skilled in the art as described in Lemke et al., J. Heterocyclic Chem. 19:1335-1340, 1982; Mosher and Soeder, J. Heterocyclic Chem. 8:855-59, 1971; Hrnciar and Svanygova Collect. Czech. Chem. Commun. 59:2734-40, 1994 the contents of which are hereby incorporated herein by reference. The amide was deacylated by heating with a strong acid in an appropriate solvent to give aniline 4. This aniline was acylated under standard conditions using an acid chloride in an appropriate solvent to give the desired product 5.

An alternative method for making compounds of the present invention is shown in Scheme 2. The intermediate triketone 3 can be deacylated with strong acid and reacylated with an appropriate acid chloride using methods known to those skilled in the art. Subsequently, triketone 6 can the be converted to the indeno[1,2-c]pyrazol-4-one ring system using the same conditions described previously in Scheme 1.

Another method for preparing the triketones 6 of Scheme 2 employs the condensation of a 1,3-diketone 6a with 3-nitrophthalic anhydride as described in Rotberg and Oshkaya, Zh. Organ. Khim. 8:84-87, 1972; Zh. Organ. Khim. 9:2548-2550, 1973, the contents of which are hereby incorporated herein by reference. The 1,3-diketones, when not commercially available can be readily prepared by one skilled in the art by the acetylation or trifluoroacetylation of the requisite methyl ketone, R¹COCH₃. Reduction of the nitro derivative 6b to the aniline 6c can be accomplished in a variety of ways including catalyic hydrogenation, treatment with zinc or iron under acidic conditions, or treatment with other reducing agents such as sodium dithionite or stannous chloride. Subsequently the aniline 6c can be converted to the indeno[1,2-c]pyrazol-4-ones of this invention by acylation followed by treatment with hydrazine as described previously in Scheme 2.

Another method for making the indeno[1,2-c]pyrazol-4-one ring system is shown in Scheme 4. Dimethyl hydrazine was reacted with 3-acetylpyridine with no solvent to give the hydrazone 7. This was treated in a similar fashion as described in Scheme 1 to give the desired intermediate 8. Additional means of preparing similar intermediates are known to one skilled in the art as described in Rappoport, J. Org. Chem. 49:2948-2953, 1984, the contents of which are hereby incorporated herein by reference. This intermediate was carried through the sequence in a similar fashion as described in Scheme 1.

Another approach to preparing indeno[1,2-c]pyrazol-4-ones is presented in Scheme 5 and can be used to prepare compounds of the present invention. Treating the intermediate 5-aminoindeno[1,2-c]pyrazol-4-one with 2-(trimethylsilyl) ethoxymethylmethyl chloride (SEMCL) and a suitable base in an inert solvent under reflux gives the SEM protected intermediate. The aniline is converted to the carbamate with phenylchloroformate using methods known to those skilled in the art. This intermediate is reacted with carbaztes in DMSO at elevated temperatures and then the SEM group is removed by treating with acid in a polar protic solvent to give the desired acylsemicarbazide-containing indenopyrazole analogs.

Other features of the invention will become apparent during the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.

EXAMPLES

Abbreviations used in the Examples are defined as follows: “° C.” for degrees Celsius, “CIMS” for chemical ionization mass spectroscopy, “eq” for equivalent or equivalents, “g” for gram or grams, “h” for hour or hours, “mg” for milligram or milligrams, “mL” for milliliter or milliliters, “mmol” for millimolar, “M” for molar, “min” for minute or minutes, “p-TsOH” for para-toluenesulphonic acid, “DMF” for dimethylformamide, and “TFA” for trifluoroacetic acid. [0141]

Example I

Preparation of 3-(4-methoxyphenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

[0142]
Step 1. Synthesis of 2 from dimethyl 3-nitrophthalate. [0143]
A solution of dimethyl 3-nitrophthalate (25 g, 105 mmol) in methanol (100 mL) was treated with 5% Pd/C (2.5 g) and hydrogenated on a Parr Shaker at 50 psi for 2 h. The solution was filtered (Celite), the filtrate collected and the solvent removed at reduced pressure. The residue was dissolved in acetic anhydride (20 mL) treated with pyridine (0.05 mL) and heated to 80° C. for 1 min. The reaction was cooled and stirred at 25° C. for 2 h. The solvent was removed at reduced pressure and the residue recrystallized from ethanol to give the product as a white solid (21 g, 79%). mp 104-105° C.; CIMS m/e calc'd for C[0144] ₁₂H₁₄NO₅: 252.0872, found 252.0888; Analysis calc'd for C₁₂H₁₃NO₅: C, 57.37; H, 5.22; N, 5.58; found: C, 57.67; H, 5.29; N, 5.77.
Step 2. Synthesis of Triketone 11 from 2. [0145]
A solution of 2 (1 g, 4.0 mmol) in dry DMF (2 mL) was treated with sodium hydride (0.15 g, 60% suspension in oil, 0.4 mmol) in one portion. After 1 h, 4-methoxyacetophenone (0.6 g, 4.0 mmol) was added in one portion and the reaction heated to 90° C. A second portion of sodium hydride (0.15 g, 60% suspension in oil, 0.4 mmol) was added and the exothermic reaction turns deep red. After 20 min, the reaction was cooled to 25° C., diluted with water (20 mL), extracted with EtOAc (10 mL) and the aqueous phase separated. The aqueous phase was acidified with 2 N HCl to pH 2 and the crude product collected. Recrystalization with ethanol gave the desired product as a yellow solid (0.4 g, 30%). mp 174-175° C.; CIMS m/e calc'd for C[0146] ₁₉H₁₆NO₅: 338.1028, found 338.1022; Analysis calc'd for C₁₉H₁₅NO₅: C, 67.65; H, 4.48; N, 4.15; found: C, 67.87; H, 4.29; N, 3.99.
Step 3. Synthesis of 12 from 11. [0147]
A solution of 11 (0.2 g, 0.6 mmol) in EtOH (5 mL) was treated with hydrazine hydrate (0.1 mL, 1.8 mmol) and p-TsOH (3 mg). The reaction was heated to reflux and stirred for 2 h. The reaction was cooled to 25° C. and the product collected as a yellow solid (0.1 g, 50%). mp 268° C.; CIMS m/e calc'd for C[0148] ₁₉H₁₆N₃O₃: 334.1192, found: 334.1168; Analysis calc'd for C₁₉H₁₅N₃O₃: C, 68.46; H, 4.54; N, 12.61; found: C, 68.81; H, 4.39; N, 12.45.

Example II

Preparation of 3-(4-methoxyphenyl)-5-(chloroacetamido)indeno[1,2-c]pyrazol-4-one

[0149]
Step 1. Synthesis of 13 from 12. [0150]
A suspension of 12 (1.0 g, 3.0 mmol) in MeOH (10 mL) was treated with conc. HCl (1 mL) and heated to reflux. After 2 h, the reaction was cooled and the product was collected as a greenish solid (0.7 g, 81%). mp 273° C.; CIMS m/e calc'd for C[0151] ₁₇H₁₄N₃O₂: 292.1086, found: 292.1080; Analysis calc'd for C₁₇H₁₃N₃O₂: C, 69.85; H, 4.83; N, 14.37; found: C, 69.99; H, 4.59; N, 14.44.
Step 2. Synthesis of 14 from 13. [0152]
A suspension of 13 (20 mg, 0.07 mmol) in dioxane (2 mL) was treated with aqueous sat. NaHCO[0153] ₃(1 mL) and chloroacetyl chloride (30 mL, 0.21 mmol). The reaction was heated to 50° C. and stirred for 2 h. The reaction was cooled, poured into water (2 mL), extracted with EtOAc (10 mL), the organic layer separated, dried (MgSO₄) and the solvent removed at reduced pressure. The solid residue was recrystallized from EtOH to give the product as a yellow solid (9 mg, 35%). mp 274° C.; CIMS m/e calc'd for C₁₉H₁₅N₃O₃Cl: 368.0802, found: 368.0818.

Example III

Preparation of 3-(4-methoxyphenyl)-5-(cyclopropylamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example II using cyclopropylacetyl chloride as the starting material. mp 289° C.; CIMS m/e calc'd for C[0154] ₂₁H₁₈N₃O₃: 360.1348, found: 360.1330.

Example IV

Preparation of 3-(4-methoxyphenyl)-5-(isopropylamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example II using isopropylacetyl chloride as the starting material. mp 288° C.; CIMS m/e calc'd for C[0155] ₂₁H₂₀N₃O₃: 362.1505, found: 362.1535.

Example V

Preparation of 3-(4-methoxyphenyl)-5-(ethylamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example II using propionyl chloride as the starting material. mp 287° C.; CIMS m/e calc'd for C[0156] ₂₀H₁₈N₃O₃: 348.1348, found: 348.1313.

Example VI

Preparation of 3-(4-methoxyphenyl)-5-(cyclopentylamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example II using cyclopentylacetyl chloride as the starting material. mp 267° C.; CIMS m/e calc'd for C[0157] ₂₃H₂₂N₃O₃: 388.1661, found: 388.1626.

Example VII

Preparation of 3-(4-methoxyphenyl)-5-(cyclobutylamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example II using cyclobutylacetyl chloride as the starting material. mp 297° C.; CIMS m/e calc'd for C[0158] ₂₂H₂₀N₃O₃: 374.1505, found: 374.1530.

Example VIII

Preparation of 3-(4-methoxyphenyl)-5-(phenylacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example II using phenylacetyl chloride as the starting material. mp 280° C.; CIMS m/e calc'd for C[0159] ₂₅H₂₀N₃O₃: 410.1505, found: 410.1533.

Example IX

Preparation of 3-(4-methoxyphenyl)-5-(butylamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example II using butyryl chloride as the starting material. mp 282° C.; CIMS m/e calc'd for C[0160] ₂₁H₂₀N₃O₃: 362.1505, found: 362.1500.

Example X

Preparation of 3-(4-methoxyphenyl)-5-((4-chlorophenyl)acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example II using 4-chlorophenylacetyl chloride as the starting material. mp 238° C.; CIMS m/e calc'd for C[0161] ₂₅H₁₉N₃O₃Cl: 444.1115, found: 444.1110.

Example XI

Preparation of 3-(4-methoxyphenyl)-5-((3-methoxyphenyl)acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example II using 3-methoxyphenylacetyl chloride as the starting material. mp>300° C.; CIMS m/e calc'd for C[0162] ₂₆H₂₂N₃O₄: 440.1610, found: 440.1620.

Example XII

Preparation of 3-(4-methoxyphenyl)-5-((4-methoxyphenyl)acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example II using 4-methoxyphenylacetyl chloride as the starting material. mp 280° C.; CIMS m/e calc'd for C[0163] ₂₆H₂₂N₃O₄: 440.1610, found: 440.1630.

Example XIII

Preparation of 3-(4-methoxyphenyl)-5-((3,4-dimethoxyphenyl)acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example II using 3,4-dimethoxyphenylacetyl chloride as the starting material. mp>300° C.; CIMS m/e calc'd for C[0164] ₂₇H₂₄N₃O₅: 470.1716, found: 470.1731.

Example XIV

Preparation of 3-(4-methoxyphenyl)-5-((2,5-dimethoxyphenyl)acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example II using 2,5-dimethoxyphenylacetyl chloride as the starting material. mp 226° C.; CIMS m/e calc'd for C[0165] ₂₇H₂₄N₃O₅: 470.1716, found: 470.1739.

Example XV

Preparation of 3-(2-methoxyphenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example I using 2-methoxyacetophenone as the starting material. mp 276° C.; CIMS m/e calc'd for C[0166] ₁₉H₁₆N₃O₃: 334.1192, found: 334.1169.

Example XVI

Preparation of 3-(3,4-dimethoxyphenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example I using 3,4-dimethoxyacetophenone as the starting material. mp>300° C.; CIMS m/e calc'd for C[0167] ₂₀H₁₈N₃O₄: 364.1297, found: 364.1288.

Example XVII

Preparation of 3-(4-methoxyphenyl)-5-((3,4-ethylenedioxyphenyl)acetamido)indeno[1,2-c]pyrazol-4-one

[0168]
Step 1. Synthesis of 15 from 11. [0169]
A suspension of 11 (5 g, 14.8 mmol) in MeOH (50 mL) was treated with conc. HCl (3 mL) and heated to reflux. After stirring for 2 h, the reaction was cooled to 0° C. and the product collected as a yellow solid (4.2 g, 96%). mp 173° C.; CIMS m/e calc'd for C[0170] ₁₇H₁₄NO₄: 296.0923, Found: 296.0901.
Step 2. Synthesis of 16 from 15. [0171]
A suspension of 15 (20 mg, 0.07 mmol) in acetone (2 mL) was treated with NaHCO[0172] ₃(10 mg) and the acid chloride of (3,4-methylenedioxyphenyl)acetic acid (prepared by heating the acid in a benzene:thionyl chloride 4:1 mixture at 50° C. for 2 h, removing the volatile components at reduced pressure, and using the crude acid chloride without further purification). The reaction was heated to 50° C. and stirred for 2 h. The reaction was cooled, poured into water (4 mL), extracted with EtOAc (10 mL), dried (MgSO₄), filtered and concentrated. The crude triketone was suspended in EtOH (2 mL), treated with hydrazine hydrate (0.05 mL) and p-TsOH (1 mg) and heated to reflux for 2 h. The reaction was cooled to 0° C. and the product filtered to give a yellow solid (6.5 mg, 20%). mp 297° C.; CIMS m/e calc'd for C₂₆H₂₀N₃O₅: 454.1403, Found: 454.1398.

Example XVIII

Preparation of 3-(4-dimethoxyphenyl)-5-((3-thiophene)acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XVII using the acid chloride of 3-thiopheneacetic acid as the starting material. mp 293° C.; CIMS m/e calc'd for C[0173] ₂₃H₁₈N₃O₃S: 416.1069, found: 416.1088.

Example XIX

Preparation of 3-(4-methoxyphenyl)-5-((2-methoxyphenyl)acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XVII using the acid chloride of 2-methoxyphenylacetic acid as the starting material. mp 255° C.; CIMS m/e calc'd for C[0174] ₂₆H₂₂N₃O₄: 440.1610, found: 440.1622.

Example XX

Preparation of 3-(4-methoxyphenyl)-5-((3,4-dichlorophenyl)acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XVII using the acid chloride of 3,4-dichlorophenylacetic acid as the starting material. mp 299° C.; CIMS m/e calc'd for C[0175] ₂₅H₁₈N₃O₃Cl₂: 478.0725, found: 478.0744.

Example XXI

Preparation of 3-(4-methoxyphenyl)-5-((2,4-dichlorophenyl)acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XVII using the acid chloride of 2,4-dichlorophenylacetic acid as the starting material. mp 286° C.; CIMS m/e calc'd for C[0176] ₂₅H₁₈N₃O₃Cl₂: 478.0725, found: 478.0734.

Example XXII

Preparation of 3-(4-methoxyphenyl)-5-((2-chlorophenyl)acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XVII using the acid chloride of 2-chlorophenylacetic acid as the starting material. mp 300° C.; CIMS m/e calc'd for C[0177] ₂₅H₁₉N₃O₃Cl: 444.1115, found: 444.1111.

Example XXIII

Preparation of 3-(4-methoxyphenyl)-5-(aminoacetamido)indeno[1,2-c]pyrazol-4-one

[0178]
A suspension of 14 (15 mg, 0.04 mmol) in EtOH (1 mL) was treated with conc. NH[0179] ₄OH (1 mL), placed in a sealed tube and heated to 80° C. for 3 h. The reaction was cooled and the solvent removed at reduced pressure. The residue was recrystallized from EtOH to give the product as a yellow solid (9 mg, 62%). mp>300° C.; CIMS m/e calc'd for C₂₀H₁₉N₄O₃: 363.1457, Found: 363.1431.

Example XXIV

Preparation of 3-(4-methoxyphenyl)-5-((2-hydroxyethyl)aminoacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII using hydroxylamine as the starting material. mp 243° C.; CIMS m/e calc'd for C[0180] ₂₁H₂₁N₄O₄: 393.1563, found: 393.1539.

Example XXV

Preparation of 3-(4-methoxyphenyl)-5-(N,N-dimethylaminoacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII using dimethylamine as the starting material. mp 279° C.; CIMS m/e calc'd for C[0181] ₂₁H₂₁N₄O₃: 377.1614, found: 377.1640.

Example XXVI

Preparation of 3-(4-methoxyphenyl)-5-(piperazinylacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII using piperazine as the starting material. mp 277° C.; CIMS m/e calc'd for C[0182] ₂₃H₂₄N₅O₃: 418.1879, found: 418.1899.

Example XXVII

Preparation of 3-(4-methoxyphenyl)-5-(4-methylpiperazinylacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII using 4-methylpiperizine as the starting material. mp>300° C.; CIMS m/e calc'd for C[0183] ₂₄H₂₆N₅O₃: 432.2036, found: 432.2030.

Example XXVIII

Preparation of 3-(4-methoxyphenyl)-5-(4-(2-hydroxyethyl)piperazinylacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII using 4-hydroxyethylpiperizine as the starting material. mp>300° C.; CIMS m/e calc'd for C[0184] ₂₅H₂₈N₅O₄: 462.2141, found: 462.2128.

Example XXIX

Preparation of 3-(4-methoxyphenyl)-5-(piperidinylacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII using piperidine as the starting material. mp 291° C.; CIMS m/e calc'd for C[0185] ₂₄H₂₅N₄O₃: 417.1927, found: 417.1955.

Example XXX

Preparation of 3-(4-methoxyphenyl)-5-(4-aminomethylpiperidinylacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII using 4-aminomethylpiperidine as the starting material. mp>300° C.; CIMS m/e calc'd for C[0186] ₂₅H₂₈N₅O₃: 446.2192, found: 446.2166.

Example XXXI

Preparation of 3-(4-methoxyphenyl)-5-(ethylaminoacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII using ethylamine as the starting material. mp 250° C.; CIMS m/e calc'd for C[0187] ₂₁H₂₁N₄O₃: 377.1614, found: 377.1644.

Example XXXII

Preparation of 3-(4-methoxyphenyl)-5-(thiomorpholinylacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII using thiomorpholine as the starting material. mp 298° C.; CIMS m/e calc'd for C[0188] ₂₃H₂₃N₄O₃S: 435.1491, found: 435.1477.

Example XXXIII

Preparation of 3-(4-methoxyphenyl)-5-(morpholinylacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII using morpholine as the starting material. mp 295° C.; CIMS m/e calc'd for C[0189] ₂₃H₂₃N₄O₄: 419.1719, found: 419.1744.

Example XXXIV

Preparation of 3-(4-methoxyphenyl)-5-(pyrrolidinylacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII using pyyrolidine as the starting material. mp 279° C.; CIMS m/e calc'd for C[0190] ₂₃H₂₃N₄O₃: 403.1770, found: 403.1761.

Example XXXV

Preparation of 3-(4-methoxyphenyl)-5-(4-pyridinylaminomethylacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII using 4-aminomethylpyridine as the starting material. mp>300° C.; CIMS m/e calc'd for C[0191] ₂₅H₂₂N₅O₃: 440.1723, found: 440.1762.

Example XXXVI

Preparation of 3-(4-methoxyphenyl)-5-((4-acetamidophenyl)acetamido)indeno[1,2-c]pyrazol-4-one

[0192]
A suspension of 18 (10 mg, 0.02 mmol) in dioxane (1 mL) was treated with aqueous sat. NaHCO[0193] ₃(0.5 mL) and acetyl chloride (0.01 mL) and heated at 50° C. for 1 h. The reaction was cooled, poured into water (5 mL), extracted with EtOAc (10 mL), the organic layer separated, dried (MgSO₄) and the solvent removed at reduced pressure. The residue was recrystallized from EtOH to give the product as a yellow solid (5.6 mg, 61%). mp 268° C.; CIMS m/e calc'd for C₂₇H₂₃N₄O₄: 467.1719, Found: 467.1730.

Example XXXVII

Preparation of 3-(4-methoxyphenyl)-5-((4-methoxycarbonylaminophenyl)acetamido) indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXXII using methylchloroformate as the starting material. mp 257° C.; CIMS m/e calc'd for C[0194] ₂₇H₂₃N₄O₅: 483.1668, found: 483.1633.

Example XXXVIII

Preparation of 3-(4-methoxyphenyl)-5-((4-aminomethylcarbonylaminophenyl)acetamido) indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII and XXXII using chloroacetyl chloride and conc. NH[0195] ₄OH as the starting materias. mp 228° C.; CIMS m/e calc'd for C₂₇H₂₄N₅O₄: 482.1828, found: 482.1844.

Example XXXIX

Preparation of 3-(4-methoxyphenyl)-5-((4-N,N-dimethylaminomethylcarbonylaminophenyl)acetamido) indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII and XXXII using chloroacetyl chloride and dimethyl amine as the starting materias. mp>300° C.; CIMS m/e calc'd for C[0196] ₂₉H₂₈N₅O₄: 510.2141, found: 510.2121.

Example XL

Preparation of 3-(4-methoxyphenyl)-5-((4-azidophenyl)acetamido)indeno[1,2-c]pyrazol-4-one

A solution of example XXXVI (20 mg, 0.04 mmol) in DMF (2 mL) was treated with 5% palladium on carbon (5 mg) and hydrogentaed at atmospheric pressure using a hydrogen baloon. After 2 h, the solution was filtered (Celite), and the solvent removed at reduced pressure. The residue was recrystallized from EtOH to give the product as a yellow solid (15 mg, 78%). mp>300° C.; CIMS m/e calc'd for C[0197] ₂₅H₁₉N₆O₃: 451.1519, found: 451.1544.

Example XLI

Preparation of 3-(4-methoxyphenyl)-5-((4-aminophenyl)acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXVII using the acid chloride of 4-azidophenylacetic acid as the starting material. mp 283° C.; CIMS m/e calc'd for C[0198] ₂₅H₂₁N₄O₃: 425.1614, found: 425.1643.

Example XLII

Preparation of 3-(4-methoxyphenyl)-5-(phenylcarbamoyl)aminoindeno [1,2-c]pyrazol-4-one

[0199]
Step 1. Synthesis of 20 from 15. [0200]
A suspension of 15 (0.5 g, 1.7 mmol) in acetone (10 mL) was treated with NaHCO[0201] ₃(0.5 g) and phenyl chloroformate. The mixture was heated to 50° C. for 2 h. The reaction was cooled, poured into water (20 mL), extracted with EtOAc (40 mL), the organic layer separated, dried (MgSO₄) and the solvent removed at reduced pressure. The residue was suspended in EtOH (10 mL) and treated with hydrazine hydrate (0.16 mL, 5.1 mmol) and p-TsOH (10 mg). The mixture was heated to reflux and stirred for 3 h. The reaction was cooled to 0° C. and the product collected as a yellow solid (0.25 g, 36%). mp 195° C.; CIMS m/e calc'd for C₂₄H₁₈N₃O₄: 412.1297, Found: 412.1308.
Step 2. Synthesis of 21 from 20. [0202]
A solution of 20 (20 mg, 0.05 mmol) in DMSO (2 mL) was treated with aniline (20 mL, mmol) and dimethylaminopyridine (1 mg). The mixture was heated to 80° C. for 2 h. The reaction was cooled, poured into water (4 mL), extracted with EtOAc (15 mL), the organic layer separated, dried (MgSO[0203] ₄) and the solvent removed at reduced pressure. The residue was recrystallized from EtOH to give the product as a yellow solid (9 mg, 44%). mp>300° C.; CIMS m/e calc'd for C₂₄H₁₉N₄O₃: 411.1457, Found: 411.1432.

Example XLIII

Preparation of 3-(4-methoxyphenyl)-5-(butylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XLII using butyl amine as the starting material. mp 252° C.; CIMS m/e calc'd for C[0204] ₂₁H₂₁N₄O₃: 377.1614, found: 377.1633.

Example XLIV

Preparation of 3-(4-methoxyphenyl)-5-(4-aminobenzylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XLII using 4-aminobenzyl amine as the starting material. mp>300° C.; CIMS m/e calc'd for C[0205] ₂₅H₂₂N₅O₃: 440.1723, found: 440.1700.

Example XLV

Preparation of 3-(4-methoxyphenyl)-5-(4-pyridylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XLII using 4-aminomethylpyridine as the starting material. mp>300° C.; CIMS m/e calc'd for C[0206] ₂₄H₂₀N₅O₃: 426.1566, found: 426.1533.

Example XLVI

Preparation of 3-(4-hydroxyphenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

[0207]
A suspension of 12 (20 mg, 0.07 mmol) in CH[0208] ₂Cl₂(2 mL) was treated with excess BBr₃(1.0 mL, 1.0 M in CH₂Cl₂) and stirred for 20 h. The reaction was slowly poured into aqueous sat. NaHCO₃(5 mL), extracted with EtOAc (10 mL), dried (MgSO₄) and concentrated. The residue was recrystallized from EtOH to give the desired product as a yellow solid (7.5 mg, 33%). mp>300° C.; CIMS m/e calc'd for C₁₈H₁₄N₃O₃: 320.1035, Found: 320.1050.

Example XLVII

Preparation of 3-(4-methoxyphenyl)-5-(formamido)indeno[1,2-c]pyrazol-4-one

[0209]
A suspension of 13 (20 mg, 0.06 mmol) in formic acid (2 mL) was heated to 100° C. for 2 h. The reaction mixture was cooled and the solvent removed at reduced pressure. The residue was recrystallized from EtOH to give the desired product as a yellow solid (12 mg, 63%). mp 280° C.; CIMS m/e calc'd for C[0210] ₁₈H₁₄N₃O₃: 320.1035, Found: 320.1040.

Example XLVIII

Preparation of 3-(3-pyridyl)-5-(acetamido)indeno [1,2-c]pyrazol-4-one

[0211]
Step 1. Synthesis of 24 from 3-acetylpyridine. [0212]
A solution of 3-acetylpyridine (1.0 g, 8.3 mmol) in benzene (3 mL) was treated with 1,1-dimethylhydrazine (0.62 mL, 8.3 mmol) and p-TsOH (5 mg). The mixture was heated to 85° C. and stirred for 3 h. The reaction was cooled and the solvent removed at reduced pressure. This crude hydrazone was treated with 1.0 M NaN(TMS)[0213] ₂in THF (16.6 mL, 16.6 mmol) at 25° C. over 5 min. After 30 min dimethyl 3-acetamidophthalate (2.1 g, 8.3 mmol) was added in one portion and the reaction heated to reflux. Stirring was continued for 6 h. The reaction was cooled and quenched by the slow addition of TFA. The solvent was removed at reduced pressure and the residue chromatographed (silica, 2.5-5% MeOH/CH₂Cl₂) to give the product as a yellow solid (0.35 g, 14%). mp 265° C.; CIMS m/e calc'd for C₁₇H₁₃N₂O₄: 309.0875, Found: 309.0888.
Step 2. Synthesis of 25 from 24. [0214]
A suspension of 24 (30 mg, 0.09 mmol) in EtOH (2 mL) was treated with hydrazine hydrate (0.05 mL) and p-TsOH (1 mg) and heated to reflux. After stirring for 2 h. the reaction was cooled and the product filtered to give a yellow solid (12 mg, 44%). mp>300° C.; CIMS m/e calc'd for C[0215] ₁₇H₁₃N₄O₂: 305.1039, Found: 305.1048.

Example XLIX

Preparation of 3-(4-pyridyl)-5-(acetamido)indeno [1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XLVIII using 4-acetylpyridine as the starting material. mp>300° C.; CIMS m/e calc'd for C[0216] ₁₇H₁₃N₄O₂: 305.1039, found: 305.1046.

Example L

Preparation of 3-(4-pyridyl)-5-(formamido)indeno [1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XLVII using 4-acetylpyridine as the starting material. mp>300° C.; CIMS m/e calc'd for C[0217] ₁₆H₁₁N₄O₂: 291.0882, found: 291.0882.

Example LI

Preparation of 3-phenyl-5-(acetamido)indeno [1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example I using acetophenone as the starting material. mp>300° C.; CIMS m/e calc'd for C[0218] ₁₈H₁₃N₃O₂: 304.1065, found: 304.1086.

Example LII

Preparation of 3-(4-methylthiophenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example I using 4′-methylthioacetophenone as the starting material. mp 283° C.; CIMS m/e calc'd for C[0219] ₁₉H₁₅N₃O₂S: 350.0956, found: 350.0963.

Example LIII

Preparation of 3-(4-methylsulphonylphenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

Prepared by oxidation of the product of example LII. mp>300° C.; CIMS m/e calc'd for C[0220] ₁₉H₁₅N₃O₄S: 382.0860, found: 382.0862.

Example LIV

Preparation of 3-(4-N,N-dimethylaminophenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example I using 4′-N,N,-dimethylaminoacetophenone as the starting material. mp>300° C.; CIMS m/e calc'd for C[0221] ₂₀H₁₈N₄O₂: 347.1496, found: 347.1508.

Example LV

Preparation of 3-(4-N,N-dimethylaminophenyl)-5-(morpholinylacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for examples II and XXIII employing the product of example LIV and morpholine as the starting materials. mp>300° C.; CIMS m/e calc'd for C[0222] ₂₄H₂₆N₅O₃: 432.2036, found: 432.2020.

Example LVI

Preparation of 3-(4-N,N-dimethylaminophenyl)-5-(dimethylaminoacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for examples II and XXIII employing the product of example LIV and dimethylamine as the starting materials. mp>300° C.; CIMS m/e calc'd for C[0223] ₂₂H₂₄N₅O₂: 390.1930, found: 390.1948.

Example LVII

Preparation of 3-(4-(1-piperidinyl)phenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example I using 4′-(1-piperidinyl)acetophenone as the starting material. mp 291° C.; CIMS m/e calc'd for C[0224] ₂₃H₂₂N₄O₂: 387.1801, found: 387.1821.

Example LVIII

Preparation of 3-(4-morpholinyl)phenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example I using 4′-morpholinylacetophenone as the starting material. mp>300° C.; CIMS m/e calc'd for C[0225] ₂₂H₂₀N₄O₃: 388.1528, found: 388.1535.

Example LIX

Preparation of 3-(4-ethoxyphenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example I using 4′-ethoxyacetophenone as the starting material. mp 288° C.; CIMS m/e calc'd for C[0226] ₂₀H₁₇N₃O₃: 348.1325, found: 348.1348.

Example LX

Preparation of 3-(4-butylphenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example I using 4′-butylacetophenone as the starting material. mp 259° C.; CIMS m/e calc'd for C[0227] ₂₂H₂₁N₃O₂: 360.1701, found: 360.1712.

Example LXI

Preparation of 3-(4-ethylphenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example I using 4′-ethylacetophenone as the starting material. mp 294° C.; CIMS m/e calc'd for C[0228] ₂₁H₁₇N₃O₂: 331.1310, found: 331.1321.

Example LXII

Preparation of 3-(4-n-propylphenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example I using 4′-n-propylacetophenone as the starting material. mp 269° C.; CIMS m/e calc'd for C[0229] ₂₁H₁₉N₃O₂: 346.1555, found: 346.1554.

Example LXIII

Preparation of 3-(4-methoxyphenyl)-5-carbamoylaminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XLII using concentrated ammonium hydroxide as the starting material. mp>300° C.; CIMS m/e calc'd for C[0230] ₁₈H₁₅N₄O₃: 335.1144, found: 335.1113.

Example LXIV

Preparation of 3-(4-methoxyphenyl)-5-(dimethylaminocarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XLII using dimethylamino hydrazine as the starting material. mp>300° C.; CIMS m/e calc'd for C[0231] ₂₀H₂₀N₅O₃: 378.1566, found: 378.1555.

Example LXV

Preparation of 3-(4-methoxyphenyl)-5-(methylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XLII using methylamine as the starting material. mp>300° C.; CIMS m/e calc'd for C[0232] ₁₉H₁₇N₄O₃: 349.1300, found: 349.1311.

Example LXVI

Preparation of 3-(4-methoxyphenyl)-5-(morpholinocarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XLII using N-aminomorpholine as the starting material. mp>300° C.; CIMS m/e calc'd for C[0233] ₂₂H₂₂N₅O₄: 420.1671, found: 420.1655.

Example LXVII

Preparation of 3-(4-methoxyphenyl)-5-(cis-2-aminocyclohexanylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XLII using cis-1,2-diaminocyclohexane as the starting material. mp>300° C.; CIMS m/e calc'd for C[0234] ₂₄H₂₆N₅O₃: 432.2035, found: 432.2020.

Example LXVIII

Preparation of 3-(4-methoxyphenyl)-5-(4-methylpiperazinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XLII using (4-amino)methylpiperazine as the starting material. mp>300° C.; CIMS m/e calc'd for C[0235] ₂₃H₂₅N₆O₃: 433.1987, found: 433.1999.

Example LXIX

Preparation of 3-(4-methoxyphenyl)-5-(4-uridomethylpiperadinylacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII using example XXX as the starting material. mp>300° C.; CIMS m/e calc'd for C[0236] ₂₆H₂₉N₆O₄: 489.2250, found: 489.2209.

Example LXX

Preparation of 3-(4-methoxyphenyl)-5-(4-(2-pyridyl)piperazinylacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII using 4-(2-pyridyl)piperazine as the starting material. mp>300° C.; CIMS m/e calc'd for C[0237] ₂₈H₂₇N₆O₃: 495.2144, found: 495.2111.

Example LXXI

Preparation of 3-(4-methoxyphenyl)-5-(4-(aminoethyl)piperazinylacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII using 4-(aminoethyl)piperazine as the starting material. mp>300° C.; CIMS m/e calc'd for C[0238] ₂₅H₂₉N₆O₃: 461.2300, found: 461.2333.

Example LXXII

Preparation of 3-(4-methoxyphenyl)-5-(4-amidopiperadinylacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII using isonipecotamide as the starting material. mp>300° C.; CIMS m/e calc'd for C[0239] ₂₅H₂₆N₅O₄: 460.1984, found: 460.1998.

Example LXXIII

Preparation of 3-(4-methoxyphenyl)-5-(4-hydroxypiperadinylacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII using 4-hydroxypiperadine as the starting material. mp>300° C.; CIMS m/e calc'd for C[0240] ₂₄H₂₅N₄O₄: 433.1875, found: 433.1844.

Example LXXIV

Preparation of 3-(4-methoxyphenyl)-5-(4-hydroxmethylypiperadinylacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII using 4-hydroxmethylypiperadine as the starting material. mp>300° C.; CIMS m/e calc'd for C[0241] ₂₅H₂₇N₄O₄: 447.2032, found: 447.2002.

Example LXXV

Preparation of 3-(4-methoxyphenyl)-5-(4-amidopiperazinylacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII using 4-amidopiperazine as the starting material. mp>300° C.; CIMS m/e calc'd for C[0242] ₂₄H₂₅N₆O₆: 493.1835, found: 493.1802.

Example LXXVI

Preparation of 3-(4-methoxyphenyl)-5-(4-dimethylaminopiperadinylacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII using 4-dimethylaminopiperadine as the starting material. mp>300° C.; CIMS m/e calc'd for C[0243] ₂₆H₃₀N₅O₅: 492.2246, found: 492.2220.

Example LXXVII

Preparation of 3-(4-methoxyphenyl)-5-(4-aminopiperadinylacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII using 4-aminopiperadine as the starting material. mp>300° C.; CIMS m/e calc'd for C[0244] ₂₄H₂₆N₅O₅: 464.1933, found: 464.1975.

Example LXXVIII

Preparation of 3-(4-(dimethylamino)phenyl)-5-((4-methyl-1-piperazinyl)acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for examples II and XXIII employing the product of example LIV and 1-methylpiperazine as the starting materials. mp>300° C.; ESI-MS m/e calc'd for C[0245] ₂₅H₂₉N₆O₂: 445.2352, found: 445.2359.

Example LXXIX

Preparation of 3-(4-(dimethylamino)phenyl)-5-((4-amino methyl-1-piperidinyl)acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for examples II and XXIII employing the product of example LIV and 4-(aminomethyl)piperidine as the starting materials. ESI-MS m/e calc'd for C[0246] ₂₆H₃₁N₆O₂: 459.2508, found: 459.2508.

Example LXXX

Preparation of 3-(4-(dimethylamino)phenyl)-5-((4-hydroxy-1-piperidinyl)acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for examples II and XXIII employing the product of example LIV and 4-hydroxypiperidine as the starting materials. mp 267° C.; ESI-MS m/e calc'd for C[0247] ₂₅H₂₈N₅O₃: 446.2192, found: 446.2206.

Example LXXXI

Preparation of 3-(4-(4-morpholinyl)phenyl)-5-(4-morpholinyl)acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for examples II and XXIII employing the product of example LVIII and morpholine as the starting materials. mp 258° C.; ESI-MS m/e calc'd for C[0248] ₂₆H₂₈N₅O₄: 474.2141, found: 474.2151.

Example LXXXII

Preparation of 3-(4-(4-morpholinyl)phenyl)-5-((4-methyl-1-piperazinyl)acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for examples II and XXIII employing the product of example LVIII and 1-methylpiperazine as the starting materials. mp 258° C.; ESI-MS m/e calc'd for C[0249] ₂₇H₃₁N₆O₃: 487.2457, found: 487.2447.

Example LXXXIII

Preparation of 3-(4-(4-morpholinyl)phenyl)-5-((4-hydroxy-1-piperidinyl)acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for examples II and XXIII employing the product of example LVIII and 4-hydroxypiperidine as the starting materials. mp 245° C.; ESI-MS m/e calc'd for C[0250] ₂₇H₃₀NSO₄: 488.2298, found: 488.2290.

Example LXXXIV

Preparation of 3-(4-(4-morpholinyl)phenyl)-5-((4-amino methyl-1-piperidinyl)acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for examples II and XXIII employing the product of example LVIII and 4-(aminomethyl)piperidine as the starting materials. mp 240° C.; ESI-MS m/e calc'd for C[0251] ₂₈H₃₃N₆O₃: 501.2614, found: 501.2619.

Example LXXXV

Preparation of 3-(4-(dimethylamino)phenyl)-5-((((4-methyl-1-piperazinyl)amino)carbonyl)amino)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for examples I, XXVII, and XLII employing the 4-(dimethylamino) acetophenone and l-amino-4-methylpiperazine as the starting materials. mp>300° C.; ESI-MS m/e calc'd for C[0252] ₂₄H₂₈N₇O₂: 446.2304, found: 446.2310.

Example LXXXVI

Preparation of 3-(i-propyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

[0253]
Step 1. Synthesis of 26 from 3-nitrophthalic Anhydride. [0254]
A solution of 3-nitrophthalic anhydride (9.7 g, 50 mmol) and 1,1,1-trifluoro-5-methyl-2,4-hexanedione (9.1 g, 50 mmol) in acetic anhydride (28.3 mL, 300 mmol) was treated with triethylamine (13.95 mL, 100 mmol) and stirred at 25° C. for 4 h. The solution was diluted with 1 N HCl (200 mL) and the precipate collected and washed with water (200 mL) and hexane (400 mL) to give the product as a yellow solid (11.1 g, 85%). mp 127-129° C.; CIMS (M+H) calc'd for C[0255] ₁₃H₁₂NO₅: 262.0715, found: 262.0694.
Step 2. Synthesis of Triketone 27 from 26. [0256]
A solution of 26 (11 g, 42 mmol) in EtOH (224 mL) and water (56 mL) was treated with zinc (90 g, 1.4 mol) and calcium chloride (3 g, 27 mmol) and heated to reflux for 16 h. The reaction was filtered (Celite) and the filtrate was concentrated at reduced pressure to give an aqueous residue which was extracted with EtOAc (100 mL). The organic layer was separated and washed with sat. EDTA (100 ml) and brine (100 mL), dried (MgSO[0257] ₄), filtered, and concentrated at reduced pressure to give a yellow solid. Trituration with hexane gave the product as a yellow solid (7.1 g, 73%). mp 241-243° C.; CIMS (M+H) calc'd for C₁₃H₁₄NO₃: 232.0974, found: 232.0962.
Step 3. Synthesis of 28 from 27. [0258]
A solution of 27 (500 mg, 2.16 mmol) in CH[0259] ₂Cl₂(5 mL) was treated with Et₃N (0.36 mL, 2.59 mmol) and stirred at 25° C. for 15 min. The reaction mixture was treated with acetyl chloride (0.18 mL, 2.38 mmol) and stirred at 25° C. for 1 h. The reaction mixture was quenched with 1 N HCl (20 mL) and extracted with EtOAc (20 mL). The organic layer was separated, dried (MgSO₄), filtered, and concentrated at reduced pressure to give a brown residue. Trituration with hexane gave the product as a tan solid (484 mg, 82%). mp 241-243° C.; CIMS (M+H) calc'd for C₁₅H₁₆NO₄: 274.1079, found: 274.1093.
Step 4. Synthesis of 29 from 28. [0260]
A solution of 28 (240 mg, 0.88 mmol) in BuOH (5 mL) was treated with hydrazine hydrate (0.055 mL, 1.76 mmol) and p-TsOH (8.4 mg, 0.044 mmol). The reaction was heated to reflux and stirred for 4 h. The reaction was cooled to 25° C. and the solvent removed at reduced pressure. Recrystalization with i-propyl alcohol gave the product collected as an off-white solid (173 mg, 73%). mp>250° C.; ESIMS (M+H) calc'd for C[0261] ₁₅H₁₆N₃O₂: 270.1242, found: 270.1258.

Example LXXXVII

Preparation of 3-(c-propyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using the c-propyl analog of 26 as the starting material. mp 220-221° C.; CIMS (M+H) calc'd for C[0262] ₁₅H₁₄N₃O₂: 268.1086, found: 268.1078.

Example LXXXVIII

Preparation of 3-(t-butyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using the t-butyl analog of 26 as the starting material. mp>250° C.; CIMS (M+H) calc'd for C[0263] ₁₆H₁₈N₃O₂: 284.1399, found: 284.1395.

Example LXXXIX

Preparation of 3-(2-thienyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using the 2-thienyl analog of 26 as the starting material. mp 269° C.; CIMS (M+H) calc'd for C[0264] ₁₆H₁₂N₃O₂S: 310.0650, found: 310.0635.

Example XC

Preparation of 3-(3-methyl-2-thienyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using the 3-methyl-2-thienyl analog of 26 as the starting material. mp 275° C.; ESIMS (M+H) calc'd for C[0265] ₁₇H₁₄N₃O₂S: 324.0811, found: 324.0807.

Example XCI

Preparation of 3-(ethyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using ammonia and the ethyl analog of 15 as the starting materials. mp>250° C.; CIMS (M+H) calc'd for C[0266] ₁₃H₁₃N₄O₂: 257.1039, found: 257.1033.

Example XCII

Preparation of 3-(n-propyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using ammonia and the n-propyl analog of 15 as the starting materials. mp 187-189° C.; CIMS (M+H) calc'd for C[0267] ₁₄H₁₅N₄O₂: 271.1195, found: 271.1187.

Example XCIII

Preparation of 3-(i-propyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using ammonia and the i-propyl analog of 15 as the starting materials. mp>250° C.; CIMS (M+H) calc'd for C[0268] ₁₄H₁₅N₄O₂: 271.1195, found: 271.1196.

Example XCIV

Preparation of 3-(c-propyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using ammonia and the c-propyl analog of 15 as the starting materials. mp 252-253° C.; ESIMS (M−H) calc'd for C[0269] ₁₄H₁₁N₄O₂: 267.0881, found: 267.0884.

Example XCV

Preparation of 3-(c-hexyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using ammonia and the c-hexyl analog of 15 as the starting materials. mp 178-179° C.; ESIMS (M+H) calc'd for C[0270] ₁₇H₁₉N₄O₂: 311.1507, found: 311.1500.

Example XCVI

Preparation of 3-(2-thienyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using ammonia and the 2-thienyl analog of 15 as the starting materials. mp 214° C.; CIMS m+calc'd for C[0271] ₁₅H₁₀N₄O₂S: 310.0517, found: 310.0524.

Example XCVII

Preparation of 3-(3-methyl-2-thienyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using ammonia and the 3-methyl-2-thienyl analog of 15 as the starting materials. mp 270° C.; ESIMS (M+H) calc'd for C[0272] ₁₆H₁₃N₄O₂S: 325.0759, found: 325.0744.

Example XCVIII

Preparation of 3-(5-methyl-2-thienyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using ammonia and the 5-methyl-2-thienyl analog of 15 as the starting materials. mp>280° C.; ESIMS (M+H) calc'd for C[0273] ₁₆H₁₃N₄O₂S: 325.0759, found: 325.0761.

Example XCIX

Preparation of 3-(5-ethylcarboxyl-2-thienyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using ammonia and the 5-ethylcarboxyl-2-thienyl analog of 15 as the starting materials. mp>280° C.; ESIMS (M+H) calc'd for C[0274] ₁₈H₁₅N₄O₄S: 383.0813, found: 383.0788.

Example C

Preparation of 3-(3-thienyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using ammonia and the 3-thienyl analog of 15 as the starting materials. mp>280° C.; ESIMS (M+H) calc'd for C[0275] ₁₅H₁₁N₄O₂S: 311.0603, found: 311.0594.

Example CI

Preparation of 3-(5-chloro-3-thienyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using ammonia and the 5-chloro-3-thienyl analog of 15 as the starting materials. mp>300° C.; ESIMS (M+H) calc'd for C[0276] ₁₅H₁₀N₄O₂SCl: 345.0209, found: 345.0213.

Example CII

Preparation of 3-(2,5-dimethyl-3-thienyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using ammonia and the 2,5-dimethyl-3-thienyl analog of 15 as the starting materials. mp>280° C.; ESIMS (M+H) calc'd for C[0277] ₁₇H₁₅N₄O₂S: 339.0916, found: 339.0905.

Example CIII

Preparation of 3-(2-furanyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using ammonia and the 2-furanyl analog of 15 as the starting materials. mp 278° C.; ESIMS (M+H) calc'd for C[0278] ₁₅H₁₁N₄O₃: 295.0831, found: 295.0838.

Example CIV

Preparation of 3-(i-propyl)-5-(N,N-dimethylaminocarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using 1,1-dimethylhydrazine and the i-propyl analog of 15 as the starting materials. mp 231-233° C.; ESIMS (M+H) calc'd for C[0279] ₁₆H₂₀N₅O₂: 314.1616, found: 314.1599.

Example CV

Preparation of 3-(c-propyl)-5-(N,N-dimethylaminocarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using 1,1-dimethylhydrazine and the c-propyl analog of 15 as the starting materials. mp XXX ° C.; ESIMS (M+H) calc'd for C[0280] ₁₆H₁₈N₅O₂: 312.1460, found: 312.1487.

Example CVI

Preparation of 3-(c-hexyl)-5-(N,N-dimethylaminocarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using 1,1-dimethylhydrazine and the c-hexyl analog of 15 as the starting materials. mp 229-231° C.; ESIMS (M+H) calc'd for C[0281] ₁₉H₂₄N₅O₂: 354.1929, found: 354.1932.

Example CVII

Preparation of 3-(2-thienyl)-5-(N,N-dimethylaminocarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using 1,1-dimethylhydrazine and the 2-thienyl analog of 15 as the starting materials. mp 279° C.; ESIMS (M+H) calc'd for C[0282] ₁₇H₁₆N₅O₂S: 354.1024, found: 354.1025.

Example CVIII

Preparation of 3-(5-methoxy-2-thienyl)-5-(N,N-dimethylaminocarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using 1,1-dimethylhydrazine and the 5-methoxy-2-thienyl analog of 15 as the starting materials. mp 280° C.; ESIMS (M+H) calc'd for C[0283] ₁₈H₁₈N₅O₃S: 384.1130, found: 384.1119.

Example CIX

Preparation of 3-(5-methyl-2-thienyl)-5-(N,N-dimethylaminocarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using 1,1-dimethylhydrazine and the 5-methyl-2-thienyl analog of 15 as the starting materials. mp>280° C.; ESIMS (M+H) calc'd for C[0284] ₁₈H₁₈N₅O₂S: 368.1181, found: 368.1171.

Example CX

Preparation of 3-(5-ethylcarboxyl-2-thienyl)-5-(N,N-dimethylaminocarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using 1,1-dimethylhydrazine and the 5-ethylcarboxyl-2-thienyl analog of 15 as the starting materials. mp 252° C.; ESIMS (M+H) calc'd for C[0285] ₂₀H₂₀N₅O₄S: 426.1236, found: 426.1251.

Example CXI

Preparation of 3-(3-thienyl)-5-(N,N-dimethylaminocarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using 1,1-dimethylhydrazine and the 3-thienyl analog of 15 as the starting materials. mp 202° C.; ESIMS (M+H) calc'd for C[0286] ₁₇H₁₆N₅O₂S: 354.1025, found: 354.1031.

Example CXII

Preparation of 3-(1-methyl-3-pyrrolyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using ammonia and the 1-methyl-3-pyrrolyl analog of 15 as the starting materials. mp>300° C.; ESIMS (M+H) calc'd for C[0287] ₁₆H₁₄N₅O₂: 308.1147, found: 308.1166.

Example CXIII

Preparation of 3-(2,5-dimethyl-3-thienyl)-5-(N,N-dimethylaminocarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using 1,1-dimethylhydrazine and the 2,5-dimethyl-3-thienyl analog of 15 as the starting materials. mp 252° C.; ESIMS (M+H) calc'd for C[0288] ₁₉H₂₀NSO₂S: 382.1338, found: 382.1357.

Example CXIV

Preparation of 3-(2-furanyl)-5-(N,N-dimethylaminocarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using 1,1-dimethylhydrazine and the 2-furanyl analog of 15 as the starting materials. mp 202° C.; ESIMS (M+H) calc'd for C[0289] ₁₇H₁₆N₅O₃: 338.1253, found: 338.1248.

Example CXV

Preparation of 3-(i-propyl)-5-(4-carbamoylpiperidinylacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII using isonipecotamide and the i-propyl analog of 14 as the starting materials. mp 224-225° C.; ESIMS (M+H) calc'd for C[0290] ₂₁H₂₆N₅O₃: 396.2035, found: 396.2036.

Example CXVI

Preparation of 3-(c-hexyl)-5-(4-carbamoylpiperidinylacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII using isonipecotamide and the c-hexyl analog of 14 as the starting materials. mp 228-229° C.; ESIMS (M+H) calc'd for C[0291] ₂₄H₃₀N₅O₃: 436.2348, found: 436.2345.

Example CXVII

Preparation of 3-(ethyl)-5-(4-aminomethylpiperidinylacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII using 4-(aminomethyl)piperidine and the ethyl analog of 14 as the starting materials. mp 174-176° C.; ESIMS (M+H) calc'd for C[0292] ₂₀H₂₆N₅O₂: 368.2086, found: 368.2078.

Example CXVIII

Preparation of 3-(i-propyl)-5-(4-aminomethylpiperidinylacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII using 4-(aminomethyl)piperidine and the i-propyl analog of 14 as the starting materials. mp 218-220° C.; ESIMS (M+H) calc'd for C[0293] ₂₁H₂₈N₅O₂: 382.2242, found: 382.2227.

Example CXIX

Preparation of 3-(c-propyl)-5-(4-aminomethylpiperidinylacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII using 4-(aminomethyl)piperidine and the c-propyl analog of 14 as the starting materials. mp 138-140° C.; ESIMS (M+H) calc'd for C[0294] ₂₁H₂₆N₅O₂: 380.2086, found: 380.2079.

Example CXX

Preparation of 3-(c-hexyl)-5-(4-aminomethylpiperidinylacetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example XXIII using 4-(aminomethyl)piperidine and the c-hexyl analog of 14 as the starting materials. mp 196-198° C.; ESIMS (M+H) calc'd for C[0295] ₂₄H₃₂N₅O₂: 422.2555, found: 422.2540.

Example CXXI

Preparation of 3-(i-propyl)-5-(4-methylpiperazinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using 1-amino-4-methylpiperazine and the i-propyl analog of 15 as the starting materials. mp 231-233° C.; ESIMS (M+H) calc'd for C[0296] ₁₉H₂₅N₆O₂: 369.2038, found: 369.2039.

Example CXXII

Preparation of 3-(5-ethylcarboxyl-2-thienyl)-5-(4-methylpiperazinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using 1-amino-4-methylpiperazine and the 5-ethylcarboxyl-2-thienyl analog of 15 as the starting materials. mp 249° C.; ESIMS (M+H) calc'd for C[0297] ₂₃H₂₅N₆O₄S: 481.1657, found: 481.1642.

Example CXXIII

Preparation of 3-(5-carboxyl-2-thienyl)-5-(4-methylpiperazinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

A solution of CXXII (30 mg, 0.05 mmol) in 3:1 THF/water (2 mL) was treated with LiOH (23 mg, 0.5 mmol) and the reaction was stirred at 25° C. for 12 h and then heated to reflux for 1 h. The organic solvent was removed at reduced pressure and the residue was partioned between EtOAc (5 mL) and water (5 mL). The organic layer was separated and the aqueous phase was adjusted to pH=2 with 1 M HCl and re-extracted with EtOAc (5 mL). The combined organic layers were dried (Na[0298] ₂SO₄), filtered and concentrated at reduced pressure to give a crude residue. Purification by reverse phase HPLC gave the product as a yellow solid (10.4 mg, 46%). mp 270° C.; ESIMS (M+H) calc'd for C₂₁H₂₁N₆O₄S: 453.1344, found: 453.1353.

Example CXXIV

Preparation of 3-(2,5-dimethyl-3-thienyl)-5-(4-methylpiperazinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using 1-amino-4-methylpiperazine and the 2,5-dimethyl-3-thienyl analog of 15 as the starting materials. mp 250° C.; ESIMS (M+H) calc'd for C[0299] ₂₂H₂₅N₆O₂S: 437.1760, found: 437.1771.

Example CXXV

Preparation of 3-(i-propyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using 4-aminomorpholine and the i-propyl analog of 15 as the starting materials. mp 256-258° C.; ESIMS (M−H) calc'd for C[0300] ₁₈H₂₀N₅O₃: 354.1566, found: 354.1543.

Example CXXVI

Preparation of 3-(N-methylcarbamoyl-4-piperidinyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using 4-aminomorpholine and the N-methylcarbamoyl-4-piperidinyl analog of 15 as the starting materials. mp 216-218° C.; ESIMS (M+H) calc'd for C[0301] ₂₂H₂₇N₆O₅: 455.2042, found: 455.2036.

Example CXXVII

Preparation of 3-(5-methyl-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using 4-aminomorpholine and the 5-methyl-2-thienyl analog of 15 as the starting materials. mp 261° C.; ESIMS (M+H) calc'd for C[0302] ₂₀H₂₀N₅O₃S: 410.1287, found: 410.1308.

Example CXXVIII

Preparation of 3-(5-chloro-3-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using 4-aminomorpholine and the 5-chloro-3-thienyl analog of 15 as the starting materials. mp 259° C.; ESIMS (M+H) calc'd for C[0303] ₁₉H₁₇N₅O₃SCl: 430.0741, found: 430.0757.

Example CXXIX

Preparation of 3-(2,5-dimethyl-3-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using 4-aminomorpholine and the 2,5-dimethyl-3-thienyl analog of 15 as the starting materials. mp>280° C.; ESIMS (M+H) calc'd for C[0304] ₂₁H₂₂N₅O₃S: 424.1443, found: 424.1431.

Example CXXX

Preparation of 3-(5-ethylcarboxyl-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI using 4-aminomorpholine and the 5-ethylcarboxyl-2-thienyl analog of 15 as the starting materials. mp 258° C.; ESIMS (M+H) calc'd for C[0305] ₂₂H₂₂N₅O₅S: 468.1341, found: 468.1331.

Example CXXXI

Preparation of 3-(5-carboxyl-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI (HYDROLYSIS OF PREVIOUS ESTER). mp 273° C.; ESIMS (M+H) calc'd for C[0306] ₂₀H₁₈N₅O₅S: 440.1028, found: 440.1026.

Example CXXXII

Preparation of 3-(5-benzylcarboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

A solution of benzylamine (0.01 mL, 0.09 mmol) in DMF (1 mL) was treated with acid CXXXI (40 mg, 0.09 mmol) and stirred at 25° C. The reaction was treated with TBTU (29 mg, 0.09 mmol) and stirred at 25° C. for 30 min. Triethylamine (0.01 mL, 0.09 mmol) was added and the reaction stirred at 25° C. for 12 h. After adding more TBTU (15 mg, 0.045 mmol) and triethylamine (0.01 mL, 0.09 mmol) the reaction was stirred at 25° C. for an additional 4 h. The reaction was diluted with EtOAc (10 mL) and water (10 mL) and the aqueous layer was extracted with EtOAc (5×10 mL). The combined organic layers were dried (Na[0307] ₂SO₄), filtered, and the solvent removed at reduced pressure. Purification of the residue using reverse phase HPLC gave the product as a yellow solid (21 mg, 42%). mp 275° C.; ESIMS (M+H) calc'd for C₂₇H₂₅N₅O₄S: 529.1659, found: 529.1682.

Example CXXXIII

Preparation of 3-(5-(4-methylpiperazinyl)carboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example CXXXII using 1-amino-4-methylpiperazine as the starting material. mp 190° C.; ESIMS (M+H) calc'd for C[0308] ₂₅H₂₉N₈O₄S: 537.2032, found: 537.2055.

Example CXXXIV

Preparation of 3-(5-(2-(1-methylpyrrolidinyl)ethyl)carboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example CXXXII using 2-(2-aminoethyl)-1-methylpyrrolidine as the starting material. mp 235° C.; ESIMS (M+H) calc'd for C[0309] ₂₇H₃₂N₇O₄S: 550.2236, found: 550.2229.

Example CXXXV

Preparation of 3-(5-(N,N-dimethylamino)carboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example CXXXII using 1,1-dimethylhydrazine as the starting material. mp 201° C.; ESIMS (M+H) calc'd for C[0310] ₂₂H₂₄N₇O₄S: 482.1610, found: 482.1588.

Example CXXXVI

Preparation of 3-(5-(2-(N,N-dimethylamino)ethyl)carboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example CXXXII using N,N-dimethylethylenediamine as the starting material. mp 190° C.; ESIMS (M+H) calc'd for C[0311] ₂₄H₂₈N₇O₄S: 510.1923, found: 510.1922.

Example CXXXVII

Preparation of 3-(5-(2-(pyrrolidinyl)ethyl)carboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example CXXXII using 1-(2-aminoethyl)pyrrolidine as the starting material. mp 224° C.; ESIMS (M+H) calc'd for C[0312] ₂₆H₃₀N₇O₄S: 536.2080, found: 536.2091.

Example CXXXVIII

Preparation of 3-(5-(2-(morpholinyl)ethyl)carboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example CXXXII using 4-(2-aminoethyl)morpholine as the starting material. mp 241° C.; ESIMS (M+H) calc'd for C[0313] ₂₆H₃₀N₇O₅S: 552.2029, found: 552.2043.

Example CXXXIX

Preparation of 3-(5-morpholinylcarboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example CXXXII using 4-aminomorpholine as the starting material. mp 271° C.; ESIMS (M+H) calc'd for C[0314] ₂₄H₂₆N₇O₅S: 524.1716, found: 524.1719.

Example CXL

Preparation of 3-(5-(3-(pyrrolidonyl)propyl)carboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example CXXXII using 1-(3-aminopropyl)-2-pyrrolidinone as the starting material. mp 260° C.; ESIMS (M+H) calc'd for C[0315] ₂₇H₃₀N₇O₅S: 564.2029, found: 564.2031.

Example CXLI

Preparation of 3-(5-(2-(3-pyridyl)ethyl)carboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example CXXXII using 3-(2-aminoethyl)pyridine as the starting material. mp 203° C.; ESIMS (M+H) calc'd for C[0316] ₂₇H₂₆N₇O₄S: 544.1766, found: 544.1760.

Example CXLII

Preparation of 3-(5-(3-(imidazolyl)propyl)carboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example CXXXII using 1-(3-aminopropyl)imidazole as the starting material. mp 263° C.; ESIMS (M+H) calc'd for C[0317] ₂₆H₂₇N₈O₄S: 547.1875, found: 547.1872.

Example CXLIII

Preparation of 3-(5-(2-(2-pyridyl)ethyl)carboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example CXXXII using 2-(2-aminoethyl)pyridine as the starting material. mp>280° C.; ESIMS (M+H) calc'd for C[0318] ₂₇H₂₆N₇O₄S: 544.1767, found: 544.1778.

Example CXLIV

Preparation of 3-(5-((2-pyridyl)methyl)carboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example CXXXII using 2-(aminomethyl)pyridine as the starting material. mp 239° C.; ESIMS (M+H) calc'd for C[0319] ₂₆H₂₄N₇O₄S: 530.1610, found: 530.1603.

Example CXLV

Preparation of 3-(5-(2-(piperidinyl)ethyl)carboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example CXXXII using 1-(2-aminoethyl)piperidine as the starting material. mp 228° C.; ESIMS (M+H) calc'd for C[0320] ₂₇H₃₂N₇O₄S: 550.2236, found: 550.2236.

Example CXLVI

Preparation of 3-(4-(trifluoromethyl)phenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example LXXXVI employing 1-(4-(trifluoromethyl)phenyl)-4,4,4-trifluoro-1,3-butanedione as the starting material. mp>300° C.; ESI[0321] ⁻-MS m/e calc'd for C₁₉H₁₁N₃O₂: 370.0804, found: 370.0809.

Example CXLVII

Preparation of 3-(4-(4-t-butoxycarbonyl-1-piperazinyl)phenyl)-5-(((4-morpholinylamino)carbonyl)amino)indeno[1,2-c]pyrazol-4-one

[0322]
Step 1. Synthesis of 30. [0323]
A solution of 4-piperazinoacetophenone (24.8 g, 121 mmol) and di-tert-butyl dicarbonate (27.8 g, 128 mmol) in 480 mL of tetrahydrofuran was refluxed for 16 h. After cooling to room temperature the solution was concentrated under vacuum. The resulting solids were washed with hexane and dried under vacuum to afford 29.4 g (80%) of the product as an off-white solid. NMR (CDCl[0324] ₃) δ 7.89 (d, 2H, J=9 Hz), 6.87 (d, 2H, J=9 Hz), 3.59 (m, 4H), 3.33 (m, 4H), 2.53 (s, 3H), 1.49 (s, 9H)
Step 2. Synthesis of 31 from 30. [0325]
To a solution of 30 (11.35 g, 37 mmol) and ethyl trifluoroacetate (5.40 mL, 45 mmol) in 50 mL of tetrahydrofuran at 25° C. was added dropwise over 15 min. 21% sodium ethoxide in ethanol (16.8 mL, 45 mmol), and the resulting solution then was stirred at 25° C. for 14 h. The reaction mixyure was diluted with water, adjusted to pH 5 with conc. hydrochloric acid, and extracted with ethyl acetate. The combined extracts was washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The resulting solid was washed with diethyl ether and dried to furnish 12.1 g (81%) of the product as an orange solid. NMR (CDCl[0326] ₃) δ 7.87 (d, 2H, J=9 Hz), 6.87 (d, 2H, J=9 Hz), 6.45 (s, 1H), 3.60 (m, 4H), 3.41 (m, 4H), 1.48 (s, 9H).
Step 3. Synthesis of CXLVII from 31. [0327]
Prepared in a similar fashion as described for examples LXXVI and XLII employing 31 and 4-aminomorpholine as starting materials. mp 242° C.; ESI-MS m/e calc'd for C[0328] ₃₀H₃₆N₇O₅574.2778, found: 574.2762.

Example CXLVIII

Preparation of 3-(4-(1-piperazinyl)phenyl)-5-(((4-morpholinylamino)carbonyl)amino)indeno[1,2-c]pyrazol-4-one

A solution of CXLVII (0.58 g, 1.0 mmol) in 20 mL of trifluoroacetic acid was stirred at 25° C. for 2 h. The reaction mixture was concentrated under vacuum, and the residue was recrystallized from ethanol to provide 0.53 g (89%) of the yellow product as its TFA-salt. mp 263° C.; ESI-MS m/e calc'd for C[0329] ₂₅H₂₈N₇O₃: 474.2254, found: 474.2280.

Example CXLIX

Preparation of 3-(4-(1-piperazinyl)phenyl)-5-((aminocarbonyl)amino)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for examples XLII and CXLVIII employing 2-(4-(4-t-butoxycarbonyl-1-piperazinyl)benzoyl)-4-amino-1,3-indanedione obtained in example CXLVII and ammonia as the starting materials. mp 257° C.; ESI-MS m/e calc'd for C[0330] ₂₁H₂₁N₆O₂: 389.1726, found: 389.1724.

Example CL

Preparation of 3-(4-(1-piperazinyl)phenyl)-5-((hydrazinocarbonyl)amino)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for examples XLII and CXLVIII employing 2-(4-(4-t-butoxycarbonyl-1-piperazinyl)benzoyl)-4-amino-1,3-indanedione obtained in example CXLVII and hydrazine as the starting materials. mp 257° C.; ESI-MS m/e calc'd for C[0331] ₂₁H₂₂N₇O₂: 404.1835, found: 404.1834.

Example CLI

Preparation of 3-(4-(1-piperazinyl)phenyl)-5-((dimethylamino)acetamido)indeno[1,2-c]pyrazol-4-one

Prepared employing 2-(4-(4-t-butoxycarbonyl-1-piperazinyl)benzoyl)-4-amino-1,3-indanedione obtained in example CXLVII as the starting material. Chloroacetylation and treatment with dimethylamine in a similar fashion as described for examples II and XXIII, followed by treatment with hydrazine and removal of the t-butoxycarbonyl group in a similar fashion as described for examples I and CXLVIII, afforded the example compound. mp 243° C.; ESI-MS m/e calc'd for C[0332] ₂₄H₂₇N₆O₂: 431.2196, found: 431.2198.

Example CLII

Preparation of 3-(4-(1-piperazinyl)phenyl)-5-((4-morpholinyl)acetamido)indeno[1,2-c]pyrazol-4-one

Prepared employing 2-(4-(4-t-butoxycarbonyl-1-piperazinyl)benzoyl)-4-amino-1,3-indanedione obtained in example CXLVII as the starting material. Chloroacetylation and treatment with morpholine in a similar fashion as described for examples II and XXIII, followed by treatment with hydrazine and removal of the t-butoxycarbonyl group in a similar fashion as described for examples I and CXLVIII, afforded the example compound. mp 259° C.; ESI-MS m/e calc'd for C[0333] ₂₆H₂₉N₆O₃: 473.2301, found: 473.2302.

Example CLIII

Preparation of 3-(4-(1-piperazinyl)phenyl)-5-((4-methyl-1-piperazinyl)acetamido)indeno[1,2-c]pyrazol-4-one

Prepared employing 2-(4-(4-t-butoxycarbonyl-1-piperazinyl)benzoyl)-4-amino-1,3-indanedione obtained in example CXLVII as the starting material. Chloroacetylation and treatment with 1-methylpiperazine in a similar fashion as described for examples II and XXIII, followed by treatment with hydrazine and removal of the t-butoxycarbonyl group in a similar fashion as described for examples I and CXLVIII, afforded the example compound. ESI-MS m/e calc'd for C[0334] ₂₇H₃₂N₇O₂: 486.2618, found: 486.2608.

Example CLIV

Preparation of 3-(4-(1-piperazinyl)phenyl)-5-((4-amino methyl-1-piperidinyl)acetamido)indeno[1,2-c]pyrazol-4-one

Prepared employing 2-(4-(4-t-butoxycarbonyl-1-piperazinyl)benzoyl)-4-amino-1,3-indanedione obtained in example CXLVII as the starting material. Chloroacetylation and treatment with 4-(aminomethyl)piperidine in a similar fashion as described for examples II and XXIII, followed by treatment with hydrazine and removal of the t-butoxycarbonyl group in a similar fashion as described for examples I and CXLVIII, afforded the example compound. mp 239° C.; ESI-MS m/e calc'd for C[0335] ₂₈H₃₄N₇O₂: 500.2774, found: 500.2772.

Example CLV

Preparation of 3-(4-(4-methyl-1-piperazinyl)phenyl)-5-(((4-morpholinylamino)carbonyl)amino)indeno[1,2-c]pyrazol-4-one

[0336]
To a solution of CXLVITI (0.17 g, 0.29 mmol) in 10 mL of methanol and 2 mL of water at 25° C. was added sequentially 37% aqueous formaldehyde (0.45 g, 5.8 mmol), sodium cyanoborohydride (0.18 g, 2.9 mmol), and 4 drops of acetic acid. The resulting solution was stirred at 25° C. for 16 h. The mixture was diluted with water. It then was made acidic (˜pH 1) with conc. hydrochloric acid and stirred for 10 min. The solution next was made basic (˜pH 13) with 50% aqueous sodium hydroxide and finally adjusted to pH 10 with 1 N hydrochloric acid. The mixture was extracted with 4:1 chloroform/isopropanol. The combined extracts were washed with water and brine, dried over anhydrous sodium sulfate, and filtered. To the filtrate was added excess trifluoroacetic acid, and the solution was concentrated under vacuum. The residue was recrystallized from isopropanol to furnish 0.16 g (92%) of the yellow product as its TFA-salt. mp 245° C.; ESI-MS m/e calc'd for C[0337] ₂₆H₃₀N₇O₃: 488.2410, found: 488.2420.

Example CLVI

Preparation of 3-(4-(4-ethyl-1-piperazinyl)phenyl)-5-(((4-morpholinylamino)carbonyl)amino)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example CLV employing CXLVIII and acetaldehyde as the starting materials. mp 245° C.; ESI-MS m/e calc'd for C[0338] ₂₇H₃₂N₇O₃: 502.2567, found: 502.2555.

Example CLVII

Preparation of 3-(4-(4-isopropyl-1-piperazinyl)phenyl)-5-(((4-morpholinylamino)carbonyl)amino)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example CLV employing CXLVIII and acetone as the starting materials. mp 253° C.; ESI-MS m/e calc'd for C[0339] ₂₈H₃₄N₇O₃: 516.2723, found: 516.2726.

Example CLVIII

Preparation of 3-(4-methoxyphenyl)-5-(2-benzoylhydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

Step 1. Synthesis of 31 from 13. [0340]
A suspension of aniline 31 (0.5 g, 1.7 mmol) in dioxane (10 mL) was treated with triethylamine (0.48 mL, 3.4 mmol) in one portion at room temperature. Then 2-(trimethylsilyl) ethyloxy chloride (SEMCl) (0.48 mL, 2.6 mmol) was added in one portion and the mixture heated to reflux for 2 h. The reaction was cooled, diluted with EtOAc (20 mL) washed with water (10 mL), dried (MgSO[0341] ₄) and the solvent removed at reduced pressure. The residue was taken up in benzene (3 mL), applied to a plug of silica gel (10 g) and eluted with EtOAc/Hexane (1:3) until all the yellow color was washed from the silica gel plug. The solvent was evaporated and the residue taken on to the next step. This material was dissolved in dioxane (10 mL) and treated with K2CO3 (0.36 g, 2.6 mmol) in one portion. Then phenylchloroformate (0.27 mL, 2.23 mmol) was added in one portion and the reaction heated to 50 C for 2 h. The reaction was cooled and the solvent removed at reduced pressure. The residue was recrystalized from EtOH to give a yellow solid (0.4 g, 43%). mp OC; CIMS m/e calculated for C₃₀H₃₂N₃O₅Si: 542.2111, found: 542.2101;
Step 2. Synthesis of Ex. CLVIII from 31. [0342]
Compound 31 (0.015 g, 0.03 mmol) in DMSO (0.2 mL) was treated with phenylcarbazte (0.008 g, 0.06 mmol) in one portion and heated to 80 C for 30 minutes. The solvent was removed at reduced pressure heating to 65 C. The residue was disolved in EtOH (0.5 mL) and treated with 4N HCl/dioxane (0.4 mL). The mixture was heated to 80 C for 20 minutes and then cooled. The desired product was filtered and air dried (0.008 g, 62%). mp>300° C.; CIMS m/e calculated for C[0343] ₂₆H₂₇N₄O₄: 459.2032, found: 459.1999;

Example CLIX

Preparation of 3-(4-methoxyphenyl)-5-(2-isonicotinoylhydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example CLVIII using 4-pyridylcarbazate as the starting material. mp 248° C.; CIMS m/e calculated for C[0344] ₂₄H₁₉N₆O₄: 455.1468, found: 455.1400;

Example CLX

Preparation of 3-(4-methoxyphenyl)-5-(2-nictinoylhydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example CLVIII using 3-pyridylcarbazate as the starting material. mp 227° C.; CIMS m/e calc'd for C[0345] ₂₄H₁₉N₆O₄: 455.1468, found: 455.1487;

Example CLXI

Preparation of 3-(4-methoxyphenyl)-5-(2-(3,4-dihydroxy benzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example CLVIII using 3,4-dihydroxyphenyl carbazate as the starting material. mp>300° C.; CIMS m/e calc'd for C[0346] ₂₅H₂₀N₅O₆: 486.1414, found: 486.1497;

Example CLXII

Preparation of 3-(4-methoxyphenyl)-5-(2-(4-hydroxy benzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example CLVIII using 4-hydroxyphenyl carbazate as the starting material. mp 283° C.; CIMS m/e calc'd for C[0347] ₂₅H₂₀N₅O₅: 470.1464, found: 470.1544;

Example CLXIII

Preparation of 3-(4-methoxyphenyl)-5-(2-(3-aminobenzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example CLVIII using 3-aminophenyl carbazate as the starting material. mp 250° C.; CIMS m/e calc'd for C[0348] ₂₅H₂₁N₆O₄: 469.1624, found: 469.1513;

Example CLXIV

Preparation of 3-(4-methoxyphenyl)-5-(2-(4-aminobenzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example CLVIII using 4-aminophenyl carbazate as the starting material. mp 247° C.; CIMS m/e calc'd for C[0349] ₂₅H₂₁N₆O₄: 469.1624, found: 469.1528;

Example CLXV

Preparation of 3-(4-methoxyphenyl)-5-(2-(2-aminobenzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example CLVIII using 2-aminophenyl carbazate as the starting material. mp 257° C.; CIMS m/e calc'd for C[0350] ₂₅H₂₁N₆O₄: 469.1624, found: 469.1548;

Example CLXVI

Preparation of 3-(4-methoxyphenyl)-5-(2-(4-N,N-dimethylamino benzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example CLVIII using 4-N,N-dimethylaminophenyl carbazate as the starting material. mp 259° C.; CIMS m/e calc'd for C[0351] ₂₇H₂₅N₆O₄: 497.1937, found: 497.1876;

Example CLXVII

Preparation of 3-(4-methoxyphenyl)-5-(2-phenethylacetyl hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example CLVIII using benzyl carbazate as the starting material. mp 269° C.; CIMS m/e calc'd for C[0352] ₂₆H₂₂N₅O₄: 468.1672, found: 468.1313;

Example CLXVIII

Preparation of 3-(4-methoxyphenyl)-5-(2-(2-hydroxy benzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example CLVIII using 2-hydroxyphenyl carbazate as the starting material. mp 280° C.; CIMS m/e calc'd for C[0353] ₂₅H₂₀N₅O₅: 470.1464, found: 470.1419;

Example CLXIX

Preparation of 3-(4-methoxyphenyl)-5-(2-methoxycarbonyl hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example CLVIII using carbazic acid methyl ester as the starting material. mp>300° C.; CIMS m/e calc'd for C[0354] ₂₀H₂₈N₅O₅: 408.1308, found: 408.1397;

Utility

Inhibition of Kinase/Cyclin Complex Enzymatic Activity

Several of the compounds disclosed in this invention were assayed for their inhibitory activity against cdk4/D1 and cdk2/E kinase complexes. Briefly, the in vitro assays employ cell lysates from insect cells expressing either of the kinases and subsequently their corresponding regulatory units. The cdk2/cyclinE is purified from insect cells expressing His-tagged cdk2 and cyclin E. The cdk/cyclin lysate is combined in a microtitre-type plate along with a kinase compatible buffer, [0355] ³²P-labeled ATP at a concentration of 50 mM, a GST-Rb fusion protein and the test compound at varying concentrations. The kinase reaction is allowed to proceeded with the radiolabled ATP, then effectively stopped by the addition of a large excess of EDTA and unlabeled ATP. The GST-Rb labeled protein is sequestered-on a GSH-Sepharose bead suspension, washed, resuspended in scintillant, and the ³²P activity detected in a scintillation counter. The compound concentration which inhibits 50% of the kinase activity was calculated for each compound. A compound was considered active if its IC₅₀was found to be less than 1 μM.

Inhibition of HCT116 Cancer Cell Proliferation

To test the cellular activity of several compounds disclosed in this invention, we examined the effect of these compounds on cultured HCT116 cells and determined their effect on cell-cycle progression by the calorimetric cytotoxcity test using sulforhodamine B (Skehan et al. J. Natl. Cancer Inst. 82:1107-12, 1990). Briefly, HCT116 cells are cultured in the presence of test compounds at increasing concentrations. At selected time points, groups of cells are fixed with trichloroacetic acid and stained with sulforhodamine B (SRB). Unbound dye was removed by washing and protein-bound dye was extracted for determination of optical density. A compound was considered active if its IC₅₀was found to be less than 10 μM.

TABLE 1

Example	R¹	R²	mass	mp
#	R¹	R²	(M ⁺H)	(° C.)

I	Methyl	4-MeOC₆H₄	334	268
II	ClCH₂	4-MeOC₆H₄	382	274
III	cyclopropyl	4-MeOC₆H₄	360	289
IV	isopropyl	4-MeOC₆H₄	352	288
V	ethyl	4-MeOC₆H₄	348	287
VI	cyclopentyl	4-MeOC₆H₄	388	267
VII	cyclobutyl	4-MeOC₆H₄	374	297
VIII	benzyl	4-MeOC₆H₄	410	280
IX	n-propyl	4-MeOC₆H₄	362	282
X	4-ClC₆H₄CH₂	4-MeOC₆H₄	444	238
XI	3-MeOC₆H₄CH₂	4-MeOC₆H₄	440	>300
XII	4-MeOC₆H₄CH₂	4-MeOC₆H₄	440	280
XIII	3,4-diMeOC₆H₄CH₂	4-MeOC₆H₄	470	>300
XIV	2,5-diMeOC₆H₄CH₂	4-MeOC₆H₄	470	226
XV	Methyl	2-MeOC₆H₄	334	276
XVI	Methyl	3,4-diMeOC₆H₄	364	>300
XVII	3,4-(OCH₂O)C₆H₄CH₂	4-MeOC₆H₄	454	297
XVIII	3-thiophenylCH₂	4-MeOC₆H₄	416	293
XIX	2-MeOC₆H₄CH₂	4-MeOC₆H₄	440	255
XX	3,4-diClOC₆H₄CH₂	4-MeOC₆H₄	479	299
XXI	2,4-diClOC₆H₄CH₂	4-MeOC₆H₄	479	286
XXII	2-ClC₆H₄CH₂	4-MeOC₆H₄	444	300
XXIII	H₂NCH₂	4-MeOC₆H₄	349	>300
XXIV	HOCH₂CH₂NHCH₂	4-MeOC₆H₄	393	243
XXV	Me₂NCH₂	4-MeOC₆H₄	377	279
XXVI	piperaziflylCH₂	4-MeOC₆H₄	418	277
XXVII	4-Me-piperaziflylCH₂	4-MeOC₆H₄	432	>300
XXVIII	4-HOCH₂CH₂-	4-MeOC₆H₄	462	>300
	piperazinylCH₂
XXIX	piperidinylCH₂	4-MeOC₆H₄	417	291
XXX	4-NH₂CH₂-	4-MeOC₆H₄	446	>300
	piperidinylCH₂
XXXI	CH₃CH₂NHCH₂	4-MeOC₆H₄	377	250
XXXII	thiornorpholiraylCH₂	4-MeOC₆H₄	435	298
XXXIII	morpholinylCH₂	4-MeOC₆H₄	419	295
XXXIV	pyrrolidinylCH₂	4-MeOC₆H₄	403	279
XXXV	4-pyridylCH₂NHCH₂	4-MeOC₆H₄	440	>300
XXXVI	4-CH₃CONHC₆H₄CH₂	4-MeOC₆H₄	467	268
XXXVII	4-CH₃OCONHC₆H₄CH₂	4-MeOC₆H₄	483	257
XXXVIII	4-NH₂CH₂CONHC₆H₄CH₂	4-MeOC₆H₄	482	228
XXXIX	4-Me₂NCH₂CONHC₆H₄CH₂	4-MeOC₆H₄	510	>300
XL	4-N3C₆H₄CH₂	4-MeOC₆H₄	451	>300
XLI	4-NH₂C₆H₄CH₂	4-MeOC₆H₄	425	283
XLII	C₆C₆H₅NH	4-MeOC₆H₄	411	>300
XLIII	CH₃CH₂CH₂NH	4-MeOC₆H₄	377	252
XLIV	4-NH₂C₆H₄CH₂NH	4-MeOC₆H₄	440	>300
XLV	4-pyridylCH₂NH	4-MeOC₆H₄	426	>300
XLVI	Methyl	4-HOC₆H₄	320	>300
XLVII	H	4-MeOC₆H₄	320	280
XLVIII	Methyl	3-pyridyl	305	>300
XLIX	Methyl	4-pyridyl	305	>300
L	H	4-pyridyl	291	>300
LI	Methyl	C₆C₆H₅	305	>300
LII	Methyl	4-MeSC₆H₄	351	283
LIII	Methyl	4-MeSO2C₆H₄	383	>300
LVI	Methyl	4-Me₂NC₆H₄	348	>300
LV	morpholinylCH₂	4-Me₂NC₆H₄	432	>300
LVI	Me₂NCH₂	4-Me₂NC₆H₄	390	>300
LVII	Methyl	4-(piperdinyl)C₆H₄	388	291
LVIII	Methyl	4-	389	>300
		(morpholinyl) C₆H₄
LIX	Methyl	4-CH₃CH₂OC₆H₄	349	288
LX	Methyl	4-CH₃CH₂CH₂CH₂C₆H₄	361	259
LXI	Methyl	4-CH₃CH₂C₆H₄	332	294
LXII	Methyl	4-CH₃CH₂CH₂C₆H₄	347	269
LXIII	NH₂	4-MeOC₆H₄	335	>300
LXIV	Me₂NNH	4-MeOC₆H₄	378	>300
LXV	MeNH	4-MeOC₆H₄	349	>300
LXVI	morpholiriylNH	4-MeOC₆H₄	420	>300
LXVII	cis-1,2-	4-MeOC₆H₄	432	>300
	diaminocyclohexanyl
LXVIII	4-	4-MeOC₆H₄	433	>300
	methylpiperazinylNH
LXVIX	4-	4-MeOC₆H₄	489	>300
	uridomethylpiperadin
	ylCH₂
LXX	4-(2-	4-MeOC₆H₄	495	>300
	pyridyl)piperazinyl
	CH₂
LXXI	4-	4-MeOC₆H₄	461	>300
	(aminoethyl)piperazl
	iylCH₂
LXXII	4-amidopiperidinylCH₂	4-MeOC₆H₄	460	>300
LXXIII	4-	4-MeOC₆H₄	433	>300
	hydroxypiperidiflYl CH₂
LXXIV	4-	4-MeOC₆H₄	447	>300
	hydroxymethylpiperid
	inylCH₂
LXXV	4-amidopiperaziflylCH₂	4-MeOC₆H₄	493	>300
LXXVI	4-	4-MeOC₆H₄	492	>300
	dimethylamiflOpiperad
	inylCH₂
LXXVII	4-aminopiperadinylCH₂	4-MeOC₆H₄	464	>300
LXXVIII	4-Me-piperazinylCH₂	4-Me₂NC₆H4	445	>300
LXXIX	4-NH₂CH₂-	4-Me₂NC₆H4	459	NA
	piperidinylCH₂
LXXX	4-OH-piperidiflYlCH₂	4-Me₂NC₆H₄	446	267
LXXXI	morpholinylCH₂	4-	474	258
		(morpholinyl) C₆H₄
LXXXII	4-Me-piperazinylCH₂	4-	258
		(morpholinyl) C₆H₄
LXXXIII	4-OH-piperidinylCH₂	4-	488	245
		(morpholinyl) C₆H₄
LXXXIV	4NH₂CH₂	4-	501	240
		(morpholinyl) C₆H₄
	piperidinyl CH₂
LXXXV	4-Me-piperazinylNH	4-Me₂NC₆H₄	446	>300
LXXXVI	Methyl	i-propyl	270	>250
LXXXVII	Methyl	c-propyl	268	220
LXXXVIII	Methyl	t-butyl	284	>250
LXXXIX	Methyl	2-thienyl	310	269
XC	Methyl	3-Me-2-thienyl	324	275
XCI	NH₂	Ethyl	257	>250
XCII	NH₂	n-propyl	271	187
XCIII	NH₂	i-propyl	271	>250
XCIV	NH₂	c-propyl	267	252
			(M-H)
XCV	NH₂	c-hexyl	311	178
XCVI	NH₂	2-thienyl	310	214
			(M+)
XCVII	NH₂	3-Me-2-thienyl	325	270
XCVIII	NH₂	5-Me-2-thienyl	325	>280
XCIX	NH₂	5-CO₂Et-2-thienyl	383	>280
C	NH₂	3-thienyl	311	>280
CI	NH₂	5-Cl-3-thienyl	345	>300
CII	NH₂	2,5-diMe-3-thienyl	339	>280
CIII	NH₂	2-furanyl	295	278
CIV	Me₂NNH	i-propyl	314	231
CV	Me₂NNH	c-propyl	312
CVI	Me₂NNH	c-hexyl	354	229
CVII	Me₂NNH	2-thienyl	354	279
CVIII	Me₂NNH	5-MeO-2-thienyl	384	280
CIX	Me₂NNH	5-Me-2-thienyl	368	>280
CX	Me₂NNH	5-CO2Et-2-thienyl	426	252
CXI	Me₂NNH	3-thienyl	354	202
CXII	NH₂	i-methyl-3-	308	>300
		pyrrolyl
CXIII	Me₂NNH	2,5-diMe-3-thienyl	382	252
CXIV	Me₂NNH	2-furanyl	338	202
CXV	4-NH₂CO-	1-propyl	396	224
	piperidinylCH₂
CXVI	4-NH₂CO-	c-hexyl	436	228
	piperidinylCH₂
CXVII	4-NH₂CH₂-	ethyl	368	174
	piperidinylCH₂
CXVIII	4-NH₂CH₂-	i-propyl	382	218
	piperidinylCH₂
CXVIX	4-NH₂CH₂-	c-propyl	380	138
	piperidinylCH₂
CXX	4-NH₂CH₂-	c-hexyl	422	196
	piperidinylCH₂
CXXI	4-CH₃-piperazinylNH	1-propyl	369	231
CXXII	4-CH₃-piperazinylNH	5-CO₂Et-2-thienyl	481	249
CXXIII	4-CH₃-piperazinylNH	5-CO₂H-2-thienyl	453	270
CXXIV	4-CH₃-piperazinylNH	2,5-diMe-3-thienyl	437	250
CXXV	morpholinylNH	1-propyl	354	256
			(M-H)
CXXVI	morpholinylNH	4-CO₂Me-	455	216
		piperidinyl
CXXVII	morpholinylNH	5-Me-2-thienyl	410	261
CXXVIII	morpholinylNH	5-Cl-3-thienyl	430	259
CXXIX	morpholinylNH	2,5-diMe-3-thienyl	424	>280
CXXX	morpholinylNH	5-CO₂Et-2-thienyl	468	258
CXXXI	morpholinylNH	5-CO₂H-2-thienyl	440	273
CXXXII	morpholinylNH	5-CONHBn-2-thienyl	529	275
CXXXIII	morpholinylNH	5-CONH(4-Me-	537	190
		piperazinyl) -2-
		thienyl
CXXXIV	morpholinylNH	5-CONHCH₂CH₂(1-Me-	550	235
		2-pyrrolidinyl) -2-
		thienyl
CXXXV	morpholinylNH	5-CONHNMe₂-2-	482	201
		thienyl
CXXXVI	morpholinylNH	5-CONHCH₂CH₂NMe₂-	510	190
		2-thienyl
CXXXVII	morpholinylNH	5-CONHCH₂CH₂(1-	536	224
		pyrrolidinyl) -2-
		thienyl
CXXXVIII	morpholinylNH	5-CONHCH₂CH₂(1-	552	241
		morpholinyl) -2-
		thienyl
CXXXIX	morpholinylNH	5-CONHmorpholinyl-	524	271
		2 -thienyl
CXL	morpholinylNH	5-CONHCH₂CH₂CH₂(1-	564	260
		pyrrolidonyl) -2-
		thienyl
CXLI	morpholinylNH	5-CONHCH₂CH₂(3-	544	203
		pyridyl) -2-thienyl
CXLII	morpholinylNH	5-CONHCH₂CH₂CH₂(1-	547	263
		imidazolyl) -2-
		thienyl
CXLIII	morpholLinylNH	5-CONHCH₂CH₂(2-	544	>280
		pyridyl) -2-thienyl
CXLIV	morpholinylNH	5-CONHCH₂(3-	530	239
		pyridyl) -2-thienyl
CXLV	morpholinylNH	5-CONHCH₂CH₂(1-	550	228
		piperidinyl) -2-
		thienyl
CXLVI	Methyl	4-CF3C₆H₄	370	>300
			(M-
			H)
CXLVII	morpholinylNH	4-(4-BoC-	574	242
		piperazinyl) C₆H4
CXLVIII	morpholinylNH	4-	474	263
		(piperazinyl) C₆H₄
CXLIX	NH₂	4-	389	257
		(piperazinyl) C₆H₄
CL	NHhd 2NH	4-	404	257
		(piperazinyl) C₆H₄
CLI	Me₂NCH₂	4-	431	243
		(piperazinyl) C₆H₄
CLII	morpholiny-CH₂	4-	473	259
		(piperazinyl) C₆H₄
CLIII	4-Me-piperazinylCH₂	4-	486	NA
		(piperazinyl) C₆H₄
CLIV	4NH₂CH₂	4-	500	239
		(piperazinyl) C₆H₄
	piperidinylCH₂
CLV	morpholinylNH	4-(4-Me-	488	245
		piperazinyl) C₆H₄
CLVI	morpholinylNH	4-(4-Et-	502	245
		piperazinyl) C₆H₄
CLVII	morpholinylNH	4-(4-i-Pr-	516	253
		piperazinyl) C₆H₄
CLVIII	C₆H₅C(O)NHNH	4-MeOC₆H₄	459	>300
CLIX	4-pyridylC(O)NHNH	4-MeOC₆H₄	455	248
CLX	3-pyridylC(O)NHNH	4-MeOC₆H₄	455	227
CLXI	3,4-dihydroxy-	4-MeOC₆H₄	486	>300
	C₆H₃C(0) NHNH
CLXII	4-hydroxy-	4-MeOC₆H₄	470	283
		C₆H₄C(0)NHNH
CLXIII	3-amino-C₆H₄C(0)NHNH	4-MeOC₆H₄	469	250
CLXIV	4-amino-C₆H₄C(O)NHNH	4-MeCC₆H₄	469	247
CLXV	2-amino-C₆H₄C(O)NHNH	4-MeOC₆H₄	469	257
CLXVI	4-N,N-dimethylamino-	4-MCOC₆H₄	497	259
	C₆H₄C (0) NHNH
CLXVII	C₆HSCH₂C(0)NHNH	4-Me0C₆H₄	468	269
CLXVIII	2-hydroxy-	4-MeOC₆H₄	470	280
	C₆H₄C(0)NHNH
CLXIX	MeOC(0)NHNH	4-MeOC₆H₄	408	>300

TABLE 2

Example
Number	R¹	R²

100	2-pyridylmethyl	4-MeOC₆H₄
101	2-pyridylmethyl	3-MeOC₆H₄
102	2-pyridylmethyl	4-NH₂C₆H₄
103	2-pyridylmethyl	3-NH₂C₆H₄
104	2-pyridylmethyl	2 -NH₂C₆H₄
105	2-pyridylmethyl	4-Me2NC₆H₄
106	2-pyridylmethyl	3-Me2NC₆H₄
107	2-pyridylmethyl	2-Me2NC₆H₄
108	2-pyridylmethyl	4-pyridyl
109	2-pyridylmethyl	3-pyridyl
110	2-pyridylmethyl	2-pyridyl
111	2-pyridylmethyl	2-thiazolyl
112	2-pyridylmethyl	2-pyrazolyl
113	2-pyridylmethyl	5-isoquinolyl
114	2-pyridylmethyl	3,4-
		methylenedioxyC₆H₃
115	2-pyridylmethyl	3,4-
		ethylenedioxyC₆H₃
116	2-pyridylmethyl	2-imidazolyl
117	2-pyridylmethyl	2-oxazolyl
118	2-pyridylmethyl	4-isoxazolyl
119	2-pyridylmethyl	4-HOC₆H₄
120	2-pyridylmethyl	3-HOC₆H₄
121	2-pyridylmethyl	3,4-diHOC₆H₄
122	2-pyridylmethyl	4-NH₂CH₂C₆H₄
123	2-pyridylmethyl	3-NH₂CH₂C₆H₄
124	3-pyridylmethyl	4-MeOC₆H₄
125	3-pyridylmethyl	3 -MeOC₆H₄
126	3-pyridylmethyl	4-NH₂C₆H₄
127	3-pyridylmethyl	3-NH₂C₆H₄
128	3-pyridylmethyl	2-NH₂C₆H₄
129	3-pyridylmethyl	4-Me₂NC₆H₄
130	3-pyridylmethyl	3-Me₂NC₆H₄
131	3-pyridylmethyl	2-Me₂NC₆H₄
132	3-pyridylmethyl	4-pyridyl
133	3-pyridylmethyl	3-pyridyl
134	3-pyridylmethyl	2-pyridyl
135	3-pyridylmethyl	2-thiazolyl
136	3-pyridylmethyl	2-pyrazolyl
137	3-pyridylmethyl	5-isoqunolyl
138	3-pyridylmethyl	3,4-
		methylenedioxyC₆H₃
139	3-pyridylmethyl	3,4-
		methylenedioxyC₆H₃
140	3-pyridylmethyl	2-imidazolyl
141	3-pyridylmethyl	2-oxazolyl
142	3-pyridylmethyl	4-isoxazolyl
143	3-pyridylmethyl	4-HOC₆H₄
144	3-pyridylmethyl	3-HOC₆H₄
145	3-pyridylmethyl	3,4-diHOC₆H₄
146	3-pyridylmethyl	4-NH₂CH₂C₆H₄
147	3-pyridylmethyl	3-NH₂CH₂C₆H₄
148	4-pyridylmethyl	4-MeOC₆H₄
149	4-pyridylmethyl	3-MeOC₆H₄
150	4-pyridylmethyl	4-NH₂C₆H₄
151	4-pyridylmethyl	3-NH₂C₆H₄
152	4-pyridylmethyl	2-NH₂C₆H₄
153	4-pyridylmethyl	4-Me₂NC₆H₄
154	4-pyridylmethyl	3-Me₂NC₆H₄
155	4-pyridylmethyl	2-Me₂NC₆H₄
156	4-pyridylmethyl	4-pyridyl
157	4-pyridylmethyl	3-pyridyl
158	4-pyridylmethyl	2-pyridyl
159	4-pyridylmethyl	2-thiazolyl
160	4-pyridylmethyl	2-pyrazolyl
161	4-pyridylmethyl	5-isoquinolyl
162	4-pyridylmethyl	3,4-
		methylenedioxyC₆H₃
163	4-pyridylmethyl	3,4-
		ethylenedioxyC₆H₃
164	4-pyridylmethyl	2-imidazolyl
165	4-pyridylmethyl	2 -oxazolyl
166	4-pyridylmethyl	4-isoxazolyl
167	4-pyridylmethyl	4-HOC₆H₄
168	4-pyridylmethyl	3-HOC₆H₄
169	4-pyridylmethyl	3, 4-diHOC₆H₄
170	4-pyridylmethyl	4-NH₂CH₂C₆H₄
171	4-pyridylmethyl	3-NH₂CH₂C₆H₄
172	2-NH₂C₆H₄CH₂	4-MeOC₆H₄
173	2 -NH₂C₆H₄CH₂	3 -MeOC~H4
174	2-NH₂C₆H₄CH₂	4-NH₂C₆H₄
175	2-NH₂C₆H₄CH₂	3-NH₂C₆H₄
176	2-NH₂C₆H₄CH₂	2-NH₂C₆H₄
177	2-NH₂C₆H₄CH₂	4-Me₂NC₆H₄
178	2-NH₂CSH4CH₂	3-Me₂NC₆H₄
179	2-NH₂C₆H₄CH₂	2-Me₂NC₆H₄
180	2-NH₂C₆H₄CH₂	4-pyridyl
181	2-NH₂C₆H₄CH₂	3-pyridyl
182	2-NH₂C₆H₄CH₂	2-pyridyl
183	2-NH₂C₆H₄CH₂	2-thiazolyl
184	2-NH₂C₆H₄CH₂	2-pyrazolyl
185	2-NH₂C₆H₄CH₂	5- isoquinolyl
186	2-NH₂C₆H₄CH₂	3,4-
		methylenedioxyC₆H₃
187	2-NH₂C₆H₄CH₂	3,4-
		ethylenedioxyC₆H₃
188	2-NH₂C₆H₄CH₂	2-imidazolyl
189	2-NH₂C₆H₄CH₂	2-oxazolyl
190	2-NH₂C₆H₄CH₂	4-isoxazolyl
191	2-NH₂C₆H₄CH₂	4-HOC₆H₄
192	2-NH₂C₆H₄CH₂	3-HOC₆H₄
193	2-NH₂C₆H₄CH₂	3,4-diHOC₆H₄
194	2-NH₂C₆H₄CH₂	4-NH₂CH₂C₆H₄
195	2-NH₂C₆H₄CH₂	3-NH₂CH₂C₆H₄
196	3-NH₂C₆H₄CH₂	3-MeOC₆H₄
197	3-NH₂C₆H₄CH₂	4-NH₂C₆H₄
198	3-NH₂C₆H₄CH₂	3-NH₂C₆H₄
199	3-NH₂C₆H₄CH₂	2-NH₂C₆H₄
200	3-NH₂C₆H₄CH₂	4-Me₂NC₆H₄
201	3-NH₂C₆H₄CH₂	3-Me₂NC₆H₄
202	3-NH₂C₆H₄CH₂	2-Me₂NC₆H₄
203	3-NH₂C₆H₄CH₂	4-pyridyl
204	3-NH₂C₆H₄CH₂	3-pyridyl
205	3-NH₂C₆H₄CH₂	2-pyridyl
206	3-NH₂C₆H₄CH₂	2-thiazolyl
207	3-NH₂C₆H₄CH₂	2-pyrazolyl
208	3-NH₂C₆H₄CH₂	5-isoquinolyl
209	3-NH₂C₆H₄CH₂	3,4-
		methylenedioxyC₆H₃
210	3-NH₂C₆H₄CH₂	3,4-
		ethylenedioxyC₅H₃
211	3-NH₂C₆H₄CH₂	2-imidazolyl
212	3-NH₂C₆H₄CH₂	2-oxazolyl
213	3-NH₂C₆H₄CH₂	4-isoxazolyl
214	3-NH₂C₆H₄CH₂	4-HOC₆H₄
215	3-NH₂C₆H₄CH₂	3-HOC₆H₄
216	3-NH₂C₆H₄CH₂	3,4-diHOC₆H₄
217	3-NH₂C₆H₄CH₂	4-NH₂CH₂C₆H₄
218	3-NH₂C₆H₄CH₂	3-NH₂CH₂C₆H₄
219	4-NH₂C₆H₄CH₂	3-MeOC₆H₄
220	4-NH₂C₆H₄CH₂	4-NH₂C₆H₄
221	4-NH₂C₆H₄CH₂	3-NH₂C₆H₄
222	4-NH₂C₆H₄CH₂	2-NH₂C₆H₄
223	4-NH₂C₆H₄CH₂	4-Me₂NC₆H₄
224	4-NH₂C₆H₄CH₂	3-Me₂NC₆H₄
225	4-NH₂C₆H₄CH₂	2-Me₂NC₆H₄
226	4-Nh₂C₆H₄Ch₂	4-pyridyl
227	4-NH₂C₆H₄CH₂	3-pyridyl
228	4-NH₂C₆H₄CH₂	2-pyridyl
229	4-NH₂C₆H₄CH₂	2-thiazolyl
230	4-NH₂C₆H₄CH₂	2-pyrazolyl
231	4-NH₂C₆H₄CH₂	5-isoquinolyl
232	4-NH₂C₆H₄CH₂	3,4-
		methylenedioxyC₆H₃
233	4-NH₂C₆H₄CH₂	3,4-
		ethylenedioxyC₆H₃
234	4-NH₂C₆H₄CH₂	2-imidazolyl
235	4-NH₂C₆H₄CH₂	2-oxazolyl
236	4-NH₂C₆H₄CH₂	4-isoxazolyl
237	4-NH₂C₆H₄CH₂	4-HOC₆H₄
238	4-NH₂C₆H₄CH₂	3-HOC₆H₄
239	4-NH₂C₆H₄CH₂	3,4-diHOC₆H₄
240	4-NH₂C₆H₄CH₂	4-NH₂CH₂C₆H₄
241	4-NH₂C₆H₄CH₂	3-NH₂CH₂C₆H₄
242	2-MeOC₆H₄CH₂	3-MeOC₆H₄
243	2-MeOC₆H₄CH₂	4-NH₂C₆H₄
244	2-MeOC₆H₄CH₂	3-NH₂C₆H₄
245	2-MeOC₆H₄CH₂	2-NH₂C₆H₄
246	2-MeOC₆H₄CH₂	4-Me₂NC₆H₄
247	2-MeOC₆H₄CH₂	3-Me₂NC₆H₄
248	2-MeOC₆H₄CH₂	2-Me₂NC₆H₄
249	2-MeOC₆H₄CH₂	4-pyridyl
250	2-MeOC₆H₄CH₂	3-pyridyl
251	2-MeOC₆H₄CH₂	2-pyridyl
252	2-MeOC₆H₄CH₂	2-thiazolyl
253	2-MeOC₆H₄CH₂	2-pyrazolyl
254	2-MeOC₆H₄CH₂	5-isoquinolyl
255	2-MeOC₆H₄CH₂	3,4-
		methylenediOXyC₆H₃
256	2-MeOC₆H₄CH₂	3,4-
		ethylenediOXyC₆H₃
257	2-MeOC₆H₄CH₂	2-imidazolyl
258	2-MeOC₆H₄CH₂	2-oxazolyl
259	2-MeOC₆H₄CH₂	4-isoxazolyl
260	2-MeOC₆H₄CH₂	4-HOC₆H₄
261	2-MeOC₆H₄CH₂	3-HOC₆H₄
262	2-MeOC₆H₄CH₂	3,4-diHOC₆H₄
263	2-MeOC₆H₄CH₂	4-NH₂CH₂C₆H₄
264	2-MeOC₆H₄CH₂	3-NH₂CH₂C₆H₄
265	3-MeOC₆H₄CH₂	3-MeOC₆H₄
266	3-MeQC₆H₄CH₂	4-NH₂C₆H₄
267	3-MeOC₆H₄CH₂	3-NH₂C₆H₄
268	3-MeOC₆H₄CH₂	2-NH₂C₆H₄
269	3-MeOC₆H₄CH₂	4-Me₂NC₆H₄
270	3-MeOC₆H₄CH₂	3-Me₂NC₆H₄
271	3-MeOC₆H₄CH₂	2-Me₂NC₆H₄
272	3-MeOC₆H₄CH₂	4-pyridyl
273	3-MeOC₆H₄CH₂	3-pyridyl
274	3-MeOC₆H₄CH₂	2-pyridyl
275	3-MeOC₆H₄CH₂	2-thiazolyl
276	3-MeOC₆H₄CH₂	2-pyrazolyl
277	3-MeOC₆H₄CH₂	5-isoquinolyl
278	3-MeOC₆H₄CH₂	3,4-
		methylenedioxyC₆H₃
279	3-MeOC₆H₄CH₂	3,4-
		ethylenedioxyC₆H₃
280	3-MeQC₆H₄CH₂	2-imidazolyl
281	3-MeOCEH4CH₂	2-oxazolyl
282	3-MeOC₆H₄CH₂	4-isoxazolyl
283	3-MeOC₆H₄CH₂	4-HOC₆H₄
284	3-MeOC₆H₄CH₂	3-HOC₆H₄
285	3-MeOC₆H₄CH₂	3,4-diHOC₆H₄
286	3-MeOC₆H₄CH₂	4-NH₂CH₂C₆H₄
287	3-MeOC₆H₄CH₂	3-NH₂CH₂C₆H₄
288	4-MeOC₆H₄CH₂	3-MeOC₆H₄
289	4-MeOC₆H₄CH₂	4-NH₂C₆H₄
290	4-MeOC₆H₄CH₂	3-NH₂C₆H₄
291	4-MeOC₆H₄CH₂	2-NH₂C₆H₄
292	4-MCOC₆H₄CH₂	4-Me₂NC₆H₄
293	4-MeOC₆H₄CH₂	3-Me₂NC₆H₄
294	4-MeOC₆H₄CH₂	2-Me₂NC₆H₄
295	4-MeOC₆H₄CH₂	4-pyridyl
296	4-MeOC₆H₄CH₂	3-pyridyl
297	4-MeQC₆H₄CH₂	2-pyridyl
298	4-MeOC₆H₄CH₂	2-thiazolyl
299	4-MeOC₆H₄CH₂	2-pyrazolyl-
300	4-MeOC₆H₄CH₂	5-isoquinolyl
301	4-MeOC₆H₄CH₂	3,4-
		methylenedioxyC₆H₃
302	4-MeOC₆H₄CH₂	3,4-
		ethylenedioxyC₆H₃
303	4-MeOC₆H₄CH₂	2-imidazolyl
304	4-MeQC₆H₄CH₂	2-oxazolyl
305	4-MeOC₆H₄CH₂	4-isoxazolyl
306	4-MeOC₆H₄CH₂	4-HOC₆H₄
307	4-MeOC₆H₄CH₂	3-HOC₆H₄
308	4-MeOC₆H₄CH₂	3,4-diHOC₆H₄
309	4-MeOC₆H₄CH₂	4-NH₂CH₂C₆H₄
310	4-MeOC₆H₄CH₂	3-NH₂CH₂C₆H₄
311	2-HOC₆H₄CH₂	4-MeOC₆H₄
312	2-HOC₆H₄CH₂	3-MeOC₆H₄
313	2-HOC₆H₄CH₂	4-NH₂C₆H₄
314	2-HOC₆H₄CH₂	3-NH₂C₆H₄
315	2-HOC₆H₄CH₂	2-NH₂C₆H₄
316	2-HOC₆H₄CH₂	4-Me₂NC₆H₄
317	2-HOC₆H₄CH₂	3-Me₂NC₆H₄
313	2-HOC₆H₄CH₂	2-Me₂NC₆H₄
319	2-HOC₆H₄CH₂	4-pyridyl
320	2-HOC₆H₄CH₂	3-pyridyl
321	2-HOC₆H₄CH₂	2-pyridyl
322	2-HOC₆H₄CH₂	2-thiazolyl
323	2-HOC₆H₄CH₂	2-pyrazolyl
324	2-HOC₆H₄CH₂	5-isoquinolyl
325	2-HOC₆H₄CH₂	3,4-
		methylenedioxyC₆H₃
326	2-HOC₆H₄CH₂	3,4-
		ethylenedioxyC₆H₃
327	2-HOC₆H₄CH₂	2-imidazolyl
328	2-HOC₆H₄CH₂	2-oxazolyl
329	2-HOC₆H₄CH₂	4-isoxazolyl
330	2-HOC₆H₄CH₂	4-HOC₆H₄
331	2-HOC₆H₄CH₂	3-HOC₆H₄
332	2-HOC₆H₄CH₂	3,4-diHOC₆H₄
333	2-HOC₆H₄CH₂	4-NH₂CH₂C₆H₄
334	2-HOC₆H₄CH₂	3-NH₂CH₂C₆H₄
335	3-HOC₆H₄CH₂	4-MeOC₆H₄
336	3-HOC₆H₄CH₂	3-MeOC₆H₄
337	3-HOC₆H₄CH₂	4-NH₂C₆H₄
338	3-HOC₆H₄CH₂	3-NH₂C₆H₄
339	3-HOC₆H₄CH₂	2-NH₂C₆H₄
340	3-HOC₆H₄CH₂	4-Me₂NC₆H₄
341	3-HOC₆H₄CH₂	3-Me₂NC₆H₄
342	3-HOC₆H₄CH₂	2-Me₂NC₆H₄
343	3-HOC₆H₄CH₂	4-pyridyl
344	3-HOC₆H₄CH₂	3-pyridyl
345	3-HOC₆H₄CH₂	2-pyridyl
346	3-HOC₆H₄CH₂	2-thiazolyl
347	3-HOC₆H₄CH₂	2-pyrazolyl
348	3-HOC₆H₄CH₂	5-isoquinolyl
349	3-HOC₆H₄CH₂	3,4-
		methylenedioxyC₆H₃
350	3-HOC₆H₄CH₂	3,4-
		ethylenedioxyC₆H₃
351	3-HOC₆H₄CH₂	2-imidazolyl
352	3-HOC₆H₄CH₂	2-oxazolyl
353	3-HOC₆H₄CH₂	4-isoxazolyl
354	3-HOC₆H₄CH₂	4-HOC₆H₄
355	3-HOC₆H₄CH₂	3-HOC₆H₄
356	3-HOC₆H₄CH₂	3,4-diHOC₆H₄
357	3-HOC₆H₄CH₂	4-NH₂CH₂C₆H₄
358	3-HOC₆H₄CH₂	3-NH₂CH₂C₆H₄
359	4-HOC₆H₄CH₂	4-MeOC₆H₄
360	4-HOC₆H₄CH₂	3-MeOC₆H₄
361	4-HOC₆H₄CH₂	4-NH₂C₆H₄
362	4-HOC₆H₄CH₂	3-NH₂C₆H₄
363	4-HOC₆H₄CH₂	2-NH₂C₆H₄
364	4-HOC₆H₄CH₂	4-Me₂NC₆H₄
365	4-HOC₆H₄CH₂	3-Me₂NC₆H₄
366	4-HOC₆H₄CH₂	2-Me₂NC₆H₄
367	4-HOC₆H₄CH₂	4-pyridyl
368	4-HOC₆H₄CH₂	3-pyridyl
369	4-HOC₆H₄CH₂	2-pyridyl
370	4-HOC₆H₄CH₂	2-thiazolyl
371	4-HOC₆H₄CH₂	2-pyrazolyl
372	4-HOC₆H₄CH₂	5-isoquinolyl
373	4-HOC₆H₄CH₂	3,4-
		methylenedioxyC₆H₃
374	4-HOC₆H₄CH₂	3,4-
		ethylenedioxyC₆H₃
375	4-HOC₆H₄CH₂	2-imidazolyl
376	4-HOC₆H₄CH₂	2-oxazolyl
377	4-HOC₆H₄CH₂	4-isoxazolyl
378	4-HOC₆H₄CH₂	4-HOC₆H₄
379	4-HOC₆H₄CH₂	3-HOC₆H₄
380	4-HOC₆H₄CH₂	314-diHOC₆H₄
381	4-HOC₆H₄CH₂	4-NH₂CH₂C₆H₄
382	4-HOC₆H₄CH₂	3-NH₂CH₂C₆H₄
383	4-ClC₆H₄CH₂	3-MeOC₆H₄
384	4-ClC₆H₄CH₂	4-NH₂C₆H₄
385	4-ClC₆H₄CH₂	3-NH₂C₆H₄
386	4-ClC₆H₄CH₂	2-NH₂C₆H₄
387	4-ClC₆H₄CH₂	4-Me₂NC₆H₄
388	4-ClC₆H₄CH₂	3-Me₂NC₆H₄
389	4-ClC₆H₄CH₂	2-Me₂NC₆H₄
390	4-ClC₆H₄CH₂	4-pyridyl
391	4-ClC₆H₄CH₂	3-pyridyl
392	4-ClC₆H₄CH₂	2-pyridyl
393	4-ClC₆H₄CH₂	2-thiazolyl
394	4-ClC₆H₄CH₂	2-pyrazolyl
395	4-ClC₆H₄CH₂	5-isoquinolyl
396	4-ClC₆H₄CH₂	3,4-
		methylenedioxyC₆H₃
397	4-ClC₆H₄CH₂	3,4-
		ethylenedioxyC₆H₃
398	4-ClC₆H₄CH₂	2-imidazolyl
399	4-ClC₆H₄CH₂	2-oxazolyl
400	4-ClC₆H₄CH₂	4-isoxazolyl
401	4-ClC₆H₄CH₂	4-HOC₆H₄
402	4-ClC₆H₄CH₂	3-HOC₆H₄
403	4-ClC₆H₄CH₂	3,4-diHOC₆H₄
404	4-ClC₆H₄CH₂	4-NH₂CH₂C₆H₄
405	4-ClC₆H₄CH₂	3-NH₂CH₂C₆H₄
406	2-NH₂CH₂C₆H₄CH₂	4-MeOC₆H₄
407	2-NH₂CH₂C₆H₄CH₂	3-MeOC₆H₄
408	2-NH₂CH₂C₆H₄CH₂	4-NHC₆H₄
409	2-NH₂CH₂C₆H₄CH₂	3-NH₂C₆H₄
410	2-NH₂CH₂C₆H₄CH₂	2-NH₂C₆H₄
411	2-NH₂CH₂C₆H₄CH₂	4-Me₂NC₆H₄
412	2-NH₂CH₂C₆H₄CH₂	3-Me₂NC₆H₄
413	2-NH₂CH₂C₆H₄CH₂	2-Me₂NC₆H₄
414	2-NH₂CH₂C₆H₄CH₂	4-pyridyl
415	2-NH₂CH₂C₆H₄CH₂	3-pyridyl
416	2-NH₂CH₂C₆H₄CH₂	2-pyridyl
417	2-NH₂CH₂C₆H₄CH₂	2-thiazolyl
418	2-NH₂CH₂C₆H₄CH₂	2-pyrazolyl
419	2-NH₂CH₂C₆H₄CH₂	5-isoquinolyl
420	2-NH₂CH₂C₆H₄CH₂	3,4-
		methylenedioxyC₆H₃
421	2-NH₂CH₂C₆H₄CH₂	3,4-
		ethylenedioxyC₆H₃
422	2-NH₂CH₂C₆H₄CH₂	2-imidazolyl
423	2-NH₂CH₂C₆H₄CH₂	2-oxazolyl
424	2-NH₂CH₂C₆H₄CH₂	4-isoxazolyl
425	2-NH₂CH₂C₆H₄CH₂	4-HOC₆H₄
426	2-NH₂CH₂C₆H₄CH₂	3-HOC₆H₄
427	2-NH₂CH₂C₆H₄CH₂	3,4-diHOC₆H₄
428	2-NH₂CH₂C₆H₄CH₂	4-NH₂CH₂C₆H₄
429	2-NH₂CH₂C₆H₄CH₂	3-NH₂CH₂C₆H₄
430	3-NH₂CH₂C₆H₄CH₂	4-MOOC₆H₄
431	3-NH₂CH₂C₆H₄CH₂	3-MeOC₆H₄
432	3-NH₂CH₂C₆H₄CH₂	4-NH₂C₆H₄
433	3-NH₂CH₂C₆H₄CH₂	3-NH₂C₆H₄
434	3-NH₂CH₂C₆H₄CH₂	2-NH₂C₆H₄
435	3-NH₂CH₂C₆H₄CH₂	4-Me₂NC₆H₄
436	3-NH₂CH₂C₆H₄CH₂	3-Me₂NC₆H₄
437	3-NH₂CH₂C₆H₄CH₂	2-Me₂NC₆H₄
438	3-NH₂CH₂C₆H₄CH₂	4-pyriclyl
439	3-NH₂CH₂C₆H₄CH₂	3-pyridyl
440	3-NH₂CH₂C₆H₄CH₂	2-pyridyl
441	3-NH₂CH₂C₆H₄CH₂	2-thiazolyl
442	3-NH₂CH₂C₆H₄CH₂	2-pyrazolyl
443	3-NH₂CH₂C₆H₄CH₂	5-isoquinolyl
444	3-NH₂CH₂C₆H₄CH₂	3,4-
		methylenedioxyC₆H₃
445	3-NH₂CH₂C₆H₄CH₂	3,4-
		ethylenediOxyC₆H₃
446	3-NH₂CH₂C₆H₄CH₂	2-imidazolyl
447	3-NH₂CH₂C₆H₄CH₂	2-oxazolyl
448	3-NH₂CH₂C₆H₄CH₂	4-isoxazolyl
449	3-NH₂CH₂C₆H₄CH₂	4-HOC₆H₄
450	3-NH₂CH₂C₆H₄CH₂	3-HOC₆H₄
451	3-NH₂CH₂C₆H₄CH₂	3,4-diHOC₆H₄
452	3-NH₂CH₂C₆H₄CH₂	4-NH₂CH₂C₆H₄
453	3-NH₂CH₂C₆H₄CH₂	3-NH₂CH₂C₆H₄
454	4-NH₂CH₂C₆H₄CH₂	4-MeOC₆H₄
455	4-NH₂CH₂C₆H₄CH₂	3-MeOC₆H₄
456	4-NH₂CH₂C₆H₄CH₂	4-NH₂C₆H₄
457	4-NH₂CH₂C₆H₄CH₂	3-NH₂C₆H₄
458	4-NH₂CH₂C₆H₄CH₂	2-NH₂C₆H₄
459	4-NH₂CH₂C₆H₄CH₂	4-Me₂NC₆H₄
460	4-NH₂CH₂C₆H₄CH₂	3-Me₂NC₆H₄
461	4-NH₂CH₂C₆H₄CH₂	2-Me₂NC₆H₄
462	4-NH₂CH₂C₆H₄CH₂	4-pyridyl
463	4-NH₂CH₂C₆H₄CH₂	3-pyridyl
464	4-NH₂CH₂C₆H₄CH₂	2-pyridyl
465	4-NH₂CH₂C₆H₄CH₂	2-thiazolyl
466	4-NH₂CH₂C₆H₄CH₂	2-pyrazolyl
467	4-NH₂CH₂C₆H₄CH₂	5-isoquinolyl
468	4-NH₂CH₂C₆H₄CH₂	3,4-
		methylenedioxyC₆H₃
469	4-NH₂CH₂C₆H₄CH₂	3,4-
		ethylenedioxyC₆H₃
470	4-NH₂CH₂C₆H₄CH₂	2-imidazolyl
471	4-NH₂CH₂C₆H₄CH₂	2-oxazolyl
472	4-NH₂CH₂C₆H₄CH₂	4-isoxazolyl
473	4-NH₂CH₂C₆H₄CH₂	4-HOC₆H₄
474	4-NH₂CH₂C₆H₄CH₂	3-HOC₆H₄
475	4-NH₂CH₂C₆H₄CH₂	3,4-diHOC₆H₄
476	4-NH₂CH₂C₆H₄CH₂	4-NH₂CH₂C₆H₄
477	4-NH₂CH₂C₆H₄CH₂	3-NH₂CH₂C₆H₄
478	2-Me₂NCH₂C₆H₄CH₂	4-MeOC₆H₄
479	2-Me₂NCH₂C₆H₄CH₂	3-MCOC₆H₄
480	2-Me₂NCH₂C₆H₄CH₂	4-NH₂C₆H₄
481	2-Me₂NCH₂C₆H₄CH₂	3-NH₂C₆H₄
482	2-Me₂NCH₂C₆H₄CH₂	2-NH₂C₆H₄
483	2-Me₂NCH₂C₆H₄CH₂	4-Me₂NC₆H₄
484	2-Me₂NCH₂C₆H₄CH₂	3-Me₂NC₆H₄
485	2-Me₂NCH₂C₆H₄CH₂	2-Me₂NC₆H₄
486	2-Me₂NCH₂C₆H₄CH₂	4-pyridyl
487	2-Me₂NCH₂C₆H₄CH₂	3-pyridyl
488	2-Me₂NCH₂C₆H₄CH₂	2-pyridyl
489	2-Me₂NCH₂C₆H₄CH₂	2-thiazolyl
490	2-Me₂NCH₂C₆H₄CH₂	2-pyrazolyl
491	2-Me₂NCH₂C₆H₄CH₂	5-isoquinolyl
492	2-Me₂NCH₂C₆H₄CH₂	3,4-
		methylenedioxyC₆H₃
493	2-Me₂NCH₂C₆H₄CH₂	3,4-
		ethylenedioxyC₆H₃
494	2-Me₂NCH₂C₆H₄CH₂	2-imidazolyl
495	2-Me₂NCH₂C₆H₄CH₂	2-oxazolyl
496	2-Me₂NCH₂C₆H₄CH₂	4-isoxazolyl
497	2-Me₂NCH₂C₆H₄CH₂	4-HOC₆H₄
498	2-Me₂NCH₂C₆H₄CH₂	3-HOC₆H₄
499	2-Me₂NCH₂C₆H₄CH₂	3,4-diHOC₆H₄
500	2-Me₂NCH₂C₆H₄CH₂	4-NH₂CH₂C₆H₄
501	2-Me₂NCH₂C₆H₄CH₂	3-NH₂CH₂C₆H₄
502	3-Me₂NCH₂C₆H₄CH₂	4-MeOC₆H₄
503	3-Me₂NCH₂C₆H₄CH₂	3-MeOC₆H₄
504	3-Me₂NCH₂C₆H₄CH₂	4-NH₂C₆H₄
505	3-Me₂NCH₂C₆H₄CH₂	3-NH₂C₆H₄
506	3-Me₂NCH₂C₆H₄CH₂	2-NH₂C₆H₄
507	3-Me₂NCH₂C₆H₄CH₂	4-Me₂NC₆H₄
508	3-Me₂NCH₂C₆H₄CH₂	3-Me₂NC₆H₄
509	3-Me₂NCH₂C₆H₄CH₂	2-Me₂NC₆H₄
510	3-Me₂NCH₂C₆H₄CH₂	4-pyridyl
511	3-Me₂NCH₂C₆H₄CH₂	3-pyridyl
512	3-Me₂NCH₂C₆H₄CH₂	2-pyridyl
513	3-Me₂NCH₂C₆H₄CH₂	2-thiazolyl
514	3-Me₂NCH₂C₆H₄CH₂	2-pyrazolyl
515	3-Me₂NCH₂C₆H₄CH₂	5-isoquinolyl
516	3-Me₂NCH₂C₆H₄CH₂	3,4-
		methylenedioxyC₆H₃
517	3-Me₂NCH₂C₆H₄CH₂	3,4-
		ethylenedioxyC₆H₃
518	3-Me₂NCH₂C₆H₄CH₂	2-imidazolyl
519	3-Me₂NCH₂C₆H₄CH₂	2-oxazolyl
520	3-Me₂NCH₂C₆H₄CH₂	4-isoxazolyl
521	3-Me₂NCH₂C₆H₄CH₂	4-HOC₆H₄
522	3-Me₂NCH₂C₆H₄CH₂	3-HOC₆H₄
523	3-Me₂NCH₂C₆H₄CH₂	3,4-diHOC₆H₄
524	3-Me₂NCH₂C₆H₄CH₂	4-NH₂CH₂C₆H₄
525	3-Me₂NCH₂C₆H₄CH₂	3-NH₂CH₂C₆H₄
526	4-Me₂NCH₂C₆H₄CH₂	4-MeOC₆H₄
527	4-Me₂NCH₂C₆H₄CH₂	3-MeOC₆H₄
528	4-Me₂NCH₂C₆H₄CH₂	4-NH₂C₆H₄
529	4-Me₂NCH₂C₆H₄CH₂	3-NH₂C₆H₄
530	4-Me₂NCH₂C₆H₄CH₂	2-NH₂C₆H₄
531	4-Me₂NCH₂C₆H₄CH₂	4-Me₂NC₆H₄
532	4-Me₂NCH₂C₆H₄CH₂	3-Me₂NC₆H₄
533	4-Me₂NCH₂C₆H₄CH₂	2-Me₂NC₆H₄
534	4-Me₂NCH₂C₆H₄CH₂	4-pyridyl
535	4-Me₂NCH₂C₆H₄CH₂	3-pyridyl
536	4-Me₂NCH₂C₆H₄CH₂	2-pyridyl
537	4-Me₂NCH₂C₆H₄CH₂	2-thiazolyl
538	4-Me₂NCH₂C₆H₄CH₂	2-pyrazolyl
539	4-Me₂NCH₂C₆H₄CH₂	5-isoquinolyl
540	4-Me₂NCH₂C₆H₄CH₂	3,4-
		methylenedioxyC₆H₃
541	4-Me₂NCH₂C₆H₄CH₂	3,4-
		ethylenedioxyC₆H₃
542	4-Me₂NCH₂C₆H₄CH₂	2-imdazolyl
543	4-Me₂NCH₂C₆H₄CH₂	2-oxazolyl
545	4-Me₂NCH₂C₆H₄CH₂	4-isoxazolyl
546	4-Me₂NCH₂C₆H₄CH₂	4-HOC₆H₄
547	4-Me₂NCH₂C₆H₄CH₂	3-HOC₆H₄
548	4-Me₂NCH₂C₆H₄CH₂	3,4-diHOC₆H₄
549	4-Me₂NCH₂C₆H₄CH₂	4-NH₂CH₂C₆H₄
550	4-Me₂NCH₂C₆H₄CH₂	3-NH₂CH₂C₆H₄
551	H	3-MeOC₆H₄
552	H	4-NH-C₆H₄
553	H	3-NH₂C₆H₄
554	H	2-NH₂C₆H₄
555	H	4-Me₂NC₆H₄
556	H	3-Me₂NC₆H₄
557	H	2-Me₂NC₆H₄
558	H	3-pyridyl
559	H	2-pyridyl
560	H	2-thiazolyl
561	H	2-pyrazolyl
562	H	5-isoquinolyl
563	H	3,4-
		methylenedioxyC₆H₃
564	H	3,4-
		ethylenedioxyC₆H₃
565	H	2-imidazolyl
566	H	2-oxazolyl
567	H	4-isoxazolyl
568	H	4-HOC₆H₄
569	H	3-HOC₆H₄
570	H	3,4-diHOC₆H₄
571	H	4-NH₂CH₂C₆H₄
572	H	3-NH₂CH₂C₆H₄
573	Me	3-MeOC₆H₄
574	Me	4-NH₂C₆H₄
575	Me	3-NH₂C₆H₄
576	Me	2-NH₂C₆H₄
577	Me	4-Me-NC₆H₄
578	Me	3-Me₂NC₆H₄
579	Me	2-Me₂NC₆H₄
580	Me	3-pyridyl
581	Me	2-pyridyl
582	Me	2-thiazolyl
583	Me	2-pyrazolyl
584	Me	5-isoquinolyl
585	Me	3,4-
		ethylenedioxyC₆H₃
586	Me	2-imidazolyl
587	Me	2-oxazolyl
588	Me	4-isoxazolyl
589	Me	3-HOC₆H₄
590	Me	3,4-diHOC-H-
591	Me	4-NH₂CH₂C₆H₄
592	Me	3-NH₂CH₂C₆H₄
593	Et	3-MeOC₆H₄
594	Et	4-NH₂C₆H₄
595	Et	3-NH₂C₆H₄
596	Et	2-NH₂C₆H₄
597	Et	4-Me₂NC₆H₄
598	Et	3-Me₂NC₆H₄
599	Et	2-Me₂NC₆H₄
600	Et	4-pyridyl
601	Et	3-pyridyl
601	Et	2-pyridyl
603	Et	2-thiazolyl
604	Et	2-pyrazolyl
605	Et	5-isoquinolyl
606	Et	3,4-
		methylenedioxyC₆H₃
607	Et	3,4-
		ethylenedioxyC₆H₃
608	Et	2-imidazolyl
609	Et	2-oxazolyl
610	Et	4-isoxazolyl
611	Et	4-HOC₆H₄
612	Et	3-HOC-H-
613	Et	3,4-diHOC₆H₄
614	Et	4-NH₂CH₂C₆H₄
615	Et	3-NH₂CH₂C₆H₄
616	Me₂NCH₂	3-MeOC₆H₄
617	Me₂NCH₂	4-NH₂C₆H₄
618	Me₂NCH₂	3-NH₂C₆H₄
619	Me₂NCH₂	2-NH₂C₆H₄
620	Me₂NCH₂	4-Me₂NC₆H₄
621	Me₂NCH₂	3-Me₂NC₆H₄
622	Me₂NCH₂	2-Me₂NC₆H₄
623	Me₂NCH₂	4-pyridyl
624	Me₂NCH₂	3-pyridyl
625	Me₂NCH₂	2-pyridyl
626	Me₂NCH₂	2-thiazolyl
627	Me₂NCH₂	2-pyrazolyl
628	Me₂NCH₂	5-isoquinolyl
629	Me₂NCH₂	3,4-
		methylenedioxyC₆H₃
630	Me₂NCH₂	3,4-
		ethylenedioxyC₆H₃
631	Me₂NCH₂	2-imidazolyl
632	Me₂NCH₂	2-oxazolyl
633	Me₂NCH₂	4-isoxazolyl
634	Me₂NCH₂	4-HOC₆H₄
635	Me₂NCH₂	3-HOC₆H₄
636	Me₂NCH₂	3,4-diHOC₆H₄
637	Me₂NCH₂	4-NH₂CH₂C₆H₄
638	Me₂NCH₂	3-NH₂CH₂C₆H₄
639	ELNHCH₂	3-MeOC₆H₄
640	EtNHCH₂	4-NH₂C₆H₄
641	EtNHCH₂	3-NH₂C₆H₄
642	EtNHCH₂	2-NH₂C₆H₄
643	EtNHCH₂	4-Me₂NC₆H₄
644	EtNHCH₂	3-Me₂NC₆H₄
645	EtNHCH₂	2-Me₂NC₆H₄
646	EtNHCH₂	4-pyridyl
647	EtNHCH₂	3-pyridyl
648	EtNHCH₂	2-pyridyl
649	EtNHCH₂	2-thiazolyl
650	EtNHCH₂	2-pyrazolyl
651	EtNHCH₂	5-isoquinolyl
652	EtNHCH₂	3,4-
		methylenedioxyC₆H₃
653	EtNHCH₂	3,4-
		ethylenedioxyC₆H₃
654	EtNHCH₂	2-imidazolyl
655	EtNHCH₂	2-oxazolyl
656	EtNHCH₂	4-isoxazolyl
657	EtNHCH₂	4-HOC₆H₄
658	EtNHCH₂	3-HOC₆H₄
659	EtNHCH₂	3,4-diHOC₆H₄
660	EtNHCH₂	4-NH₂CH₂C₆H₄
661	EtNHCH₂	3-NH₂CH₂C₆H₄
662	HOCH₂CH₂NHCH₂	3-Me₂C-H-
663	HOCH₂CH₂NHCH₂	4-NH₂C₆H₄
664	HOCH₂CH₂NHCH₂	3-NH₂C₆H₄
665	HOCH₂CH₂NHCH₂	2-NH₂C₆H₄
666	HOCH₂CH₂NHCH₂	4-Me₂NC₆H₄
667	HOCH₂CH₂NHCH₂	3-Me₂NC₆H₄
668	HOCH₂CH₂NI-ICH₂	2-Me₂NC₆H₄
669	HOCH₂CH₂NHCH₂	4-pyridyl
670	HOCH₂CH₂NHCH₂	3-pyridyl
671	HOCH₂CH₂NHCH₂	2-pyridyl
672	HOCH₂CH₂NHCH₂	2-thiazolyl
673	HOCH₂CR2NHCH₂	2-pyrazolyl
674	HOCH₂CH₂NHCH₂	5-isoquinolyl
675	HOCH₂CH₂NHCH₂	3,4-
		methylenedioxyC₆H₃
676	HOCH₂CH₂NHCH₂	3,4-
		ethylenedioxyC₆H₃
677	HOCH₂CH₂NHCH₂	2-imidazolyl
678	HOCH₂CH₂NHCH₂	2-oxazolyl
679	HOCH₂CH₂NHCH₂	4-isoxazolyl
680	HOCH₂CH₂NHCH₂	4-HOC₆H₄
681	HOCH₂CH₂NHCH₂	3-HOC₆H₄
682	HOCH₂CH₂NHCH₂	3,4-diHOC₆H₄
683	HOCH₂CH₂NHCH₂	4-NH₂CH₂C₆H₄
684	HOCH₂CH₂NHCH₂	3-NH₂CH₂C₆H₄
685	H₂NCH₂CH₂NHCH₂	4-Me₂C₆H₄
686	H₂NCH₂CH₂NHCH₂	3-MeOC₆H₄
687	H₂NCH₂CH₂NHCH₂	4-NH₂C₆H₄
688	H₂NCH₂CH₂NHCH₂	3-NH₂C₆H₄
689	H₂NCH₂CH₂NHCH₂	2-NH₂C₆H₄
690	H₂NCH₂CH₂NHCH₂	4-Me₂NC₆H₄
691	H₂NCH₂CH₂NIICH₂	3-Me₂NC₆H₄
692	H₂NCH₂CH₂NHCH₂	2-Me₂NC₆H₄
693	H₂NCH₂CH₂NHCH₂	4-pyridyl
694	H₂NCH₂CH₂NHCH₂	3-pyridyl
695	H₂NCH₂CH₂NHCH₂	2-pyridyl
696	H₂NCH₂CH₂NHCH₂	2-thiazolyl
697	H₂NCH₂CH₂NHCH₂	2-pyrazolyl
698	H₂NCH₂CH₂NHCH₂	5-isoquinolyl
699	H₂NCH₂CH₂NHCH₂	3,4-
		methylenedioxyC₆H₃
700	H₂NCH₂CH₂NHCH₂	3,4-
		ethylenedioxyC₆H₃
701	H₂NCH₂CH₂NHCH₂	2-imidazolyl
702	H₂NCH₂CH₂NHCH₂	2-oxazolyl
703	H₂NCH₂CH₂NHCH₂	4-isoxazolyl
704	H₂NCH₂CH₂NHCH₂	4-HOC₆H₄
705	H₂NCH₂CH₂NHCH₂	3-HOC₆H₄
706	H₂NCH₂CH₂NHCH₂	3,4-diHOC₆H₄
707	H₂NCH₂CH₂NHCH₂	4-N112CH₂C₆H₄
708	H₂NCH₂CH₂NHCH₂	3-NH₂CH₂C₆H₄
709	Me₂NCH₂CH₂NHCH₂	4-MeOC₆H₄
710	Me₂NCH₂CH₂NHCH₂	3-MeOC₆H₄
111	Me₂NCH₂CH₂NHCH₂	4-NH₂C₆H₄
712	Me₂NCH₂CH₂NHCH₂	3-NH₂C₆H₄
713	Me₂NCH₂CH₂NHCH₂	2-NH₂C₆H₄
714	Me₂NCH₂CH₂NHCH₂	4-Me₂NC₆H₄
715	Me₂NCH₂CH₂NHCH₂	3-Me₂NC₆H₄
716	Me₂NCH₂CH₂NHCH₂	2-Me₂NC₆H₄
717	Me₂NCH₂CH₂NHCH₂	4-pyridyl
718	Me₂NCH₂CH₂NHCH₂	3-pyridyl
719	Me₂NCH₂CH₂NHCH₂	2-pyridyl
720	Me₂NCH₂CH₂NHCH₂	2-thiazolyl
721	Me₂NCH₂CH₂NHCH₂	2-pyrazolyl
722	Me₂NCH₂CH₂NHCH₂	5-isoquinolyl
723	Me₂NCH₂CH₂NHCH₂	BA-
		methylenedioxyC₆H₃
724	Me₂NCH₂CH₂NHCH₂	3,4-
		ethylenedioxyC₆H₃
725	Me₂NCH₂CH₂NHCH₂	2-imidazolyl
726	Me₂NCH₂CH₂NHCH₂	2-oxazolyl
727	Me₂NCH₂CH₂NHCH₂	4-isoxazolyl
728	Me₂NCH₂CH₂NHCH₂	4-H0C₆H₄
729	Me₂NCH₂CH₂NHCH₂	3-HOC₆H₄
730	Me₂NCH₂CH₂NHCH₂	3 ,4-diHOC₆H₄
731	Me₂NCH₂CH₂NHCH₂	4-NH₂CH₂C₆H₄
732	Me₂NCH₂CH₂NHCH₂	3-NH₂CH₂C₆H₄
733	1-morpholinylmethyl	3-MeOC₆H₄
734	1-morpholinylmethyl	4-NH-C₆H₄
735	1-morphoinlylmethyl	3-NH₂C₆H₄
736	1-morpholinylmethyl	2-NH₂C₆H₄
737	1-morpholinylmethyl	4-Me₂NC₆H₄
738	1-morpholinylmethyl	3-Me₂NC₆H₄
739	1-morpholinylmethyl	2-Me₂NC₆H₄
740	1-morpholinylmethyl	4-pyridyl
741	1-morpholinylmethyl	3-pyridyl
742	1-morpholinylmethyl	2-pyridyl
743	1-morpholinylmethyl	2-thiazolyl
744	1-morpholinylmethyl	2-pyrazolyl
745	1-morpholinylmethyl	5-isoquinolyl
746	1-morpholinylmethyl	3,4-
		methylenedioxyC₆H₃
747	1-morpholinylmethyl	3,4-
		ethylenedioxyC₆H₃
748	1-morpholinylmethyl	2-imidazolyl
749	1-morpholinylmethyl	2-oxazolyl
750	1-morpholinylmethyl	4-isoxazolyl
751	1-morpholinylmethyl	4-HOC₆H₄
752	1-morpholinylmethyl	3-HOC₆H₄
753	1-morpholinylmethyl	3,4-diHOC₆H₄
754	1-morpholinylmethyl	4-NH₂CH₂C₆H₄
755	1-morpholinylmethyl	3-NH₂CH₂C₆H₄
756	1-thiomorpholinylmethyl	3-MeOC₆H₄
757	1-thiomorpholinylmethyl	4-NH₂C₆H₄
758	1-thiomorpholinylmethyl	3-NH₂C₆H₄
759	1-thiomorpholinylmethyl	2-NH₂C₆H₄
760	1-thiomorpholinylmethyl	4-Me-NC₆H₄
761	1-thiomorpholinylmethyl	3-Me₂NC₆H₄
762	1-thiomorpholinylmethyl	2-Me₂NC₆H₄
763	1-thiomorpholinylmethyl	4-pyridyl
764	1-thiomorpholinylmethyl	3-pyridyl
765	1-thiomorpholinylmethyl	2-pyridyl
766	1-thiomorpho1inylmethyl	2-thiazolyl
767	1-thiomorpholinylmethyl	2-pyrazolyl
768	1-thiomorpholinylmethyl	5-isoquinolyl
769	1-thiomorpholinylmethyl	3,4-
		methylenedioxyC₆H₃
770	1-thiomorpholinylmethyl	3,4-
		ethylenedioxyC₆H₃
771	l-thiomorpholinylmethyl	2-imidazolyl
772	1-thiomorpholinylmethyl	2-oxazolyl
773	1-thiomorpholinylmethyl	4-isoxazolyl
774	1-thiomorpholinylmethyl	4-HOC₆H₄
775	1-thiomorpholinylmethyl	3-HOC6H-
776	1-thiomorpholinylmethyl	3,4-diHOC₆H₄
777	1-thiomorpholinylmethyl	4-Me₂CH₂C₆H₄
778	1-thiomorpholinylmethyl	3-NH₂CH₂C₆H₄
779	1-piperazinylmethyl	3-Me₂C₆H₄
780	1-piperazinylmethyl	4-NH₂C₆H₄
781	1-piperazinylmethyl	3-NH₂C₆H₄
782	1-piperazinylmethyl	2-NH₂C₆H₄
783	1-piperazinylmethyl	4-Me-NC-H-
784	1-piperazinylmethyl	3-Me₂NC₆H₄
785	1-piperazinylmethyl	2-Me₂NC₆H₄
786	1-piperazinylmethyl	4-pyridyl
787	1-piperazinylmethyl	3-pyridyl
788	1-piperazinylmethyl	2-pyridyl
789	1-piperazinylmethyl	2-thiazolyl
790	1-piperazinylmethyl	2-pyrazolyl
791	1-piperazinylmethyl	5-isoquinolyl
792	1-piperazinylmethyl	3,4-
		methylenedioxyC₆H₃
793	1-piperazinylmethyl	3,4-
		ethylenedioxyC₆H₃
794	1-piperazinylmethyl	2-imidazolyl
795	1-piperazinylmethyl	2-oxazolyl
796	1-piperazinylmethyl	4-isoxazolyl
797	1-piperazinylmethyl	4-HOC₆H₄
798	1-piperazinylmethyl	3-HOC₆H₄
799	1-piperazinylmethyl	3,4-diHOC₆H₄
800	1-piperazinylmethyl	4-NH₂CH₂C₆H₄
801	1-piperazinylmethyl	3-NH₂CH₂C₆H₄

TABLE 3

Example
Number	R¹	R²

802	2-pyridylmethyl	4-MeOC₆H₄
803	2-pyridylmethyl	3-MeOC₆H₄
804	2-pyridylmethyl	4-NH₂C₆H₄
805	2-pyridylmethyl	3-NH₂C₆H₄
806	2-pyridylmethyl	2-NH₂C₆H₄
807	2-pyridylmethyl	4-Me₂NC₆H₄
808	2-pyridylmethyl	3-Me₂NC₆H₄
809	2-pyridylmethyl	2-Me₂NC₆H₄
810	2-pyridylmethyl	4-pyridyl
811	2-pyridylmethyl	3-pyridyl
812	2-pyridylmethyl	2-pyridyl
813	2-pyridylmethyl	2-thiazolyl
814	2-pyridylmethyl	2-pyrazolyl
815	2-pyridylmethyl	5-isoquinolyl
816	2-pyridylmethyl	3,4-
		methylenedioxyC₆H₃
817	2-pyridylmethyl	3,4-
		ethylenedioxyC₆H₃
818	2-pyridylmethyl	2-imidazolyl
819	2-pyridylmethyl	2-oxazolyl
820	2-pyridylmethyl	4-isoxazolyl
821	2-pyridylmethyl	4-HOC₆H₄
822	2-pyridylmethyl	3-HOC₆H₄
823	2-pyridylmethyl	3,4-diHOC₆H₄
824	2-pyriclymethyl	4-NH₂CH₂C₆H₄
825	2-pyridyirmthyl	3-NH₂CH₂C₆H₄
826	3-pyridyirmthyl	4-MeOC₆H₄
827	3-pyridylmethyl	3-MeOC₆H₄
828	3-pyridylmethyl	4-NH₂C₆H₄
829	3-pyridylmethyl	3-NH₂C₆H₄
830	3-pyridylmethyl	2-NH₂C₆H₄
831	3-pyridylmethyl	4-Me₂NC₆H₄
832	3-pyridylmethyl	3-Me₂NC₆H₄
833	3-pyridylmethyl	2-Me₂NC₆H₄
834	3-pyridylmethyl	4-pyridyl
835	3-pyridyilmethyl	3-pyridyl
836	3-pyridylmethyl	2-pyridyl
837	3-pyridylmethyl	2-thiazolyl
838	3-pyridylmethyl	2-pyrazolyl
839	3-pyridylmethyl	5-isoquinolyl
840	3-pyridylmethyl	3,4-
		methylenedioxyC₆H₃
841	3-pyridylmethyl	3,4-
		ethylenedioxyC₆H₃
842	3-pyridylmethyl	2-imidazolyl
843	3-pyridylmethyl	2-oxazolyl
844	3-pyridylmethyl	4-isoxazolyl
845	3-pyridylmethyl	4-HOC₆H₄
846	3-pyridylmethyl	3-HOC₆H₄
847	3-pyridylmethyl	3,4-diHOC₆H₄
848	3-pyridylmethyl	4-NH₂CH₂C₆H₄
849	3-pyridylmethyl	3-NH₂CH₂C₆H₄
850	4-pyridylmethyl	4-MeOC₆H₄
851	4-pyridylmethyl	3-MeOC₆H₄
852	4-pyridylmethyl	4-NH₂C₆H₄
853	4-pyridylmethyl	3-NH₂C₆H₄
854	4-pyridylmethyl	2-NH₂C₆H₄
855	4-pyridylmethyl	4-Me₂NC₆H₄
856	4-pyridylmethyl	3-Me₂NC₆H₄
857	4-pyridylmethyl	2-Me₂NC₆H₄
858	4-pyridylmethyl	4-pyridyl
859	4-pyridylmethyl	3-pyridyl
860	4-pyridylmethyl	2-pyridyl
861	4-pyridylmethyl	2-thiazolyl
862	4-pyridylmethyl	2-pyrazolyl
863	4-pyridylmethyl	5-isoquinolyl
864	4-pyridylmethyl	3,4-
		methylenedioxyC₆H₃
865	4-pyridylmethyl	3,4-
		ethyl enedioxyC₆H₃
866	4-pyridylmethyl	2-imidazolyl
867	4-pyridylmethyl	2-oxazolyl
868	4-pyridylmethyl	4-isoxazolyl
869	4-pyridylmethyl	4-HOC₆H₄
870	4-pyridylmethyl	3-HOC₆H₄
871	4-pyridylmethyl	3,4-diHOC₆H₄
872	4-pyridylmethyl	4-NH₂CH₂C₆H₄
873	4-pyridylmethyl	3-NH₂CH₂C₆H₄
874	2-NH₂C₆H₄	4-MeOC₆H₄
875	2-NH₂C₆H₄	3-MeOC₆H₄
876	2-NH₂C₆H₄	4-NH₂C₆H₄
877	2-NH₂C₆H₄	3-NH₂C₆H₄
878	2-NH₂C₆H₄	2-NH₂C₆H₄
879	2-NH₂C₆H₄	4-Me₂NC₆H₄
880	2-NH₂C₆H₄	3-Me₂NC₆H₄
881	2-NH₂C₆H₄	2-Me₂NC₆H₄
882	2-NH₂C₆H₄	4-pyridyl
883	2-NH₂C₆H₄	3-pyridyl
884	2-NH₂C₆H₄	2-pyridyl
885	2-NH₂C₆H₄	2-thiazolyl
886	2-NH₂C₆H₄	2-pyrazolyl
887	2-NH₂C₆H₄	5-isoquinolyl
888	2-NH₂C₆H₄	3,4-
		methylenedioxyC₆H₃
889	2-NH₂C₆H₄	3,4-
		ethylenedioxyC₆H₃
890	2-NH₂C₆H₄	2-imidazolyl
891	2-NH₂C₆H₄	2-oxazolyl
892	2-NH₂C₆H₄	4-isoxazolyl
893	2-NH₂C₆H₄	4-HOC₆H₄
894	2-NH₂C₆H₄	3-HOC₆H₄
895	2-NH₂C₆H₄	3,4-diHOC₆H₄
896	2-NH₂C₆H₄	4-NH₂CH₂C₆H₄
897	2-NH₂C₆H₄	3-NH₂CH₂C₆H₄
898	3-NH₂C₆H₄	4-MeOC₆H₄
899	3-NH₂C₆H₄	3-MeOC₆H₄
900	3-NH₂C₆H₄	4-NH₂C₆H₄
901	3-NH₂C₆H₄	3-NH₂C₆H₄
902	3-NH₂C₆H₄	2-NH₂C₆H₄
903	3-NH₂C₆H₄	4-Me₂NC₆H₄
904	3-NH₂C₆H₄	3-Me₂NC₆H₄
905	3-NH₂C₆H₄	2-Me₂NC₆H₄
906	3-NH₂C₆H₄	4-pyridyl
907	3-NH₂C₆H₄	3-pyridyl
908	3-NH₂C₆H₄	2-pyridyl
909	3-NH₂C₆H₄	2-thiazolyl
910	3-NH₂C₆H₄	2-pyrazolyl
911	3-NH₂C₆H₄	5-isoquinolyl
912	3-NH₂C₆H₄	3,4-
		methylenedioxyC₆H₃
913	3-NH₂C₆H₄	3,4-
		ethylenedioxyC₆H₃
914	3-NH₂C₆H₄	2-imidazolyl
915	3-NH₂C₆H₄	2-oxazolyl
916	3-NH₂C₆H₄	4-isoxazolyl
917	3-NH₂C₆H₄	4-HOC₆H₄
918	3-NH₂C₆H₄	3-HOC₆H₄
919	3-NH₂C₆H₄	3,4-diHOC₆H₄
920	3-NH₂C₆H₄	4-NH₂CH₂C₆H₄
921	3-NH₂C₆H₄	3-NH₂CH₂C₆H₄
922	4-NH₂C₆H₄	4-NH₂CH₂C₆H₄
923	4-NH₂C₆H₄	3-MeOC₆H₄
924	4-NH₂C₆H₄	4-NH₂C₆H₄
925	4-NH₂C₆H₄	3-NH₂C₆H₄
926	4-NH₂C₆H₄	2-NH₂C₆H₄
927	4-NH₂C₆H₄	4-Me₂NC₆H₄
928	4-NH₂C₆H₄	3-Me₂NC₆H₄
930	4-NH₂C₆H₄	2-Me₂NC₆H₄
931	4-NH₂C₆H₄	4-pyridyl
932	4-NH₂C₆H₄	3-pyridyl
933	4-NH₂C₆H₄	2-pyridyl
934	4-NH₂C₆H₄	2-thiazolyl
935	4-NH₂C₆H₄	2-pyrazolyl
936	4-NH₂C₆H₄	5-isoquinolyl
937	4-NH₂C₆H₄	3,4-
		methylenedioxyC₆H₃
938	4-NH₂C₆H₄	3,4-
		ethylenedioxyC₆H₃
939	4-NH₂C₆H₄	3,4-
		ethylenedioxyC₆H₃
940	4-NH₂C₆H₄	2-oxazolyl
941	4-NH₂C₆H₄	4-isoxazolyl
942	4-NH₂C₆H₄	4-HOC₆H₄
943	4-NH₂C₆H₄	3-HOC₆H₄
944	4-NH₂C₆H₄	3,4-diHOC₆H₄
945	4-NH₂C₆H₄	4-NH₂CH₂C₆H₄
946	4-NH₂C₆H₄	3-NH₂CH₂C₆H₄
947	2-MeOC₆H₄	4-MeOC₆H₄
948	2-MeOC₆H₄	3-MeOC₆H₄
949	2-MeOC₆H₄	4-NH₂C₆H₄
950	2-MeOC₆H₄	3-NH₂C₆H₄
951	2-MeOC₆H₄	2-NH₂C₆H₄
952	2-MeOC₆H₄	4-Me₂NC₆H₄
953	2-MeOC₆H₄	3-Me₂NC₆H₄
954	2-MeOC₆H₄	2-Me₂NC₆H₄
955	2-MeOC₆H₄	4-pyridyl
956	2-MeOC₆H₄	3-pyridyl
957	2-MeOC₆H₄	2-pyridyl
958	2-MeOC₆H₄	2-thiazolyl
959	2-MeOC₆H₄	2-pyrazolyl
960	2-MeOC₆H₄	5-isoquinolyl
961	2-MeOC₆H₄	3,4-
		methylenedioxy₆H₃
962	2-MeOC₆H₄	3,4-
		ethylenedioxy₆H₃
963	2-MeOC₆H₄	2-imidazolyl
964	2-MeOC₆H₄	2-oxazolyl
965	2-MeOC₆H₄	4-isoxazolyl
966	2-MeOC₆H₄	4-HOC₆H₄
967	2-MeOC₆H₄	3-HOC₆H₄
968	2-MeOC₆H₄	3,4-diHOC₆H₄
969	2-MeOC₆H₄	4-NH₂CH₂C₆H₄
970	2-MeOC₆H₄	3-NH₂CH₂C₆H₄
971	3-MeOC₆H₄	4-MeOC₆H₄
972	3-MeOC₆H₄	3-MeOC₆H₄
973	3-MeOC₆H₄	4-NH₂C₆H₄
974	3-MeOC₆H₄	3-NH₂C₆H₄
975	3-MeOC₆H₄	2-NH₂C₆H₄
976	3-MeOC₆H₄	4-Me₂NC₆H₄
977	3-MeOC₆H₄	3-Me₂NC₆H₄
978	3-MeOC₆H₄	2-Me₂NC₆H₄
979	3-MeOC₆H₄	4-pyridyl
980	3-MeOC₆H₄	3-pyridyl
981	3-MeOC₆H₄	2-pyridyl
982	3-MeOC₆H₄	2-thiazolyl
983	3-MeOC₆H₄	2-pyrazolyl
984	3-MeOC₆H₄	5-isoquinolyl
985	3-MeOC₆H₄	3,4-
		methylenedioxyC₆H₃
986	3-MeOC₆H₄	3,4-
		ethylenedioxyC₆H₃
987	3-MeOC₆H₄	2-imidazolyl
988	3-MeOC₆H₄	2-oxazolyl
989	3-MeOC₆H₄	4-isoxazolyl
990	3-MeOC₆H₄	4-HOC₆H₄
991	3-MeOC₆H₄	3-HOC₆H₄
992	3-MeOC₆H₄	3,4-diHOC₆H₄
993	3-MeOC₆H₄	4-NH₂CH₂C₆H₄
994	3-MeOC₆H₄	3-NH₂CH₂C₆H₄
995	4-MeOC₆H₄	4-MeOC₆H₄
996	4-MeOC₆H₄	3-MeOC₆H₄
997	4-MeOC₆H₄	4-NH₂C₆H₄
998	4-MeOC₆H₄	3-NH₂C₆H₄
999	4-MeOC₆H₄	2-NH₂C₆H₄
1000	4-MeOC₆H₄	4-Me₂NC₆H₄
1001	4-MeOC₆H₄	3-Me₂NC₆H₄
1002	4-MeOC₆H₄	2-Me₂NC₆H₄
1003	4-MeOC₆H₄	4-pyridyl
1004	4-MeOC₆H₄	3-pyridyl
1005	4-MeOC₆H₄	2-pyridyl
1006	4-MeOC₆H₄	2-thiazolyl
1007	4-MeOC₆H₄	2-pyrazolyl
1008	4-MeOC₆H₄	5-isoquinolyl
1009	4-MeOC₆H₄	3,4-
		methylenedioxy₆H₃
1010	4-MeOC₆H₄	3,4-
		ethylenedioxyC₆H₃
1011	4-MeOC₆H₄	2-imidazolyl
1012	4-MeOC₆H₄	2-oxazolyl
1013	4-MeOC₆H₄	4-isoxazolyl
1014	4-MeOC₆H₄	4-HOC₆H₄
1015	4-MeOC₆H₄	3-HOC₆H₄
1016	4-MeOC₆H₄	3,4-diHOC₆H₄
1017	4-MeOC₆H₄	4-NH₂CH₂C₆H₄
1018	4-MeOC₆H₄	3-NH₂CH₂C₆H₄
1019	2-HOC₆H₄	4-MeOC₆H₄
1020	2-HOC₆H₄	3-MeOC₆H₄
1021	2-HOC₆H₄	4-NH₂C₆H₄
1022	2-HOC₆H₄	3-NH₂C₆H₄
1023	2-HOC₆H₄	2-NH₂C₆H₄
1024	2-HOC₆H₄	4-Me₂NC₆H₄
1025	2-HOC₆H₄	3-Me₂NC₆H₄
1026	2-HOC₆H₄	2-Me₂NC₆H₄
1027	2-HOC₆H₄	4-pyridyl
1028	2-HOC₆H₄	3-pyridyl
1029	2-HOC₆H₄	2-pyridyl
1030	2-HOC₆H₄	2-thiazolyl
1031	2-HOC₆H₄	2-pyrazolyl
1032	2-HOC₆H₄	5-isoquinolyl
1033	2-HOC₆H₄	3,4-
		methylenedioXyC₆H₃
1034	2-HOC₆H₄	3,4-
		ethylenedioxyC₆H₃
1035	2-HOC₆H₄	2-imidazolyl
1036	2-HOC₆H₄	2-oxazolyl
1037	2-HOC₆H₄	4-isoxazolyl
1038	2-HOC₆H₄	4-HOC₆H₄
1039	2-HOC₆H₄	3-HOC₆H₄
1040	2-HOC₆H₄	3,4-diHOC₆H₄
1041	2-HOC₆H₄	4-NH₂CH₂C₆H₄
1042	2-HOC₆H₄	3-NH₂CH₂C₆H₄
1043	3-HOC₆H₄	4-MeOC₆H₄
1044	3-HOC₆H₄	3-MeOC₆H₄
1045	3-HOC₆H₄	4-NH₂C₆H₄
1046	3-HOC₆H₄	3-NH₂C₆H₄
1047	3-HOC₆H₄	2-NH₂C₆H₄
1048	3-HOC₆H₄	4-Me₂NC₆H₄
1049	3-HOC₆H₄	3-Me₂NC₆H₄
1050	3-HOC₆H₄	2-Me₂NC₆H₄
1051	3-HOC₆H₄	4-pyridyl
1052	3-HOC₆H₄	3-pyridyl
1053	3-HOC₆H₄	2-pyridyl
1054	3-HOC₆H₄	2-thiazolyl
1055	3-HOC₆H₄	2-pyrazolyl
1056	3-HOC₆H₄	5-isoquinolyl
1057	3-HOC₆H₄	3,4-
		methylenedioxyC₆H₃
1058	3-HOC₆H₄	3,4-
		ethylenedioxyC₆H₃
1059	3-HOC₆H₄	2-imidazolyl
1060	3-HOC₆H₄	2-oxazolyl
1061	3-HOC₆H₄	4-isoxazolyl
1062	3-HOC₆H₄	4-HOC₆H₄
1063	3-HOC₆H₄	3-HOC₆H₄
1064	3-HOC₆H₄	3,4-diHOC₆H₄
1065	3-HOC₆H₄	4-NH₂CH₂C₆H₄
1066	3-HOC₆H₄	3-NH₂CH₂C₆H₄
1067	4-HOC₆H₄	4-MeOC₆H₄
1068	4-HOC₆H₄	3-MeOC₆H₄
1069	4-HOC₆H₄	4-NH₂C₆H₄
1070	4-HOC₆H₄	3-NH₂C₆H₄
1071	4-HOC₆H₄	2-NH₂C₆H₄
1072	4-HOC₆H₄	4-Me₂NC₆H₄
1073	4-HOC₆H₄	3-Me₂NC₆H₄
1074	4-HOC₆H₄	2-Me₂NC₆H₄
1075	4-HOC₆H₄	4-pyridyl
1076	4-HOC₆H₄	3-pyridyl
1077	4-HOC₆H₄	2-pyridyl
1078	4-HOC₆H₄	2-thiazolyl
1079	4-HOC₆H₄	2-pyrazolyl
1080	4-HOC₆H₄	5-isoquinolyl
1081	4-HOC₆H₄	3,4-
		methylenedioxyC₆H₃
1082	4-HOC₆H₄	3,4-
		ethylenedioxyC₆H₃
1083	4-HOC₆H₄	2-imidazolyl
1084	4-HOC₆H₄	2-oxazolyl
1085	4-HOC₆H₄	4-isoxazolyl
1086	4-HOC₆H₄	4-HOC₆H₄
1087	4-HOC₆H₄	3-HOC₆H₄
1088	4-HOC₆H₄	3,4-diHOC₆H₄
1089	4-HOC₆H₄	4-NH₂CH₂C₆H₄
1090	4-HOC₆H₄	3-NH₂CH₂C₆H₄
1091	4-C1C₆H₄	4-MeOC₆H₄
1092	4-ClC₆H₄	3-MeOC₆H₄
1093	4-ClC₆H₄	4-NH₂C₆H₄
1094	4-ClC₆H₄	3-NH₂C₆H₄
1095	4-ClC₆H₄	2-NH₂C₆H₄
1096	4-ClC₆H₄	4-Me₂NC₆H₄
1097	4-ClC₆H₄	3-Me₂NC₆H₄
1098	4-ClC₆H₄	2-Me₂NC₆H₄
1099	4-ClC₆H₄	4-pyridyl
1100	4-ClC₆H₄	3-pyridyl
1101	4-ClC₆H₄	2-pyridyl
1102	4-ClC₆H₄	2-thiazolyl
1103	4-ClC₆H₄	2-pyrazolyl
1104	4-ClC₆H₄	5-isoquinolyl
1105	4-ClC₆H₄	3,4-
		methylenedioxyC₆H₃
1106	4-ClC₆H₄	3,4-
		ethylenedioxyC₆H₃
1107	4-ClC₆H₄	2-imidazolyl
1108	4-ClC₆H₄	2-oxazolyl
1109	4-ClC₆H₄	4-isoxazolyl
1110	4-ClC₆H₄	4-HOC₆H₄
1111	4-ClC₆H₄	3-HOC₆H₄
1112	4-ClC₆H₄	3,4-diHOC₆H₄
1113	4-ClC₆H₄	4-NH₂CH₂C₆H₄
1114	4-ClC₆H₄	3-NH₂CH₂C₆H₄
1115	2-NH₂CH₂C₆H₄	4-MeOC₆H₄
1116	2-NH₂CH₂C₆H₄	3-MeOC₆H₄
1117	2-NH₂CH₂C₆H₄	4-NH₂C₆H₄
1118	2-NH₂CH₂C₆H₄	3-NH₂C₆H₄
1119	2-NH₂CH₂C₆H₄	2-NH₂C₆H₄
1120	2-NH₂CH₂C₆H₄	4-Me₂NC₆H₄
1121	2-NH₂CH₂C₆H₄	3-Me₂NC₆H₄
1122	2-NH₂CH₂C₆H₄	2-Me₂NC₆H₄
1123	2-NH₂CH₂C₆H₄	4-pyridyl
1124	2-NH₂CH₂C₆H₄	3-pyridyl
1125	2-NH₂CH₂C₆H₄	2-pyridyl
1126	2-NH₂CH₂C₆H₄	2-thiazolyl
1127	2-NH₂CH₂C₆H₄	2-pyrazolyl
1128	2-NH₂CH₂C₆H₄	5-isoquinolyl
1129	2-NH₂CH₂C₆H₄	3,4-
		methylenedioxyC₆H₃
1130	2-NH₂CH₂C₆H₄	3,4-
		ethylenedioxyC₆H₃
1131	2-NH₂CH₂C₆H₄	2-imidazolyl
1132	2-NH₂CH₂C₆H₄	2-oxazolyl
1133	2-NH₂CH₂C₆H₄	4-isoxazolyl
1134	2-NH₂CH₂C₆H₄	4-HOC₆H₄
1135	2-NH₂CH₂C₆H₄	3-HOC₆H₄
1136	2-NH₂CH₂C₆H₄	3,4-diHOC₆H₄
1137	2-NH₂CH₂C₆H₄	4-NH₂CH₂C₆H₄
1138	2-NH₂CH₂C₆H₄	3-NH₂CH₂C₆H₄
1139	3-NH₂CH₂C₆H₄	4-MeOC₆H₄
1140	3-NH₂CH₂C₆H₄	3-MCOC₆H₄
1141	3-NH₂CH₂C₆H₄	4-NH₂C₆H₄
1142	3-NH₂CH₂C₆H₄	3-NH₂C₆H₄
1143	3-NH₂CH₂C₆H₄	2-NH₂C₆H₄
1144	3-NH₂CH₂C₆H₄	4-Me₂NC₆H₄
1145	3-NH₂CH₂C₆H₄	3-Me₂NC₆H₄
1146	3-NH₂CH₂C₆H₄	2-Me₂NC₆H₄
1147	3-NH₂CH₂C₆H₄	4-pyridyl
1148	3-NH₂CH₂C₆H₄	3-pyridyl
1149	3-NH₂CH₂C₆H₄	2-pyridyl
1150	3-NH₂CH₂C₆H₄	2-thiazolyl
1151	3-NH₂CH₂C₆H₄	2-pyrazolyl
1152	3-NH₂CH₂C₆H₄	5-isoquinolyl
1153	3-NH₂CH₂C₆H₄	3,4-
		methylenedioxyC₆H₃
1154	3-NH₂CH₂C₆H₄	3,4-
		ethylenedioxyC₆H₃
1155	3-NH₂CH₂C₆H₄	2-imidazolyl
1156	3-NH₂CH₂C₆H₄	2-oxazolyl
1157	3-NH₂CH₂C₆H₄	4-isoxazolyl
1158	3-NH₂CH₂C₆H₄	4-HOC₆H₄
1159	3-NH₂CH₂C₆H₄	3-HOC₆H₄
1160	3-NH₂CH₂C₆H₄	3,4-diHOC₆H₄
1161	3-NH₂CH₂C₆H₄	4-NH₂CH₂C₆H₄
1162	3-NH₂CH₂C₆H₄	3-NH₂CH₂C₆H₄
1163	4-NH₂CH₂C₆H₄	4-MeOC₆H₄
1164	4-NH₂CH₂C₆H₄	3-MeOC₆H₄
1165	4-NH₂CH₂C₆H₄	4-NH₂C₆H₄
1166	4-NH₂CH₂C₆H₄	3-NH₂C₆H₄
1167	4-NH₂CH₂C₆H₄	2-NH₂C₆H₄
1168	4-NH₂CH₂C₆H₄	4-Me₂NC₆H₄
1169	4-NH₂CH₂C₆H₄	3-Me₂NC₆H₄
1170	4-NH₂CH₂C₆H₄	2-Me₂NC₆H₄
1171	4-NH₂CH₂C₆H₄	4-pyridyl
1172	4-NH₂CH₂C₆H₄	3-pyridyl
1173	4-NH₂CH₂C₆H₄	2-pyridyl
1174	4-NH₂CH₂C₆H₄	2-thiazolyl
1175	4-NH₂CH₂C₆H₄	2-pyrazolyl
1176	4-NH₂CH₂C₆H₄	5-isoquinolyl
1177	4-NH₂CH₂C₆H₄	3,4-
		methylenedioxy₆H₃
1178	4-NH₂CH₂C₆H₄	3,4-
		ethylenedioxy₆H₃
1179	4-NH₂CH₂C₆H₄	2-imidazolyl
1180	4-NH₂CH₂C₆H₄	2-oxazolyl
1181	4-NH₂CH₂C₆H₄	4-isoxazolyl
1182	4-NH₂CH₂C₆H₄	4-HOC₆H₄
1183	4-NH₂CH₂C₆H₄	3-HOC₆H₄
1184	4-NH₂CH₂C₆H₄	3,4-diHOC₆H₄
1185	4-NH₂CH₂C₆H₄	4-NH₂CH₂C₆H₄
1186	4-NH₂CH₂C₆H₄	3-NH₂CH₂C₆H₄
1187	2-Me₂NCH₂C₆H₄	4-MeOC₆H₄
1188	2-Me₂NCH₂C₆H₄	3-MeOC₆H₄
1189	2-Me₂NCH₂C₆H₄	4-NH₂C₆H₄
1190	2-Me₂NCH₂C₆H₄	3-NH₂C₆H₄
1191	2-Me₂NCH₂C₆H₄	2-NH₂C₆H₄
1192	2-Me₂NCH₂C₆H₄	4-Me₂NC₆H₄
1193	2-Me₂NCH₂C₆H₄	3-Me₂NC₆H₄
1194	2-Me₂NCH₂C₆H₄	2-Me₂NC₆H₄
1195	2-Me₂NCH₂C₆H₄	4-pyridyl
1196	2-Me₂NCH₂C₆H₄	3-pyridyl
1197	2-Me₂NCH₂C₆H₄	2-pyridyl
1198	2-Me₂NCH₂C₆H₄	2-thiazolyl
1199	2-Me₂NCH₂C₆H₄	2-pyrazolyl
1200	2-Me₂NCH₂C₆H₄	5-isoquinolyl
1201	2-Me₂NCH₂C₆H₄	3,4-
		methylenedioxyC₆H₃
1202	2-Me₂NCH₂C₆H₄	3,4-
		ethylenedioxyC₆H₃
1203	2-Me₂NCH₂C₆H₄	2-imidazolyl
1204	2-Me₂NCH₂C₆H₄	2-oxazolyl
1205	2-Me₂NCH₂C₆H₄	4-isoxazolyl
1206	2-Me₂NCH₂C₆H₄	4-HOC₆H₄
1207	2-Me₂NCH₂C₆H₄	3-HOC₆H₄
1208	2-Me₂NCH₂C₆H₄	3,4-diHOC₆H₄
1209	2-Me₂NCH₂C₆H₄	4-NH₂CH₂C₆H₄
1210	2-Me₂NCH₂C₆H₄	3-NH₂CH₂C₆H₄
1211	3-Me₂NCH₂C₆H₄	4-MeOC₆H₄
1212	3-Me₂NCH₂C₆H₄	3-MeOC₆H₄
1213	3-Me₂NCH₂C₆H₄	4-NH₂C₆H₄
1214	3-Me₂NCH₂C₆H₄	3-NH₂C₆H₄
1215	3-Me₂NCH₂C₆H₄	2-NH₂C₆H₄
1216	3-Me₂NCH₂C₆H₄	4-Me₂NC₆H₄
1217	3-Me₂NCH₂C₆H₄	3-Me₂NC₆H₄
1218	3-Me₂NCH₂C₆H₄	2-Me₂NC₆H₄
1219	3-Me₂NCH₂C₆H₄	4-pyridyl
1220	3-Me₂NCH₂C₆H₄	3-pyridyl
1221	3-Me₂NCH₂C₆H₄	2-pyridyl
1222	3-Me₂NCH₂C₆H₄	2-thiazolyl
1223	3-Me₂NCH₂C₆H₄	2-pyrazolyl
1224	3-Me₂NCH₂C₆H₄	5-isoquinolyl
1225	3-Me₂NCH₂C₆H₄	3,4-
		methylenedioxyC₆H₃
1226	3-Me₂NCH₂C₆H₄	3,4-
		ethylenedioxyC₆H₃
1227	3-Me₂NCH₂C₆H₄	2-imidazolyl
1228	3-Me₂NCH₂C₆H₄	2-oxazolyl
1229	3-Me₂NCH₂C₆H₄	4-isoxazolyl
1230	3-Me₂NCH₂C₆H₄	4-HOC₆H₄
1231	3-Me₂NCH₂C₆H₄	3-HOC₆H₄
1232	3-Me₂NCH₂C₆H₄	3,4-diHOC₆H₄
1233	3-Me₂NCH₂C₆H₄	4-NH₂CH₂C₆H₄
1234	3-Me₂NCH₂C₆H₄	3-NH₂CH₂C₆H₄
1235	4-Me₂NCH₂C₆H₄	4-MeOC₆H₄
1236	4-Me₂NCH₂C₆H₄	3-MeOC₆H₄
1237	4-Me₂NCH₂C₆H₄	4-NH₂C₆H₄
1238	4-Me₂NCH₂C₆H₄	3-NH₂C₆H₄
1239	4-Me₂NCH₂C₆H₄	2-NH₂C₆H₄
1240	4-Me₂NCH₂C₆H₄	4-Me₂NC₆H₄
1241	4-Me₂NCH₂C₆H₄	3-Me₂NC₆H₄
1242	4-Me₂NCH₂C₆H₄	2-Me₂NC₆H₄
1243	4-Me₂NCH₂C₆H₄	4-pyridyl
1244	4-Me₂NCH₂C₆H₄	3-pyridyl
1245	4-Me₂NCH₂C₆H₄	2-pyridyl
1246	4-Me₂NCH₂C₆H₄	2-thiazolyl
1247	4-Me₂NCH₂C₆H₄	2-pyrazolyl
1248	4-Me₂NCH₂C₆H₄	5-isoquinolyl
1249	4-Me₂NCH₂C₆H₄	3,4-
		methylenedioxyC₆H₃
1250	4-Me₂NCH₂C₆H₄	3,4-
	ethylenedioxyC₆H₃
1251	4-Me₂NCH₂C₆H₄	2-imidazolyl
1252	4-Me₂NCH₂C₆H₄	2-oxazolyl
1253	4-Me₂NCH₂C₆H₄	4-isoxazolyl
1254	4-Me₂NCH₂C₆H₄	4-HOC₆H₄
1255	4-Me₂NCH₂C₆H₄	3-HOC₆H₄
1256	4-Me₂NCH₂C₆H₄	3,4-diHOC₆H₄
1257	4-Me₂NCH₂C₆H₄	4-NH₂CH₂C₆H₄
1258	4-Me₂NCH₂C₆H₄	3-NH₂CH₂C₆H₄
1259	H	4-MeOC₆H₄
1260	H	3-MeOC₆H₄
1261	H	4-NH₂C₆H₄
1262	H	3-NH₂C₆H₄
1263	H	2-NH₂C₆H₄
1264	H	4-Me₂NC₆H₄
1265	H	3-Me₂NC₆H₄
1266	H	2-Me₂NC₆H₄
1267	H	4-pyridyl
1268	H	3-pyridyl
1269	H	2-pyridyl
1270	H	2-thiazolyl
1271	H	2-pyrazolyl
1272	H	5-isoquinolyl
1273	H	3,4-
		methylenedioxyC₆H₃
1274	H	3,4-
		methylenedioxyC₆H₃
1275	H	2-imidazolyl
1276	H	2-oxazolyl
1277	H	4-isoxazolyl
1278	H	4-HOC₆H₄
1279	H	3-HOC₆H₄
1280	H	3,4-diHOC₆H₄
1281	H	4-NH₂CH₂C₆H₄
1282	H	3-NH₂CH₂C₆H₄
1283	Me	4-MeOC₆H₄
1284	Me	3-MeOC₆H₄
1285	Me	4-NH-hd 2C₆H₄
1286	Me	3-NH₂C₆H₄
1287	Me	2-NH₂C₆H₄
1288	Me	4-Me₂NC₆H₄
1289	Me	3-Me₂NC₆H₄
1290	Me	2-Me₂NC₆H₄
1291	Me	4-pyridyl
1292	Me	3-pyridyl
1293	Me	2-pyridyl
1294	Me	2-thiazolyl
1295	Me	2-pyrazolyl
1296	Me	5-isoquinolyl
1297	Me	3,4-
		methylenedioxyC₆H₃
1298	Me	3,4-
		ethylenedioxy₆H₃
1299	Me	2-imidazolyl
1300	Me	2-oxazolyl
1301	Me	4-isoxazolyl
1302	Me	4-HOC₆H₄
1303	Me	3-HOC₆H₄
1304	Me	3,4-diHOC₆H₄
1305	Me	4-NH₂CH₂C₆H₄
1306	Me	3-NH₂CH₂C₆H₄
1307	Et	4-MeOC₆H₄
1308	Et	3-MeOC₆H₄
1309	Et	4-NH₂C₆H₄
1310	Et	3-NH₂C₆H₄
1311	Et	2-NH₂C₆H₄
1312	Et	4-Me₂NC₆H₄
1313	Et	3-Me₂NC₆H₄
1314	Et	2-Me₂NC₆H₄
1315	Et	4-pyridyl
1316	Et	3-pyridyl
1317	Et	2-pyridyl
1318	Et	2-thiazolyl
1319	Et	2-pyrazolyl
1320	Et	5-isoquinolyl
1321	Et	3,4-
		methylenedioxyC₆H₃
1322	Et	3,4-
		ethylenedioxyC₆H₃
1323	Et	2-imidazolyl
1324	Et	2-oxazolyl
1325	Et	4-isoxazolyl
1326	Et	4-HOC₆H₄
1327	Et	3-HOC₆H₄
1328	Et	3,4-diHOC₆H₄
1329	Et	4-NH₂CH₂C₆H₄
1330	Et	3-NH₂CH₂C₆H₄
1331	2-NH₂C₆H₄CH₂	4-MeOC₆H₄
1332	2-NH₂C₆H₄CH₂	3-MeOC₆H₄
1333	2-NH₂C₆H₄CH₂	4-NH₂C₆H₄
1334	2-NH₂C₆H₄CH₂	3-NH₂C₆H₄
1335	2-NH₂C₆H₄CH₂	2-NH₂C₆H₄
1336	2-NH₂C₆H₄CH₂	4-Me₂NC₆H₄
1337	2-NH₂C₆H₄CH₂	3-Me₂NC₆H₄
1338	2-NH₂C₆H₄CH₂	2-Me₂NC₆H₄
1339	2-NH₂C₆H₄CH₂	4-pyridyl
1340	2-NH₂C₆H₄CH₂	3-pyridyl
1341	2-NH₂C₆H₄CH₂	2-pyridyl
1342	2-NH₂C₆H₄CH₂	2-thiazolyl
1343	2-NH₂C₆H₄CH₂	2-pyrazolyl
1344	2-NH₂C₆H₄CH₂	5-isoquinolyl
1345	2-NH₂C₆H₄CH₂	3,4-
		methylenedioxy₆H₃
1346	2-NH₂C₆H₄CH₂	3,4-
		ethylenedioxyC₆H₃
1347	2-NH₂C₆H₄CH₂	2-imidazolyl
1348	2-NH₂C₆H₄CH₂	2-oxazolyl
1349	2-NH₂C₆H₄CH₂	4-isoxazolyl
1350	2-NH₂C₆H₄CH₂	4-HOC₆H₄
1351	2-NH₂C₆H₄CH₂	3-HOC₆H₄
1352	2-NH₂C₆H₄CH₂	3,4-diHOC₆H₄
1353	2-NH₂C₆H₄CH₂	4-NH₂CH₂C₆H₄
1354	2-NH₂C₆H₄CH₂	3-NH₂CH₂C₆H₄
1355	3-NH₂C₆H₄CH₂	4-MeOC₆H₄
1356	3-NH₂C₆H₄CH₂	3-MeOC₆H₄
1357	3-NH₂C₆H₄CH₂	4-NH₂C₆H₄
1358	3-NH₂C₆H₄CH₂	3-NH₂C₆H₄
1359	3-NH₂C₆H₄CH₂	2-NH₂C₆H₄
1360	3-NH₂C₆H₄CH₂	4-Me₂NC₆H₄
1361	3-NH₂C₆H₄CH₂	3-Me₂NC₆H₄
1362	3-NH₂C₆H₄CH₂	2-Me₂NC₆H₄
1363	3-NH₂C₆H₄CH₂	4-pyridyl
1364	3-NH₂C₆H₄CH₂	3-pyridyl
1365	3-NH₂C₆H₄CH₂	2-pyridyl
1366	3-NH₂C₆H₄CH₂	2-thiazolyl
1367	3-NH₂C₆H₄CH₂	2-pyrazolyl
1367	3-NH₂C₆H₄CH₂	5-isoquinolyl
1369	3-NH₂C₆H₄CH₂	3,4
		methylenedioxyC₆H₃
1370	3-NH₂C₆H₄CH₂	3,4-
		ethylenedioxyC₆H₃
1371	3-NH₂C₆H₄CH₂	2-imidazolyl
1372	3-NH₂C₆H₄CH₂	2-oxazolyl
1373	3-NH₂C₆H₄CH₂	4-isoxazolyl
1374	3-NH₂C₆H₄CH₂	4-HOC₆H₄
1375	3-NH₂C₆H₄CH₂	3-HOC₆H₄
1376	3-NH₂C₆H₄CH₂	3,4-diHOC₆H₄
1377	3-NH₂C₆H₄CH₂	4-NH₂CH₂C₆H₄
1378	3-NH₂C₆H₄CH₂	3-NH₂CH₂C₆H₄
1379	4-NH₂C₆H₄CH₂	4-MeOC₆H₄
1380	4-NH₂C₆H₄CH₂	3-MeOC₆H₄
1381	4-NH₂C₆H₄CH₂	4-NH₂C₆H₄
1382	4-NH₂C₆H₄CH₂	3-NH₂C₆H₄
1383	4-NH₂C₆H₄CH₂	2-NH₂C₆H₄
1384	4-NH₂C₆H₄CH₂	4-Me₂NC₆H₄
1385	4-NH₂C₆H₄CH₂	3-Me₂NC₆H₄
1386	4-NH₂C₆H₄CH₂	2-Me₂NC₆H₄
1387	4-NH₂C₆H₄CH₂	4-pyridyl
1388	4-NH₂C₆H₄CH₂	3-pyridyl
1389	4-NH₂C₆H₄CH₂	2-pyridyl
1390	4-NH₂C₆H₄CH₂	2-thiazolyl
1391	4-NH₂C₆H₄CH₂	2-pyrazolyl
1392	4-NH₂C₆H₄CH₂	5-isoquinolyl
1393	4-NH₂C₆H₄CH₂	3,4
		methylenedioxyC₆H₃
1394	4-NH₂C₆H₄CH₂	3,4
		ethylenedioxyC₆H₃
1395	4-NH₂C₆H₄CH₂	2-imidazolyl
1396	4-NH₂C₆H₄CH₂	2-oxazolyl
1397	4-NH₂C₆H₄CH₂	4-isoxazolyl
1398	4-NH₂C₆H₄CH₂	4-HOC₆H₄
1399	4-NH₂C₆H₄CH₂	3-HOC₆H₄
1400	4-NH₂C₆H₄CH₂	3,4-diHOC₆H₄
1401	4-NH₂C₆H₄CH₂	4-NH₂CH₂C₆H₄
1402	4-NH₂C₆H₄CH₂	3-NH₂CH₂C₆H₄
1403	2-MeOC₆H₄CH₂	4-MeOC₆H₄
1404	2-MeOC₆H₄CH₂	3-MeOC₆H₄
1405	2-MeOC₆H₄CH₂	4-NH₂C₆H₄
1406	2-MeOC₆H₄CH₂	3-NH₂C_H ₄
1407	2-MeOC₆H₄CH₂	2-NH₂C₆H₄
1408	2-MeOC₆H₄CH₂	4-Me₂NC₆H₄
1409	2-MeOC₆H₄CH₂	3-Me₂NC₆H₄
1410	2-MeOC₆H₄CH₂	2-Me₂NC₆H₄
1411	2-MeOC₆H₄CH₂	4-pyridyl
1412	2-MeOC₆H₄CH₂	3-pyridyl
1413	2-MeOC₆H₄CH₂	2-pyridyl
1414	2-MeOC₆H₄CH₂	2-thiazolyl
1415	2-MeOC₆H₄CH₂	2-pyrazolyl
1416	2-MeOC₆H₄CH₂	5-isoquinolyl
1417	2-MeOC₆H₄CH₂	3,4-
		methylenedioxyC₆H₃
1418	2-MeOC₆H₄CH₂	3,4-
		ethylenedioxyC₆H₃
1419	2-MeOC₆H₄CH₂	2-imidazolyl
1420	2-MeOC₆H₄CH₂	2-oxazolyl
1421	2-MeOC₆H₄CH₂	4-isoxazolyl
1422	2-MeOC₆H₄CH₂	4-HOC₆H₄
1423	2-MeOC₆H₄CH₂	3-HOC₆H₄
1424	2-MeOC₆H₄CH₂	3,4-diHOC₆H₄
1425	2-MeOC₆H₄CH₂	4-NH₂CH₂C₆H₄
1426	2-MeOC₆H₄CH₂	3-NH₂CH₂C₆H₄
1427	3-MeOC₆H₄CH₂	4-MeOC₆H₄
1428	3-MeOC₆H₄CH₂	3-MeOC₆H₄
1429	3-MeOC₆H₄CH₂	4-NH₂C₆H₄
1430	3-MeOC₆H₄CH₂	3-NH₂C₆H₄
1431	3-MeOC₆H₄CH₂	2-NH₂C₆H₄
1432	3-MeOC₆H₄CH₂	4-Me₂NC₆H₄
1433	3-MeOC₆H₄CH₂	3-Me₂NC₆H₄
1434	3-MeOC₆H₄CH₂	2-Me₂NC₆H₄
1435	3-MeOC₆H₄CH₂	4-pyridyl
1436	3-MeOC₆H₄CH₂	3-pyridyl
1437	3-MeOC₆H₄CH₂	2-pyridyl
1438	3-MeOC₆H₄CH₂	2-thiazolyl
1439	3-MeOC₆H₄CH₂	2-pyrazolyl
1440	3-MeOC₆H₄CH₂	5-isoquinolyl
1441	3-MeOC₆H₄CH₂	3,4
		methylenedioxyC₆H₃
1442	3-MeOC₆H₄CH₂	3,4-
		ethylenedioxyC₆H₃
1443	3-MeOC₆H₄CH₂	2-imidazolyl
1444	3-MeOC₆H₄CH₂	2-oxazolyl
1445	3-MeOC₆H₄CH₂	4-isoxazolyl
1446	3-MeOC₆H₄CH₂	4-HOC₆H₄
1447	3-MeOC₆H₄CH₂	3-HOC₆H₄
1448	3-MeOC₆H₄CH₂	3,4-diHOC₆H₄
1449	3-MeOC₆H₄CH₂	4-NH₂CH₂C₆H₄
1450	3-MeOC₆H₄CH₂	3-NH₂CH₂C₆H₄
1451	4-MeOC₆H₄CH₂	4-MeOC₆H₄
1452	4-MeOC₆H₄CH₂	3-MeOC₆H₄
1453	4-MeOC₆H₄CH₂	4-NH₂C₆H₄
1454	4-MeOC₆H₄CH₂	3-NH₂C₆H₄
1455	4-MeOC₆H₄CH₂	2-NH₂C₆H₄
1456	4-MeOC₆H₄CH₂	4-Me₂NC₆H₄
1457	4-MeOC₆H₄CH₂	3-Me₂NC₆H₄
1458	4-MeOC₆H₄CH₂	2-Me₂NC₆H₄
1459	4-MeOC₆H₄CH₂	4-pyridyl
1460	4-MeOC₆H₄CH₂	3-pyridyl
1461	4-MeOC₆H₄CH₂	2-pyridyl
1462	4-MeOC₆H₄CH₂	2-thiazolyl
1463	4-MeOC₆H₄CH₂	2-pyrazolyl
1464	4-MeOC₆H₄CH₂	5-isoquinolyl
1465	4-MeOC₆H₄CH₂	3,4-
		methylenedioxyC₆H₃
1466	4-MeOC₆H₄CH₂	3,4-
		ethylenedioxyC₆H₃
1467	4-MeOC₆H₄CH₂	2-imidazolyl
1468	4-MeOC₆H₄CH₂	2-oxazolyl
1469	4-MeOC₆H₄CH₂	4-isoxazolyl
1470	4-MeOC₆H₄CH₂	4-HOC₆H₄
1471	4-MeOC₆H₄CH₂	3-HOC₆H₄
1472	4-MeOC₆H₄CH₂	3,4-diHOC₆H₄
1473	4-MeOC₆H₄CH₂	4-NH₂CH₂C₆H₄
1474	4-MeOC₆H₄CH₂	3-NH₂CH₂C₆H₄
1475	2-HOC₆H₄CH₂	4-MeOC₆H₄
1476	2-HOC₆H₄CH₂	3-MeOC₆H₄
1477	2-HOC₆H₄CH₂	4-NH₂C₆H₄
1478	2-HOC₆H₄CH₂	3-NH₂C₆H₄
1479	2-HOC₆H₄CH₂	2-NH₂C₆H₄
1480	2-HOC₆H₄CH₂	4-Me₂NC₆H₄
1481	2-HOC₆H₄CH₂	3-Me₂NC₆H₄
1482	2-HOC₆H₄CH₂	2-Me₂NC₆H₄
1483	2-HOC₆H₄CH₂	4-pyridyl
1484	2-HOC₆H₄CH₂	3-pyridyl
1485	2-HOC₆H₄CH₂	2-pyridyl
1486	2-HOC₆H₄CH₂	2-thiazolyl
1487	2-HOC₆H₄CH₂	2-pyrazolyl
1488	2-HOC₆H₄CH₂	5-isoquinolyl
1489	2-HOC₆H₄CH₂	3,4-
		methylenedioxy₆H₃
1490	2-HOC₆H₄CH₂	3,4-
		ethylenedioxy₆H₃
1491	2-HOC₆H₄CH₂	2-imidazolyl
1492	2-HOC₆H₄CH₂	2-oxazolyl
1493	2-HOC₆H₄CH₂	4-isoxazolyl
1494	2-HOC₆H₄CH₂	4-HOC₆H₄
1495	2-HOC₆H₄CH₂	3-HOC₆H₄
1496	2-HOC₆H₄CH₂	3,4-diHOC₆H₄
1497	2-HOC₆H₄CH₂	4-NH₂CH₂C₆H₄
1498	2-HOC₆H₄CH₂	3-NH₂CH₂C₆H₄
1499	3-HOC₆H₄CH₂	4-MeOC₆H₄
1500	3-HOC₆H₄CH₂	3-MeOC₆H₄
1501	3-HOC₆H₄CH₂	4-NH₂C₆H₄
1502	3-HOC₆H₄CH₂	3-NH₂C₆H₄
1503	3-HOC₆H₄CH₂	2-NH₂C₆H₄
1504	3-HOC₆H₄CH₂	4-Me₂NC₆H₄
1505	3-HOC₆H₄CH₂	3-Me₂NC₆H₄
1506	3-HOC₆H₄CH₂	2-Me₂NC₆H₄
1507	3-HOC₆H₄CH₂	4-pyridyl
1508	3-HOC₆H₄CH₂	3-pyridyl
1509	3-HOC₆H₄CH₂	2-pyridyl
1510	3-HOC₆H₄CH₂	2-thiazolyl
1511	3-HOC₆H₄CH₂	2-pyrazolyl
1512	3-HOC₆H₄CH₂	5-isoquinolyl
1513	3-HOC₆H₄CH₂	3,4-
		methylenedioxyC₆H₃
1514	3-HOC₆H₄CH₂	3,4-
		ethylenedioxyC₆H₃
1514	3-HOC₆H₄CH₂	2-imidazolyl
1516	3-HOC₆H₄CH₂	2-oxazolyl
1517	3-HOC₆H₄CH₂	4-isoxazolyl
1518	3-HOC₆H₄CH₂	4-HOC₆H₄
1519	3-HOC₆H₄CH₂	3-HOC₆H₄
1520	3-HOC₆H₄CH₂	3,4-diHOC₆H₄
1521	3-HOC₆H₄CH₂	4-NH₂CH₂C₆H₄
1522	3-HOC₆H₄CH₂	3-NH₂CH₂C₆H₄
1523	4-HOC₆H₄CH₂	4-MeOC₆H₄
1524	4-HOC₆H₄CH₂	3-MeOC₆H₄
1525	4-HOC₆H₄CH₂	4-NH₂C₆H₄
1526	4-HOC₆H₄CH₂	3-NH₂C₆H₄
1527	4-HOC₆H₄CH₂	2-NH₂C₆H₄
1528	4-HOC₆H₄CH₂	4-Me₂NC₆H₄
1529	4-HOC₆H₄CH₂	3-Me₂NC₆H₄
1530	4-HOC₆H₄CH₂	2-Me₂NC₆H₄
1531	4-HOC₆H₄CH₂	4-pyridyl
1532	4-HOC₆H₄CH₂	3-pyridyl
1533	4-HOC₆H₄CH₂	2-pyridyl
1534	4-HOC₆H₄CH₂	2-thiazolyl
1535	4-HOC₆H₄CH₂	2-pyrazolyl
1536	4-HOC₆H₄CH₂	5-isoquinolyl
1537	4-HOC₆H₄CH₂	3,4-
		methylenedioxyC₆H₃
1538	4-HOC₆H₄CH₂	3,4
		ethylenedioxyC₆H₃
1539	4-HOC₆H₄CH₂	2-imidazolyl
1540	4-HOC₆H₄CH₂	2-oxazolyl
1541	4-HOC₆H₄CH₂	4-isoxazolyl
1542	4-HOC₆H₄CH₂	4-HOC₆H₄
1543	4-HOC₆H₄CH₂	3-HOC₆H₄
1544	4-HOC₆H₄CH₂	3,4-diHOC₆H₄
1545	4-HOC₆H₄CH₂	4-NH₂CH₂C₆H₄
1546	4-HOC₆H₄CH₂	3-NH₂CH₂C₆H₄
1547	4-ClC₆H₄CH₂	4-MeOC₆H₄
1548	4-ClC₆H₄CH₂	3-MeOC₆H₄
1549	4-ClC₆H₄CH₂	4-NH₂C₆H₄
1550	4-ClC₆H₄CH₂	3-NH₂C₆H₄
1551	4-ClC₆H₄CH₂	2-NH₂C₆H₄
1552	4-ClC₆H₄CH₂	4-Me₂NC₆H₄
1553	4-ClC₆H₄CH₂	3-Me₂NC₆H₄
1554	4-ClC₆H₄CH₂	2-Me₂NC₆H₄
1555	4-ClC₆H₄CH₂	4-pyridyl
1556	4-ClC₆H₄CH₂	3-pyridyl
1557	4-ClC₆H₄CH₂	2-pyridyl
1558	4-ClC₆H₄CH₂	2-thiazolyl
1559	4-ClC₆H₄CH₂	2-pyrazolyl
1560	4-ClC₆H₄CH₂	5-isoquinolyl
1561	4-ClC₆H₄CH₂	3,4
		methylenedioxyC₆H₃
1562	4-ClC₆H₄CH₂	3,4
		ethylenedioxyC₆H₃
1563	4-ClC₆H₄CH₂	2-imidazolyl
1564	4-ClC₆H₄CH₂	2-oxazolyl
1565	4-ClC₆H₄CH₂	4-isoxazolyl
1566	4-ClC₆H₄CH₂	4-HOC₆H₄
1567	4-ClC₆H₄CH₂	3-HOC₆H₄
1568	4-ClC₆H₄CH₂	3,4-diHOC₆H₄
1569	4-ClC₆H₄CH₂	4-NH₂CH₂C₆H₄
1570	4-ClC₆H₄CH₂	3-NH₂CH₂C₆H₄
1571	2-NH₂CH₂C₆H₄CH₂	4-MeOC₆H₄
1572	2-NH₂CH₂C₆H₄CH₂	3-MeOC₆H₄
1573	2-NH₂CH₂C₆H₄CH₂	4-NH₂C₆H₄
1574	2-NH₂CH₂C₆H₄CH₂	3-NH₂C₆H₄
1575	2-NH₂CH₂C₆H₄CH₂	2-NH₂C₆H₄
1576	2-NH₂CH₂C₆H₄CH₂	4-Me₂NC₆H₄
1577	2-NH₂CH₂C₆H₄CH₂	3-Me₂NC₆H₄
1578	2-NH₂CH₂C₆H₄CH₂	2-Me₂NC₆H₄
1579	2-NH₂CH₂C₆H₄CH₂	4-pyridyl
1580	2-NH₂CH₂C₆H₄CH₂	3-pyridyl
1581	2-NH₂CH₂C₆H₄CH₂	2-pyridyl
1582	2-NH₂CH₂C₆H₄CH₂	2-thiazolyl
1583	2-NH₂CH₂C₆H₄CH₂	2-pyrazolyl
1584	2-NH₂CH₂C₆H₄CH₂	5-isoquinolyl
1585	2-NH₂CH₂C₆H₄CH₂	3,4-
		methylenedioxyC₆H₃
1586	2-NH₂CH₂C₆H₄CH₂	3,4-
		ethylenedioxyC₆H₃
1587	2-NH₂CH₂C₆H₄CH₂	2-imidazolyl
1588	2-NH₂CH₂C₆H₄CH₂	2-oxazolyl
1589	2-NH₂CH₂C₆H₄CH₂	4-isoxazolyl
1590	2-NH₂CH₂C₆H₄CH₂	4-HOC₆H₄
1591	2-NH₂CH₂C₆H₄CH₂	3-HOC₆H₄
1592	2-NH₂CH₂C₆H₄CH₂	3,4-diHOC₆H₄
1593	2-NH₂CH₂C₆H₄CH₂	4-NH-I2CH₂C₆H₄
1594	2-NH₂CH₂C₆H₄CH₂	3-NH₂CH₂C₆H₄
1595	3-NH₂CH₂C₆H₄CH₂	4-MeOC₆H₄
1596	3-NH₂CH₂C₆H₄CH₂	3-MeOC₆H₄
1597	3-NH₂CH₂C₆H₄CH₂	4-NH₂C₆H₄
1598	3-NH₂CH₂C₆H₄CH₂	3-NH₂C₆H₄
1599	3-NH₂CH₂C₆H₄CH₂	2-NH₂C₆H₄
1600	3-NH₂CH₂C₆H₄CH₂	4-Me₂NC₆H₄
1601	3-NH₂CH₂C₆H₄CH₂	3-Me₂NC₆H₄
1602	3-NH₂CH₂C₆H₄CH₂	2-Me₂NC₆H₄
1603	3-NH₂CH₂C₆H₄CH₂	4-pyridyl
1604	3-NH₂CH₂C₆H₄CH₂	3-pyridyl
1605	3-NH₂CH₂C₆H₄CH₂	2-pyridyl
1606	3-NH₂CH₂C₆H₄CH₂	2-thiazolyl
1607	3-NH₂CH₂C₆H₄CH₂	2-pyrazolyl
1608	3-NH₂CH₂C₆H₄CH₂	5-isoquinolyl
1609	3-NH₂CH₂C₆H₄CH₂	3,4-
		methylenedioxyC₆H₃
1610	3-NH₂CH₂C₆H₄CH₂	3,4-
		ethylenedioxyC₆H₃
1611	3-NH₂CH₂C₆H₄CH₂	2-imidazolyl
1612	3-NH₂CH₂C₆H₄CH₂	2-oxazolyl
1613	3-NH₂CH₂C₆H₄CH₂	4-isoxazolyl
1614	3-NH₂CH₂C₆H₄CH₂	4-HOC₆H₄
1615	3-NH₂CH₂C₆H₄CH₂	3-HOC₆H₄
1616	3-NH₂CH₂C₆H₄CH₂	3,4-diHOC₆H₄
1617	3-NH₂CH₂C₆H₄CH₂	4-NH₂CH₂C₆H₄
1618	3-NH₂CH₂C₆H₄CH₂	3-NH₂CH₂C₆H₄
1619	4-NH₂CH₂C₆H₄CH₂	4-MeOC₆H₄
1620	4-NH₂CH₂C₆H₄CH₂	3-MeOC₆H₄
1621	4-NH₂CH₂C₆H₄CH₂	4-NH₂C₆H₄
1622	4-NH₂CH₂C₆H₄CH₂	3-NH₂C₆H₄
1623	4-NH₂CH₂C₆H₄CH₂	2-NH₂C₆H₄
1624	4-NH₂CH₂C₆H₄CH₂	4-Me₂NC₆H₄
1625	4-NH₂CH₂C₆H₄CH₂	3-Me₂NC₆H₄
1626	4-NH₂CH₂C₆H₄CH₂	2-Me₂NC₆H₄
1627	4-NH₂CH₂C₆H₄CH₂	4-pyridyl
1628	4-NH₂CH₂C₆H₄CH₂	3-pyridyl
1629	4-NH₂CH₂C₆H₄CH₂	2-pyridyl
1630	4-NH₂CH₂C₆H₄CH₂	2-thiazolyl
1631	4-NH₂CH₂C₆H₄CH₂	2-pyrazolyl
1632	4-NH₂CH₂C₆H₄CH₂	5-isoquinolyl
1633	4-NH₂CH₂C₆H₄CH₂	3,4
		methylenedioxyC₆H₃
1634	4-NH₂CH₂C₆H₄CH₂	3,4
		ethylenedioxyC₆H₃
1635	4-NH₂CH₂C₆H₄CH₂	2-imidazolyl
1636	4-NH₂CH₂C₆H₄CH₂	2-oxazolyl
1637	4-NH₂CH₂C₆H₄CH₂	4-isoxazolyl
1638	4-NH₂CH₂C₆H₄CH₂	4-HOC₆H₄
1639	4-NH₂CH₂C₆H₄CH₂	3-HOC₆H₄
1640	4-NH₂CH₂C₆H₄CH₂	3,4-diHOC₆H₄
1641	4-NH₂CH₂C₆H₄CH₂	4-NH₂CH₂C₆H₄
1642	4-NH₂CH₂C₆H₄CH₂	3-NH₂CH₂C₆H₄
1643	2-Me₂NCH₂C₆H₄CH₂	4-MeOC₆H₄
1644	2-Me₂NCH₂C₆H₄CH₂	3-MeOC₆H₄
1645	2-Me₂NCH₂C₆H₄CH₂	4-NH₂C₆H₄
1646	2-Me₂NCH₂C₆H₄CH₂	3-NH₂C₆H₄
1647	2-Me₂NCH₂C₆H₄CH₂	2-NH₂C₆H₄
1648	2-Me₂NCH₂C₆H₄CH₂	4-Me₂NC₆H₄
1649	2-Me₂NCH₂C₆H₄CH₂	3-Me₂NC₆H₄
1650	2-Me₂NCH₂C₆H₄CH₂	2-Me₂NC₆H₄
1651	2-Me₂NCH₂C₆H₄CH₂	4-pyridyl
1652	2-Me₂NCH₂C₆H₄CH₂	3-pyridyl
1653	2-Me₂NCH₂C₆H₄CH₂	2-pyridyl
1654	2-Me₂NCH₂C₆H₄CH₂	2-thiazolyl
1655	2-Me₂NCH₂C₆H₄CH₂	2-pyrazolyl
1656	2-Me₂NCH₂C₆H₄CH₂	5-isoquinolyl
1657	2-Me₂NCH₂C₆H₄CH₂	3,4
		methylenedioxyC₆H₃
1658	2-Me₂NCH₂C₆H₄CH₂	3,4
		ethylenedioxyC₆H₃
1659	2-Me₂NCH₂C₆H₄CH₂	2-imidazolyl
1660	2-Me₂NCH₂C₆H₄CH₂	2-oxazolyl
1661	2-Me₂NCH₂C₆H₄CH₂	4-isoxazolyl
1662	2-Me₂NCH₂C₆H₄CH₂	4-HOC₆H₄
1663	2-Me₂NCH₂C₆H₄CH₂	3-HOC₆H₄
1664	2-Me₂NCH₂C₆H₄CH₂	3,4-diHOC₆H₄
1665	2-Me₂NCH₂C₆H₄CH₂	4-NH₂CH₂C₆H₄
1666	2-Me₂NCH₂C₆H₄CH₂	3-NH₂CH₂C₆H₄
1667	3-Me₂NCH₂C₆H₄CH₂	4-MeOC₆H₄
1668	3-Me₂NCH₂C₆H₄CH₂	3-MeOC₆H₄
1669	3-Me₂NCH₂C₆H₄CH₂	4-NH₂C₆H₄
1670	3-Me₂NCH₂C₆H₄CH₂	3-NH₂C₆H₄
1671	3-Me₂NCH₂C₆H₄CH₂	2-NH₂C₆H₄
1672	3-Me₂NCH₂C₆H₄CH₂	4-Me₂HC₆H₄
1673	3-Me₂NCH₂C₆H₄CH₂	3-Me₂NC₆H₄
1674	3-Me₂NCH₂C₆H₄CH₂	2-Me₂NC₆H₄
1675	3-Me₂NCH₂C₆H₄CH₂	4-pyridyl
1676	3-Me₂NCH₂C₆H₄CH₂	3-pyridyl
1677	3-Me₂NCH₂C₆H₄CH₂	2-pyridyl
1678	3-Me₂NCH₂C₆H₄CH₂	2-thiazolyl
1679	3-Me₂NCH₂C₆H₄CH₂	2-pyrazolyl
1680	3-Me₂NCH₂C₆H₄CH₂	5-isoquinolyl
1681	3-Me₂NCH₂C₆H₄CH₂	3,4-
		methylenedioxyC₆H₃
1682	3-Me₂NCH₂C₆H₄CH₂	3,4
		ethylenedioxyC₆H₃
1683	3-Me₂NCH₂C₆H₄CH₂	2-imidazolyl
1684	3-Me₂NCH₂C₆H₄CH₂	2-oxazolyl
1685	3-Me₂NCH₂C₆H₄CH₂	4-isoxazolyl
1686	3-Me₂NCH₂C₆H₄CH₂	4-HOC₆H₄
1687	3-Me₂NCH₂C₆H₄CH₂	3-HOC₆H₄
1688	3-Me₂NCH₂C₆H₄CH₂	3,4-diHOC₆H₄
1689	3-Me₂NCH₂C₆H₄CH₂	4-NH₂CH₂C₆H₄
1690	3-Me₂NCH₂C₆H₄CH₂	3-NH₂CH₂C₆H₄
1691	4-Me₂NCH₂C₆H₄CH₂	4-MeOC₆H₄
1692	4-Me₂NCH₂C₆H₄CH₂	3-MeOC₆H₄
1693	4-Me₂NCH₂C₆H₄CH₂	4-NH₂C₆H₄
1694	4-Me₂NCH₂C₆H₄CH₂	3-NH₂C₆H₄
1695	4-Me₂NCH₂C₆H₄CH₂	2-NH₂C₆H₄
1696	4-Me₂NCH₂C₆H₄CH₂	4-Me₂NC₆H₄
1697	4-Me₂NCH₂C₆H₄CH₂	3-Me₂NC₆H₄
1698	4-Me₂NCH₂C₆H₄CH₂	2-Me₂NC₆H₄
1699	4-Me₂NCH₂C₆H₄CH₂	4-pyridyl
1700	4-Me₂NCH₂C₆H₄CH₂	3-pyridyl
1701	4-Me₂NCH₂C₆H₄CH₂	2-pyridyl
1702	4-Me₂NCH₂C₆H₄CH₂	2-thiazolyl
1703	4-Me₂NCH₂C₆H₄CH₂	2-pyrazolyl
1704	4-Me₂NCH₂C₆H₄CH₂	5-isoquinolyl
1705	4-Me₂NCH₂C₆H₄CH₂	3,4-
		methylenedioxyC₆H₃
1706	4-Me₂NCH₂C₆H₄CH₂	3,4-
		ethylenedioxyC₆H₃
1707	4-Me₂NCH₂C₆H₄CH₂	2-imidazolyl
1708	4-Me₂NCH₂C₆H₄CH₂	2-oxazolyl
1709	4-Me₂NCH₂C₆H₄CH₂	4-isoxazolyl
1710	4-Me₂NCH₂C₆H₄CH₂	4-HOC₆H₄
1711	4-Me₂NCH₂C₆H₄CH₂	3-HOC₆H₄
1712	4-Me₂NCH₂C₆H₄CH₂	3,4-diHOC₆H₄
1713	4-Me₂NCH₂C₆H₄CH₂	4-NH₂CH₂C₆H₄
1714	4-Me₂NCH₂C₆H₄CH₂	3-NH₂CH₂C₆H₄

TABLE 4

Example
Number	R¹	R²

1715	Methyl	4-MeOC₆H₄
1716	ClCH₂	4-MeOC₆H₄
1717	cyclopropyl	4-MeOC₆H₄
1718	isopropyl	4-MeOC₆H₄
1719	ethyl	4-MeOC₆H₄
1720	cyclopentyl	4-MeOC₆H₄
1721	cyclobutyl	4-MeOC₆H₄
1722	benzyl	4-MeOC₆H₄
1723	n-propyl	4-MeOC₆H₄
1724	4-ClC₆H₄CH₂	4-MeOC₆H₄
1725	3-MeOC₆H₄CH₂	4-MeOC₆H₄
1726	4-MeOC₆H₄CH₂	4-MeOC₆H₄
1727	3,4-diMeOC₆H₄CH₂	4-MeOC₆H₄
1728	2,5-diMeOC₆H₄CH₂	4-MeOC₆H₄
1729	Methyl	2-MeOC₆H₄
1730	Methyl	3,4-diMeOC₆H₄
1731	3,4-(OCH₂O)C₆H₄CH₂	4-MeOC₆H₄
1732	3-thiophenylCH₂	4-MeOC₆H₄
1733	2-MeOC₆H₄CH₂	4-MeOC₆H₄
1734	3,4-diClOC₆H₄CH₂	4-MeOC₆H₄
1735	2,4-diClOC₆H₄CH₂	4-MeOC₆H₄
1736	2-ClC₆H₄CH₂	4-MeOC₆H₄
1737	H₂NCH₂	4-MeOC₆H₄
1738	HOCH₂NHCH₂CH₂	4-MeOC₆H₄
1739	Me₂NCH₂	4-MeOC₆H₄
1740	piperazinylCH₂	4-MeOC₆H₄
1741	4-Me-piperazinylCH₂	4-MeOC₆H₄
1742	4-HOCH₂CH₂—	4-MeOC₆H₄
	piperazinylCH₂
1743	piperidinylCH₂	4-MeOC₆H₄
1744	4-NH₂CH₂—	4-MeOC₆H₄
	piperidinylCH₂
1745	CH₃CH₂NHCH₂	4-MeOC₆H₄
1746	thiomorpholinylCH₂	4-MeOC₆H₄
1747	morpholinylCH₂	4-MeOC₆H₄
1748	pyyrolidinylCH₂	4-MeOC₆H₄
1749	4-pyridylCH₂NHCH₂	4-MeOC₆H₄
1750	4-CH₃CONHC₆H₄CH₂	4-MeOC₆H₄
1751	4-CH₃OCONHC₆H₄CH₂	4-MeOC₆H₄
1752	4-NH₂CH₂CONHC₆H₄CH₂	4-MeOC₆H₄
1753	4-Me₂NCH₂CONHC₆H₄CH₂	4-MeOC₆H₄
1754	4-N₃C₆H₄CH₂	4-MeOC₆H₄
1755	4-NH₂C₆H₄CH₂	4-MeOC₆H₄
1756	C₆H₅NH	4-MeOC₆H₄
1757	CH₃CH₂CH₂NH	4-MeOC₆H₄
1758	4-NH₂C₆H₄CH₂NH	4-MeOC₆H₄
1759	4-pyridyCH₂NH	4-MeOC₆H₄
1760	Methyl	4-HOC₆H₄
1761	H	4-MeOC₆H₄
1762	Methyl	3-pyridyl
1763	Methyl	4-pyridyl
1764	H	4 -pyridyl
1765	Methyl	C₆H₅
1766	Methyl	4-MeSC₆H₄
1767	Methyl	4-MeSO₂C₆H₄
1768	Methyl	4-Me₂NC₆H₄
1769	MorpholinylCH₂	4-Me₂NC₆H₄
1770	Me₂NCH₂	4-Me₂NC₆H₄
1771	Me₂NCH₂	4-(piperdinyl)C₆H₄
1772	Me₂NCH₂	4-(morpholinyl)-
		C₆H₄
1773	Me₂NCH₂	4-CH₃CH₂OC₆H₄
1774	Me₂NCH₂	4-CH₃CH₂CH₂CH₂C₆H₄
1775	Me₂NCH₂	4-CH₃CH₂C₆H₄
1776	Me₂NCH₂	4-CH₃CH₂CH₂C₆H₄

Claims

What is claimed is:

1. A compound according to formula (I):

3-(4-methoxyphenyl)-5-(2-methoxycarbonyl hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein:

X is selected from the group: O, S, and NR;

R is selected from the group: H, C_1-4alkyl, and NR⁵R^5a;

R¹is selected from the group: H, C_1-10alkyl substituted with 0-3 R^c, C_2-10alkenyl substituted with 0-3 R^c, C_2-10alkynyl substituted with 0-3 R^c, —NHR⁴, C_3-10carbocycle substituted with 0-5 R^a, and 3-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 R^b;

R²is selected from the group: H, C_1-10alkyl substituted with 0-3 R^c, C_2-10alkenyl substituted with 0-3 R^c, C_2-10alkynyl substituted with 0-3 R^c, —(CF₂)_mCF₃, C_3-10carbocycle substituted with 0-5 R^a, and 3-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 R^b;

R³is selected from the group: H, halo, —CN, NO₂, C_1-4haloalkyl, NR R^5a, NR⁵NR⁵R^5a, NR⁵C(O)OR⁵, NR⁵C(O)R⁵═O, OR⁵, COR⁵, CO₂R⁵, CONR⁵R^5a, NHC(O)NR⁵R^5a, NHC(S)NR⁵R^5a, SO₂NR⁵R^5a, SO₂R^5b, C_1-4alkyl, phenyl, benzyl, C_1-4alkyl substituted with 1-3 R^c, C_5-10alkyl substituted with C_2-10alkenyl optionally substituted with 0-3 R₆, C_2-10alkynyl substituted with 0-3 R⁶, —(CF₂)_mCF₃, C_3-10carbocycle substituted with 0-5 R⁶, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R⁶; and

provided that if R³is phenyl, it is substituted with 1-5 R^a;

R⁴is independently at each occurrence selected from the group: H, —CN, C_1-4alkyl, C_1-4haloalkyl, NR³R^3a, NR³C(O)OR³, NR³C(O)R³, OR³, COR³, CO₂R³, CONR³R^3a, NHC(O)NR³R^3a, NHC(S)NR³R^3a, SO₂NR³R^3a, SO₂R^3b, C_3-10carbocycle substituted with 0-5 R^a, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R³;

provided that at least one R³is present and that this R³is selected from the group: C_1-4alkyl substituted with 1-3 R⁶, C_5-10alkyl substituted with C_2-10alkenyl optionally substituted with 0-3 R⁶, C_2-10alkynyl substituted with 0-3 R⁶, —(CF₂)_mCF₃, C_3-10carbocycle substituted with 0-5 R⁶, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R⁶;

R^ais independently at each occurrence selected from the group: halo, —CN, N₃, NO₂, C_1-4alkyl, C_1-4haloalkyl, NR³R^3a, ═O, OR³, COR³, CO₂R³, CONR³R^3a, NHC(O)NR³R^3a, NHC(S)NR³R^3a, NR³C(O)OR³, NR³C(O)R³, SO₂NR³R^3a, SO₂R^3b, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

alternatively, when two Ra's are present on adjacent carbon atoms they combine to form —OCH₂O— or —OCH₂CH₂O—;

R^bis independently at each occurrence selected from the group: halo, —CN, NO₂, C_1-4alkyl, C_1-4haloalkyl, NR³R^3a, NR³C(O)OR³, NR³C(O)R³, OR³, COR³, CO₂R³, CONR³R^3a, NHC(O)NR³R^3a, NHC(S)NR³R^3a, SO₂NR³R^3a, and SO₂R^3b;

R^cis independently at each occurrence selected from the group: halo, —CN, NO₂, C_1-4alkyl, C_1-4haloalkyl, NR³R^3a, NR⁵NR⁵R^5a, NR³C(O)OR³, NR³C(O)R³, ═O, OR³, COR³, CO₂R³, CONR³R^3a, NHC(O)NR³R^3a, NHC(S)NR³R^3a, SO₂NR³R^3a, SO₂R^3b, C_3-10carbocycle substituted with 0-5 R^a, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R³;

R^3ais selected from the group: H, C_1-4alkyl, phenyl, and benzyl;

alternatively, R³and R^3a, together with the nitrogen atom to which they are attached, form a heterocycle having 4-8 atoms in the ring containing an additional 0-1 N, S, or O atom and substituted with 0-3 R^3c;

R^3bis selected from the group: H, C_1-4alkyl, phenyl, and benzyl;

R^3cis independently at each occurrence selected from the group: halo, —CN, N₃, NO₂, C_1-4alkyl, C_1-4haloalkyl, NR³R^3a, ═O, OR³, COR³, CO₂R³, CONR³R^3b, NHC(O)NR³R^3b, NHC(S)NR³R^3b, NR³C(O)OR³, NR³C(O)R³, SO₂NR³R^3b, SO₂R^3b, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

R⁵is independently selected from the group: H, C_1-4alkyl, phenyl and benzyl;

R^5ais independently selected from the group: H, C_1-4alkyl, phenyl and benzyl;

R^5bis independently selected from the group: H, C_1-4alkyl, phenyl and benzyl;

R⁶is independently at each occurrence selected from the group: halo, —CN, NO₂, C_1-4alkyl, C_1-4haloalkyl, NR⁵R⁵, NR⁵NR⁵R^5a, NR⁵C(O)OR⁵, NR⁵C(O)R⁵, ═O, OR⁵, COR⁵, CO₂R⁵, CONR⁵R^5a, NHC(O)NR⁵R^5a, NHC(S)NR⁵R^5a, SO₂NR⁵R^5a, SO₂R^5b, C_3-10carbocycle substituted with 0-5 R⁵, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R⁵; and

m is selected from 0, 1, 2, and 3.

2. A compound according to claim 1, wherein:

X is selected from the group: O, S, and NR;

R is selected from the group: H, C_1-4alkyl, and NR⁵R^5a;

R¹is selected from the group: H, C_1-5alkyl substituted with 0-3 R^c, C_2-5alkenyl substituted with 0-3 R^c, C_2-5alkynyl substituted with 0-3 R^c, —NHR⁴, C_3-6carbocycle substituted with 0-5 R^a, and 3-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 R^b;

R²is selected from the group: H, C_1-5alkyl substituted with 0-3 R^c, C_2-5alkenyl substituted with 0-3 R^c, C_2-5alkynyl substituted with 0-3 R^c, —(CF₂)_mCF₃, C_3-6carbocycle substituted with 0-5 R^a, and 3-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 R^b;

R³is selected from the group: H, halo, —CN, NO₂, C_1-4haloalkyl, NR R^5a, NR⁵NR⁵R^5a, NR⁵C(O)OR⁵, NR⁵C(O)R⁵, ═O, OR⁵, COR⁵, CO₂R⁵, CONR⁵R^5a, NHC(O)NR⁵R^5a, NHC(S)NR⁵R^5a, SO₂NR⁵R^5a, SO₂R^5b, C_1-4alkyl, phenyl, benzyl, C_1-4alkyl substituted with 1-3 R^c, CS-1O alkyl substituted with C_2-10alkenyl optionally substituted with 0-3 R⁶, C_2-10alkynyl substituted with 0-3 R⁶, —(CF₂)_mCF₃, C_3-10carbocycle substituted with 0-5 R⁶, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R⁶; and

provided that if R³is phenyl, it is substituted with 1-5 R^a;

R^ais independently at each occurrence selected from the group: halo, —CN, N₃, NO₂, C_1-4alkyl, C_1-4haloalkyl, NR³R^3a, NR³C(O)OR³, NR³C(O)R³, ═O, OR³, COR³, CO₂R³, CONR³R^3a, NHC(O)NR³R^3a, NHC(S)NR³R^3a, SO₂NR³R^3a, SO₂R^3b, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

alternatively, when two R^a's are present on adjacent carbon atoms they combine to form —OCH₂O— or —OCH₂CH₂O—;

R^cis independently at each occurrence selected from the group: halo, —CN, NO₂, C_1-4alkyl, C_1-4haloalkyl, NR³R^3a, NR³C(O)OR³, NR³C(O)R³, NR⁵NR⁵R^5a, ═O, OR³, COR³, CO₂R³, CONR³R^3a, NHC(O)NR³R^3a, NHC(S)NR³R^3a, SO₂NR³R^3a, SO₂R^3b, C_3-10carbocycle substituted with 0-5 R^a, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R³;

R^3ais selected from the group: H, C_1-4alkyl, phenyl, and benzyl;

R^3bis selected from the group: H, C_1-4alkyl, phenyl, and benzyl;

R^3cis independently at each occurrence selected from the group: halo, —CN, N₃, NO₂, C_1-4alkyl, C_1-4haloalkyl, NR³R^3b, ═O, OR³, COR³, CO₂R³, CONR³R^3b, NHC(O)NR³R^3b, NHC(S)NR³R^3b, NR³C(O)OR³, NR³C(O)R³, SO₂NR³R^3b, SO₂R^3b, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

R⁵is independently selected from the group: H, C_1-4alkyl, phenyl, and benzyl;

R^5ais independently selected from the group: H, C_1-4alkyl, phenyl and benzyl;

R^5bis independently selected from the group: H, C_1-4alkyl, phenyl, and benzyl;

m is selected from 0, 1, 2, and 3.

3. A compound according to claim 2, wherein:

X is selected from the group: O and S;

R¹is selected from the group: H, C_1-5alkyl substituted with 0-3 R^c, C_2-5alkenyl substituted with 0-3 R^c, —NHR⁴, C_3-6carbocycle substituted with 0-5 R^a, and 3-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 R^b;

R²is selected from the group: H, C_1-5alkyl substituted with 0-3 R^c, C_2-5alkenyl substituted with 0-3 R^c, —(CF₂)_mCF₃, C_3-6carbocycle substituted with 0-5 R^a, and 3-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 R^b;

R³is selected from the group: H, halo, —CN, NO₂, Cl-₄haloalkyl, NR⁵R⁵, NR⁵NR⁵R^5a, NR⁵C(O)OR⁵, NR⁵C(O)R⁵, ═O, OR⁵, COR⁵, CO₂R⁵, CONR⁵R^5a, NHC(O)NR⁵R^5a, NHC(S)NR⁵R^5a, SO₂NR⁵R^5a, SO₂R^5b, C_1-4alkyl, phenyl, benzyl, C_1-4alkyl substituted with 1-3 R^c, C_5-10alkyl substituted with C_2-10alkenyl optionally substituted with 0-3 R⁶, C_2-10alkynyl substituted with 0-3 R⁶, —(CF₂)_mCF₃, C_3-10carbocycle substituted with 0-5 R⁶, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R⁶; and

provided that if R³is phenyl, it is substituted with 1-5 R^a;

provided that at least one R³is present and that this R³is selected from the group: C_1-4alkyl substituted with 1-3 R⁶, C_5-10alkyl substituted with C_2-10alkenyl optionally substituted with 0-3 R₆, C_2-10alkynyl substituted with 0-3 R⁶, —(CF₂)_mCF₃, C_3-10carbocycle substituted with 0-5 R⁶, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R⁶;

R^ais independently at each occurrence selected from the group: halo, —CN, N₃, C_1-4alkyl, C_1-4haloalkyl, NR³R^3a, NR³C(O)R³C(O)R³, OR³, COR³, CO₂R³,

CONR³R^3a, NHC(O)NR³R^3a, SO₂NR³R^3a, SO₂R^3b, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

R^bis independently at each occurrence selected from the group: halo, —CN, C_1-4alkyl, C_1-4haloalkyl, NR³R^3a, NR³C(O)OR³, NR³C(O)R³, OR³, COR³, CO₂R³, CONR³R^3a, NHC(O)NR³R^3a, SO₂NR³R^3a, and SO₂R^3b;

R^cis independently at each occurrence selected from the group: halo, —CN, C_1-4alkyl, C_1-4haloalkyl, NR³R^3a, NR⁵NR⁵R^5a, NR³C(O)OR³, NR³C(O)R³, ═O, OR³, COR³, CO₂R³, CONR³R^3a, NHC(O)NR³R^3a, SO₂NR³R^3a, SO₂R^3b, C_3-10carbocycle substituted with 0-5 R^a, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R³;

R^3ais selected from the group: H, C_1-4alkyl, phenyl, and benzyl;

alternatively, R³and R^3a, together with the nitrogen atom to which they are attached, form a heterocycle having 5-6 atoms in the ring containing an additional 0-1 N, S, or O atom and substituted with 0-3 R^3c;

R^3bis selected from the group: H, C_1-4alkyl, phenyl, and benzyl;

R^5ais independently selected from the group: H, C_1-4alkyl, phenyl and benzyl;

m is selected from 0, 1, 2, and 3.

4. A compound according to claim 3, wherein:

X is selected from the group: O and S;

R¹is selected from the group: H, C_1-5alkyl substituted with 0-2 R^c, —NHR⁴, C_3-6carbocycle substituted with 0-5 R^a, and 5-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 R^b;

R²is selected from the group: H, C_1-5alkyl substituted with 0-3 R^c, —(CF₂)_mCF₃, C_3-6carbocycle substituted with 0-5 R^a, and 5-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-3 R^b;

R³is selected from the group: H, halo, —CN, NO₂, C_1-4haloalkyl, NR⁵R^5a, NR⁵NR⁵R^5a, NR⁵C(O)OR⁵, NR⁵C(O)R⁵, ═O, OR⁵, COR⁵, CO₂R⁵, CONR⁵R^5a, NHC(O)NR⁵R^5a, NHC(S)NR⁵R^5a, SO₂NR⁵R^5a, SO₂R^5b, C_1-4alkyl, phenyl, benzyl, C_1-4alkyl substituted with 1-3 R^c, C_5-10alkyl substituted with C_2-10alkenyl optionally substituted with 0-3 R⁶, C_2-10alkynyl substituted with 0-3 R⁶, —(CF₂)_mCF₃, C_3-10carbocycle substituted with 0-5 R⁶, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R⁶; and

provided that if R³is phenyl, it is substituted with 1-5 R^a;

R^ais independently at each occurrence selected from the group: halo, —CN, N₃, C_1-4alkyl, C_1-4haloalkyl, NR³R^3a, NR³C(O)OR³, NR³C(O)R³, OR³, COR³, CO₂R^{3, CONR} ³R^3a, NHC(O)NR³R^3a, SO₂NR³R^3a, SO₂R^3b, and 5-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

R^bis independently at each occurrence selected from the group: halo, C_1-4alkyl, C_1-4haloalkyl, NR³R^3a, NR³C(O)OR³, NR³C(O)R³, OR³, COR³, CO₂R³, CONR³R^3a, NHC(O)NR³R^3a, SO₂NR³R^3a, and SO₂R^3b;

R^cis independently at each occurrence selected from the group: halo, C_1-4alkyl, C_1-4haloalkyl, NR³R^3a, NR⁵NR⁵R^5a, NR³C(O)OR³, NR³C(O)R³, OR³, COR³, CO₂R³, CONR³R^3a, NHC(O)NR³R^3a, SO₂NR³R^3a, SO₂R^3b, C_3-10carbocycle substituted with 0-5 R^a, and 5-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R³;

R^3ais selected from the group: H, C_1-4alkyl, phenyl, and benzyl;

R^3bis selected from the group: H, C_1-4alkyl, phenyl, and benzyl;

R⁵is independently selected from the group: H and C_1-4alkyl;

R^5ais independently selected from the group: H, C_1-4alkyl, phenyl and benzyl;

R^5bis independently selected from the group: H and C_1-4alkyl;

m is selected from 0, 1, 2, and 3.

5. A compound according to claim 1, wherein the compound is selected from:

(a) 3-(4-methoxyphenyl)-5(2-benzoylhydrazinecarboxamido)indeno [1,2-c]pyrazol-4-one;

(b) 3-(4-methoxyphenyl)-5-(2-isonicotinoylhydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

(c) 3-(4-methoxyphenyl)-5-(2-nictinoylhydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

(d) 3-(4-methoxyphenyl)-5-(2-(3,4-dihydroxybenzoyl)hydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

(e) 3-(4-methoxyphenyl)-5-(2-(4-hydroxybenzoyl)hydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

(f) 3-(4-methoxyphenyl)-5-(2-(3-aminobenzoyl)hydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

(g) 3-(4-methoxyphenyl)-5-(2-(4-aminobenzoyl)hydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

(h) 3-(4-methoxyphenyl)-5-(2-(2-aminobenzoyl)hydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

(i) 3-(4-methoxyphenyl)-5-(2-(4-N,N-dimethylaminobenzoyl) hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

(j) 3-(4-methoxyphenyl)-5-(2-phenethylacetylhydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

(k) 3-(4-methoxyphenyl)-5-(2-(2-hydroxybenzoyl)hydrazine carboxamido)indeno[1,2-c]pyrazol-4-one; and

(l) 3-(4-methoxyphenyl)-5-(2-methoxycarbonyl hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

or pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1.

7. A method of treating cancer and proliferative diseases comprising: administering to a host in need of such treatment a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.

8. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1.

9. A method of treating cancer and proliferative diseases comprising: administering to a host in need of such treatment a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.

10. A compound according to formula (II)

or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein:

X is selected from the group: O and NR;

R is selected from the group: H, C_1-4alkyl, NR³R^3a, and C_1-4alkyl substituted with 1-3 R^c;

R³is selected from the group: H, halo, —CN, NO₂, C_1-4haloalkyl, NR⁵R^5a, NR⁵NR⁵R^5a, NR⁵C(O)OR⁵, NR⁵C(O)R⁵, ═O, OR⁵, COR⁵, CO₂R⁵, CONR⁵R^5a, NHC(O)NR⁵R^a, NHC(S) NR⁵R^5a, SO₂NR⁵R^5a, SO₂R^5b, C_1-4alkyl, phenyl, benzyl, C_1-4alkyl substituted with 1-3 R^c, C_5-10alkyl substituted with C_2-10alkenyl optionally substituted with 0-3 R⁶, C_2-10alkynyl substituted with 0-3 R⁶, —(CF₂)_mCF₃, C_3-10carbocycle substituted with 0-5 R⁶, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R⁶; and

provided that if R³is phenyl, it is substituted with 1-5 R^a;

R^3ais selected from the group: H, C_1-4alkyl, phenyl, and benzyl;

R^3bis selected from the group: H, C_1-4alkyl, phenyl, and benzyl;

R⁵is independently selected from the group: H, C_1-4alkyl, phenyl and benzyl;

R^5ais independently selected from the group: H, C_1-4alkyl, phenyl, and benzyl;

R⁶is independently at each occurrence selected from the group: halo, —CN, NO₂, C_1-4alkyl, C_1-4haloalkyl, NR⁵R⁵, NR⁵NR⁵R^5a, NR⁵C(O)OR, NR⁵C(O)R⁵, ═O, OR⁵, COR⁵, CO₂R⁵, CONR⁵R^5a, NHC(O)NR 5R^5a, NHC(S)NR R^5a, SO₂NR⁵R^5a, SO₂R^5b, C_3-10carbocycle substituted with 0-5 R⁵, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R⁵;

R^ais independently at each occurrence selected from the group: H, halo, C_1-4alkyl, NR³R^3a, and R³;

R^dis independently at each occurrence selected from the group: OR³, COR³, and NR³R^3a; and

m is selected from 0, 1, 2, and 3.

11. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 8.

12. A method of treating cancer and proliferative diseases comprising: administering to a host in need of such treatment a therapeutically effective amount of a compound of claim 8, or a pharmaceutically acceptable salt or prodrug form thereof.